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Abstract  
The aim of this PhD was to elucidate the factors that influence anticoagulation 
response to the oral anticoagulants, warfarin and non-vitamin K antagonist oral 
anticoagulants (NOACs). Identification of the factors which influence clinical response 
to these agents could lead to improvements in patient management and treatment 
safety.   
In a cross-sectional study, the mean TTR over a 12 months period was significantly 
higher in hospital monitored patients (78%) (P=0.001) compared to those monitored in 
general practice (71%) or at their homes (68%). Domiciliary monitored patients had the 
least TTR among the three groups although they had the highest numbers of dose 
changes and INR monitoring events. In a further longitudinal study of patients on 
warfarin for up to 14 years, the TTR according to age was significantly lower in home 
monitored patients, with this group having a higher probability of having poor 
anticoagulation control (TTR ≤65%). 
In an ex-vivo study, rivaroxaban in vitamin K deficient older subjects produced a 
greater prolongation of both PT and modified PT, and a greater suppression in the rate 
and amount of thrombin generation compared to vitamin K replete younger subjects. 
Therefore, poor vitamin K intake could play a role in the reported incidences of bleeding 
associated with NOACs 
We had previously demonstrated that daily vitamin K supplementation causes an 
increase in warfarin daily dose requirement which varies between different patients 
and is related to VKORC1 genotype.  Based upon these observations we set out to 
test our hypothesis that patients on warfarin therapy with the VKORC1(-1639)GG 
polymorphism could have poorer anticoagulation control than those with GA or AA 
genotypes as a result of variable dietary intake of vitamin K. However, the study results 
failed to confirm this hypothesis. 
Patients on warfarin therapy scheduled for an invasive surgery have to stop taking 
the drug for a fixed number of days to avoid peri-operative bleeding. However, there is 
variance in the rate by which INR falls after stopping warfarin. I found that patients with 
CYP2C9 variant alleles (CYP2C9*2*2 or CYP2C9*2*3) were >8 times (95% CI = 2.25–
33.25) more likely to have INR of ≥ 1.5 before the planned day of surgery than those 
with wild-type genotype. In a further study, patient age and CYP2C9 *2*2 & *2*3 
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genotype were found to significantly influence the time required to reach an INR of 1.5 
following warfarin cessation. VKORC1 genotype had no effect on the rate of INR 
decline.  
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CHAPTER. 1 INTRODUCTION  
 
1.1. Vitamin K Antagonists 
1.1.1.  Introduction 
The ideal anticoagulant (blood thinning drug) would be one which abolishes blood 
clotting where it is not wanted without causing bleeding. Such an agent does not yet 
exist in clinical practice. For decades coumarins have been used for the treatment and 
prevention of venous thromboembolism, including deep vein thrombosis, pulmonary 
embolism and thromboembolic complications of cardiac valve replacement or atrial 
fibrillation.  Meeting a stable and therapeutic effect is clinically important to the safety 
of warfarin.  However, the clinical management of patients on warfarin therapy is 
complicated by the fact that the drug has a narrow therapeutic window, interacts with 
many co-administered drugs and food and there is wide intra- and inter-individual 
variability in anticoagulation response, with the dose required to reach therapeutic 
anticoagulation in individual patients differing by a factor of 10 or more [1].   
 
1.1.1.1. Definition  
Coumarins are vitamin K antagonists (VKAs). They cause anticoagulation by 
inhibiting the recycling of vitamin K. This leads to depletion of vitamin K-dependent 
coagulation factors II, VII, IX and X. Warfarin is the most commonly used coumarin 
worldwide. Acenocoumarol and phenprocoumon are other close derivatives of warfarin 
which are used in several European countries [2]. The chemical structures of VKAs 
are shown in Figure 1-1.  
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Figure 1-1: Chemical structure of vitamin K antagonists 
      
1.1.1.2. History of coumarin use 
At the turn of the twentieth century the high demand for new housing and farmland 
in Northern America led to the destruction of natural grasses used by cattle for grazing. 
Sweet clover was grown extensively as an alternative animal feed. During the 1920s, 
in Canada and northern parts of America, veterinarians observed that cattle were dying 
of internal haemorrhage but the cause for this was unknown. It was found that 
haemorrhage took place when wet and spoiled sweet clover was fed to cattle.  The 
symptoms of this “sweet clover disease” appeared within 15 days of ingestion, and the 
animal died within 30 to 50 days thereafter. The cause for bleeding in cattle which were 
fed on spoilt sweet clover was identified ten years later by Karl Link (1901-1978) and 
his senior student Wilhelm Schoeffel.  Link identified the responsible substance as 
dicoumarol (3, 3’-methylene-bis [4-hydroxycoumarin]), a naturally occurring coumarin 
in mouldy hay (Melilotus alba and M. officinalis). Moreover, in 1939, Link found that 
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administration of vitamin K1 reversed dicoumarol action. The (3-a-acetonylbenzyl-4-
hydroxycoumarin) product was given the name of Warfarin, (warf-) since it was brought 
to light by Wisconsin Alumni Research Foundation, and (-arin) from the coumarin 
group. In 1948, warfarin was initially promoted as a rodenticide, then in 1955, 
introduced clinically under the name “Coumadin”. The main benefits of warfarin 
compared to other anticoagulants, heparin and dicoumarol, are its high oral 
bioavailability and high water solubility.  The benefits of coumarins as oral 
anticoagulants were successfully demonstrated in a randomized clinical trial for the 
first time in 1960 for patients with pulmonary embolism [3, 4]. 
       
1.1.2. Blood coagulation  
When an animal is wounded a blood clotting process takes place rapidly at the site 
of injury to prevent bleeding.  Blood clotting through the coagulation cascade is a 
process that encompasses a series of reactions known as the extrinsic (tissue factor) 
pathway, intrinsic (contact) pathway, and common pathway.  
The extrinsic pathway is so called as one of the coagulation factors, Factor III 
thromboplastin, does not exist in circulating blood. The extrinsic pathway includes also 
factors IV calcium and VII proconvertin. The required coagulation factors in the intrinsic 
pathway are all contained in circulating blood, hence its name. Factors included in the 
intrinsic pathway are VIII antihemophilic, IX Christmas, XI plasma thromboplastin 
antecedent, and XII Hageman. Coagulation factors I fibrinogen, II prothrombin, V 
prothrombin accelerator, X Stuart (Power), and XIII fibrin-stabilizing factor are common 
factors across the two pathways[5]. The various coagulation factors and their 
prominence in the coagulation cascade are listed in Table 1-1.  
 
 
 
 
 
 
 4 
 
 
 
Table 1-1: Coagulation factors  
Factor number Factor name  
Extrinsic pathway   
III Thromboplastin, tissue factor 
IV Calcium  
VII Proconvertin  
Intrinsic pathway   
VIII Antihemophilic factor 
IX Christmas factor  
XI Plasma thromboplastin antecedent 
XII Hageman factor 
Common pathway  
I Fibrinogen  
II Prothrombin  
V Prothrombin accelerator 
X Stuart (Power) 
XIII Fibrin-stabilizing factor 
 
 
After vascular injury and blood exposure to tissue factor, the coagulation cascade 
is initiated. This stimulates the extrinsic pathway (heavy arrows in Figure 1-2). Once 
thrombin is generated, the intrinsic pathway (small arrows in Figure 1-2) is stimulated, 
which leads to factor XI activation. Both of the two pathways are joined by factor Xa 
formation (common pathway). Then, factor Xa triggers prothrombinase enzyme which 
converts prothrombin to thrombin. Fibrinogen is converted by thrombin to insoluble 
fibrin to create a clot [6, 7] 
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Figure 1-2: Intrinsic (small arrows) and extrinsic (heavy arrows) pathways 
involved in blood coagulation cascade.  PL=phospholipid [6].   
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1.1.3. Clinical indications for warfarin 
In well-designed clinical trials, warfarin has proved its efficacy in the treatment and 
prevention of thromboembolism. The three indications for which warfarin is most 
commonly used are:  
 Atrial fibrillation 
 Venous thrombosis  
 Metallic prosthetic heart valves 
     
Atrial fibrillation   
Atrial fibrillation (AF) is a major health problem as patients with atrial fibrillation are 
susceptible to developing atrial thrombi, and the risk of stroke from cardioembolism is 
increased  4-5 fold compared with those in sinus rhythm [8, 9].  In the presence of AF, 
strokes are more often lethal or result in more disability than in its absence [10]. In 
developed countries, AF prevalence affects at least 1% of the population; however, 
across the world this prevalence varies [11]. A US study has shown that blacks, Asians, 
and Hispanic populations have a significantly lower AF prevalence compared to white 
people [12, 13].   Since the prevalence of AF rises with ageing, the prevalence of stroke 
also rises in older subjects [12, 13]. Atrial fibrillation is associated with up to 15% of all 
strokes, and 25% of strokes in individuals above 80 years.  
Two meta-analyses have demonstrated that stroke was  reduced by around 62-
64% and 22% in AF patients treated with adjusted-dose warfarin and antiplatelet 
agents  respectively; relative risk reduction for warfarin compared with antiplatelet 
agents was around 36-40% [14, 15].  In another meta-analysis study, in patients with 
AF treated with warfarin, risk of systemic embolism was halved compared to those 
treated with antiplatelet agents (OR=0.50, 95%CI=0.33-0.75), with risk of major 
bleeding being equal in the two groups (OR=1.07, 95% CI=0.85-1.34). Compared with 
placebo, warfarin reduced the risk of stroke by 71% (OR=0.29, 95% CI=0.08-1.07), 
outweighing absolute risk of harm, although relative risk of major bleeding was 
increased 3-fold (OR=3.01, 95% CI=1.31-6.92) [16]. As ischaemic stroke risk can be 
reduced by around two thirds by anticoagulation, patients with atrial fibrillation should 
be considered for treatment with oral anticoagulants [17, 18].   
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The original CHADS2 scoring scheme, which combines several risk predictors into 
a 7-point scale (0–6), was developed to help in decision making about anticoagulation 
for patients with AF by estimating an individual's risk of stroke. Patients receive one 
point for having any of the following: Cardiac failure, Hypertension, Age 75 years or 
above, Diabetes mellitus and two points for previous history of Stroke or transient 
ischaemic attack [19]. According to ACCP guidelines 9th edition 2012, those scoring 
zero on CHADS2 (low risk) are considered as AF individuals who should be treated 
with or without aspirin. AF individuals with CHADS2 score of one (intermediate risk) 
should be treated with warfarin rather than aspirin or a combination of aspirin and 
clopidogrel; whereas warfarin should be used with CHADS2 score of two or higher (high 
risk) if there are no contraindications [18].  However, the CHADS2 scoring scheme has 
been recently refined to include other risk factors for stroke in AF. Data from the Euro 
Heart Survey on Atrial Fibrillation were used  to generate the 10-point (0-9) CHA2DS2-
VASc score [20]. Scoring determinants with their assigned points are as follows:  
 Congestive heart failure or left ventricular ejection fraction ≤40% (1 point); 
 Hypertension (1 point); 
 Age ≥75 years (2 points); 
 Diabetes (1 point); 
 Stroke/Transient ischemic attack (TIA)/thromboembolism (2 points); 
 Vascular disease (myocardial infarction, peripheral arterial disease, or aortic 
plaque) (1 point); 
 Age 65 to 74 years (1 point); and 
 Sex category female (1 point)   
A CHA2DS2-VASc score of zero is categorized as “low” risk and may not require 
anticoagulation, a score of 1 as “low-moderate” risk and should consider antiplatelet or 
anticoagulation therapy, and a score of equal or more than 2 as “moderate-high” risk 
and should consider anticoagulation therapy [20]. According to latest NICE guidelines 
about AF management, patients with a CHA2DS2-VASc score of 1 or more should be 
treated with anticoagulants (a vitamin K antagonist or a NOAC); aspirin as 
monotherapy is not recommended for stroke prevention for people with atrial fibrillation 
[21, 22]. Table 1-2 shows the rate of thromboembolism according to CHA2DS2-VASc 
scoring system.  
 8 
 
 
Table 1-2: Thromboembolism frequency at one year based on CHA2DS2-VASc 
Scoring System 
CHA2DS2-VASc 
Score 
Number of 
patients 
Number of 
TE Events 
TE Rate During 
one year (95% CI) 
0 103 0 0% (0-0) 
1 162 1 0.6% (0.0-3.4) 
2 184 3 1.6% (0.3-4.7) 
3 203 8 3.9% (1.7-7.6) 
4 208 4 1.9% (0.5-4.9) 
5 95 3 3.2% (0.7-9.0) 
6 57 2 3.6% (0.4-12.3) 
7 25 2 8.0% (1.0-26.0) 
8 9 1 11.1% (0.3-48.3) 
9 1 1 100% (2.5-100) 
Total 1,084 25 P Value for trend 0.003 
TE = thromboembolism, CI= confidence interval (Adapted from Lip, 2010 [20])  
 
      
Deep venous thrombosis (DVT) and pulmonary embolism (PE) 
Venous thromboembolism (VTE), which encompasses DVT and PE, is a common 
disease which is associated with high morbidity and mortality. Incidence of first VTE is 
around 1 per 1000 persons annually; and for those aged 75 years or older it increases 
to at least 5 per 1000 persons annually [23]. Around 10-20% of hospital medical 
inpatients could be expected to develop a VTE [24]. At initial VTE diagnosis, 42% of 
the patients present with DVT, 44% with PE, and 14% with both [25]. In around 10% 
of patients, clinically diagnosed PEs are rapidly fatal (within one hour), with an 
additional 5% mortality subsequently.  Thrombosis will recur within 3 months in around 
50% of non-treated patients with symptomatic DVT or PE. With recurrent VTE, the 
mortality rate is 2-3 times higher with PE compared to DVT [26]. The mortality rate 
within one month of diagnosis is around 6% for patients with DVT [27], and 12% for 
individuals with PE [28]. The mortality rate in patients with PE has been estimated to 
be twice that of DVT [29].   Generally, around 25-50% of patients presenting with first-
time VTE have an idiopathic condition, without a recognizable risk factor [29]. When 
no anticoagulant is used as prophylaxis, the incidence of DVT is estimated to be 42-
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57% and 41-85% with total hip arthroplasty (THA) and total knee arthroplasty (TKA), 
respectively, with a 0.1-2% and 0.1-1.7% incidence of fatal PE respectively [30].    
Anticoagulant therapy in patients with DVT or PE has two aims. First, 
anticoagulation used for treating the thrombotic event limits the extension of the 
thrombus, hence, permitting the fibrinolytic system to resolve the thrombus, a process 
which might take a total of 6 weeks. Second, it prevents, to a large extent, the 
development of additional thrombi. Therefore, for thrombus resolution, anticoagulation 
is required for 3 months or more, according to the clinical conditions. Whether to stop 
anticoagulants at 3 months or continue the therapy indefinitely is determined by the 
risk of recurrence, and secondarily affected by bleeding risk and patient preferences 
[31-33]. Therefore, treatment of VTE with anticoagulants has been classified into three 
stages: initial treatment, long-term treatment, and extended anticoagulation.    
During the initiation of warfarin treatment, overlapping (bridging) treatment with 
rapid-onset injectable anticoagulants (such as heparin or low molecular weight 
heparin) is recommended because of warfarin's slow onset of action [34]. However, 
with the new oral anticoagulants (NOACs), which have been introduced for clinical use 
recently, bridging treatment is not required owing to their quick onset of anticoagulant 
effect.  The use of new oral anticoagulants are recommended as long-term 
anticoagulant therapy over warfarin according to recent antithrombotic therapy for 
venous thromboembolism (VTE) disease guidelines published in Feb 2016 [33]. 
Further detailed information on NOACs is provided later in this chapter.       
    
Mechanical heart valve prostheses 
Prevention of valve thrombosis and systemic embolism is the main goal of 
anticoagulation in the presence of a mechanical prosthetic heart valve. Without 
antithrombotic treatment, the risk of major embolism has been estimated as 4.0 per 
100 patient-years, while the risk is decreased to 1.0 per 100 patient-years when oral 
anticoagulation is used [35]. Moreover, by using oral anticoagulation, the risk of valve 
thrombosis was decreased by 80% when compared with no treatment [35]. Thus, 
patients with mechanical prosthetic heart valves should be anticoagulated indefinitely. 
Aspirin is recommended in addition to warfarin in patients with mechanical heart valves 
who have additional risk factors which include atrial fibrillation, previous 
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thromboembolism, left ventricular dysfunction, and hypercoagulable condition  [36].   
The use of NOACs  in patients with prosthetic heart valve is not recommended because 
of the increased risk of thromboembolism [37].   
 
1.1.4. Determination of anticoagulation activity    
Prothrombin time (PT) is a laboratory test used for warfarin dosing and monitoring. 
PT varies depending on the thromboplastin used to measure how long the blood takes 
to clot.  The result, expressed as prothrombin time ratio (PTR), was initially used for 
monitoring warfarin dosing, but the non-standardization of thromboplastin led to 
problems.  Thus, if the commercial thromboplastin was less responsive, larger doses 
of warfarin were given to reach the target PTR. This led to over anticoagulation and a 
high incidence of bleeding. Therefore, a model was adopted by the World Health 
Organization (WHO) in 1982 to convert the PTR obtained by any reagent to an 
International Normalized Ratio (INR). This made a uniformity of anticoagulation control 
worldwide.  
The INR is calculated using the following formula: 
INR={
𝑃𝑇 (𝑝𝑎𝑡𝑖𝑒𝑛𝑡)
𝑃𝑇 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙
}
𝐼𝑆𝐼
=𝑃𝑇𝑅𝐼𝑆𝐼, where ISI is the international sensitivity index. ISI is 
quantified by commercial manufacturers for the specific thromboplastin reagent used 
in each batch and reported in the product package insert. 
Levels of three of the four vitamin K-dependent clotting factors, II, VII, and X, are 
reflected by the INR status. At the initiation or discontinuation of warfarin, PT/INR 
changes will reflect changes in the concentration of FVII, then FX, and finally FII; that 
is attributed to the different half-lives of these clotting factors (FVII=2-9 hours, FX=17-
44 hours, and FII=60-72 hours) [38].  After discontinuation of warfarin and without 
vitamin K administration, the INR level should  normalize within five to ten days as the 
mean effective warfarin half-life is around 40 hours [39].         
   For prevention of thromboembolism due to mechanical heart valve,  the 
recommended INR is between 2.5 and  3.5.  For most other conditions an INR target 
range of 2.0 to 3.0 is recommended ( Table 1-3 ).  
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Table 1-3: Clinical indications for warfarin 
Indication  INR target 
range 
VTE and pulmonary embolus 
Atrial fibrillation 
Coronary artery disease (controversial) 
Mechanical heart valves in aortic position 
Bioprosthetic heart valves in patients with risk factors* 
Secondary prevention of cerebrovascular accident (CVA) after failing 
antiplatelet therapy  
Secondary prophylaxis in antiphospholipid syndrome (APS) 
  
2.0 - 3.0 
APS patients who have VTE on therapeutic VKA 
Mechanical heart valves in mitral position 
Mechanical heart valves in aortic position with high risk factors* 
2.5 - 3.5 
*high risk patients include those with atrial fibrillation, previous VTE, left ventricular dysfunction, and 
hypercoagulable conditions. (Adapted from Moualla, 2011) [4]   
 
Recommendations for INR targets come mainly from clinical trials carried out in 
white/western, mainly Caucasian, people. These recommendations have been 
traditionally used to manage anticoagulation treatment in all ethnic groups.  More 
recently, it has been advised that an individualized target INR should be used to take 
into account the differences in ethnicity [40, 41].  
 
1.1.5. Epidemiology of anticoagulation use 
It is calculated that, in the UK,  over 1% of the population (around 600,000 
individuals) are prescribed warfarin [42]; about 8% of those above 80 years are taking 
warfarin, with the number of people requiring anticoagulation therapy rising due to a 
greater prevalence of AF associated with population longevity[3]. In the developed 
countries around 1-2% of the population are prescribed anticoagulants [43], and there 
were more than 33 million prescriptions dispensed in the US in 2011 [44].   
The use of new oral anticoagulants (NOACs) is increasing; however, warfarin 
currently remains the most commonly prescribed oral anticoagulant agent,  accounting  
for more than 75% of usage[45].   
 
 
 
 12 
 
1.1.6. Pharmacology and mechanism of action of warfarin 
The post ribosomal activation of clotting factors II,VII, IX, and X takes place by -
carboxylation of their N-terminals in the liver. The carboxylation reaction is catalyzed 
by the -glutamyl carboxylase enzyme which requires reduced vitamin K (vitamin K 
hydroquinone) as a cofactor. Vitamin K-hydroquinone is oxidized by -glutamyl 
carboxylase to 2,3 vitamin K epoxide. Anticoagulation by warfarin (which has a similar 
chemical structure to that of vitamin K) is accomplished by competitive inhibition of the 
vitamin K 2,3-epoxide reductase enzyme (VKOR) which is responsible for the repeated 
interconversion of the reduced form of vitamin K and its 2,3 epoxide in conjunction with 
-glutamyl carboxylase in the vitamin K cycle. Eventually, by the effect of warfarin on 
the vitamin K epoxide reductase complex 1 (VKORC1), regeneration of the reduced 
form of vitamin K is blocked.  The pharmacological action of warfarin is shown in Figure 
1-3.   
 
Figure 1-3: Warfarin mode of action and metabolism [1]  
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1.1.7. Pharmacokinetics and metabolism of warfarin 
Warfarin, which is marketed as a racemic mixture (50/50) of S and R enantiomers, 
is rapidly and completely absorbed from the gastrointestinal tract.  S- and R- warfarin 
result from asymmetry in warfarin carbon number 9. The S-enantiomer is 
pharmacologically three to five times more potent and has a shorter elimination half-
life (24-33 hours) than the R-enantiomer (35-58 hours) [46, 47].  Cytochromes P450 
(CYP), part of the microsomal mono oxygenase group of enzymes, are responsible for 
the oxidation of many exogenous chemicals and drugs, in addition to numerous 
endogenous substances. S-warfarin is metabolized mainly by the CYP2C9 enzyme. 
Genetic polymorphism, which influences both S- and R-warfarin metabolism, will be 
covered in section 1.1.18.   R-warfarin is metabolized by more than one CYP enzyme, 
as shown in Figure 1-3.  Racemic warfarin has a half-life of around 36-42 hours.  The 
elimination half-lives of the other VKAs acenocoumarol and phenprocoumon are 1.8–
6.6 and 110–130 hours, respectively [47]. Warfarin pharmacokinetic parameters are 
summarized in Table 1-4.  
  
Table 1-4: Pharmacokinetic parameters of warfarin 
     Warfarin  
Peak serum concentration  
Bioavailability (%) 
Protein binding (%) 
Elimination kinetics 
Metabolism 
 
Excretion (%) 
 
Half-life (hours) 
 
0.3–4 hours 
~ 100 
>99 
First-order 
Major: hydroxylation by hepatic cytochrome p450  enzymes 
Minor: keto reduction 
Renal: 80 
Faeces: 20 
R enantiomer: 35–58 
    S enantiomer: 24–33 
(Adapted from Lee, 2011) [48]   
  
 
1.1.8. Warfarin pharmacodynamics 
 Warfarin is a specific inhibitor of the vitamin K epoxide reductase enzyme (VKOR), 
which was identified in 1974 [49]. The VKOR enzyme is encoded by the vitamin K 
epoxide reductase complex subunit 1 (VKORC1) [50], which will be covered in section 
1.1.18. Warfarin exerts its anticoagulation activity by preventing the ability of VKORC1 
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to regenerate the active, reduced form of vitamin K (vitamin K hydroquinone) from its 
epoxide form.  The main target step in the coagulation cascade for warfarin is the 
conversion of prothrombin to thrombin, with the latter having an approximate half-life 
of 96 hours. There is a time lag for the full anticoagulant effect of warfarin. The 
anticoagulant effect of warfarin during the first 48 hours following warfarin initiation is 
dependent on the reduction of factors VII and IX (with half-lives of 5 and 24 hours, 
respectively). For acute anticoagulation four to five days overlap treatment with 
unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is 
recommended when starting warfarin therapy, as the activities of factors II (half-life = 
30-40 hours) and X (half-life = 60-70 hours) decrease slowly due to their long half-lives. 
Warfarin has no role in factors II, VII, IX, and X catabolism, lowering their plasma 
concentrations indirectly.  
  
1.1.9. Time-in-therapeutic range (TTR) 
TTR is a method of estimating quality of anticoagulation management and is 
defined as the estimated total percentage of time that the INR is within a pre-
determined therapeutic range [46]. TTR is a key method used to gauge the quality of 
VKA anticoagulation treatment [51, 52]. TTR is mainly calculated using the linear 
interpolation model  (assuming changes between consecutive INR readings are linear 
over time), also known as the Rosendaal method [53].  The Rosendaal method has 
been recommended by the American College of Chest Physicians (ACCP) for 
assessing sufficiency and quality of anticoagulation. It has been established that risk 
of major bleeding, ischaemic stroke, and all-cause mortality can be significantly 
predicted by TTR [54]. Moreover, it has been demonstrated that anticoagulation quality 
broadly differs between different countries. For example, as reported in RELY trial in 
the warfarin treated group, Taiwan had the lowest mean TTR of 44% and the highest 
was in Sweden at 77% (rank 1st ), whereas the mean TTR in the UK was 72% (rank 
4th ) [55]. An example of TTR calculation is shown in Appendix (A) page 213.  
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1.1.10. Frequency in range (FIR) 
FIR is another method of assessing the quality of anticoagulation control, it is also 
known as proportion of INRs in the therapeutic range and number of tests in range. It 
is estimated as the percentage of the total INR readings that are in the therapeutic 
range during the selected time interval. FIR has the advantage of being easier to 
estimate and can effectively be done manually compared to TTR which is relatively 
difficult measure to estimate and need a software programme. A recent study reported 
that the TTR and FIR showed widespread variability and disagreement, in which TTR 
values were higher than FIR at the patient level. The study suggested that TTR and 
FIR are not equivalent and cannot be used interchangeably [56]. Table 1-5 shows the 
advantages and disadvantages of TTR and FIR in assessing anticoagulation control. 
 
Table 1-5 Advantages and disadvantages of frequency in range and time in 
therapeutic range methods   
Methodology Advantage Disadvantage 
Frequency of INR in 
range (FIR) 
• Simple to calculate 
• Requires only one INR value per patient 
in clinic population 
• More frequent testing in unstable 
patients may bias overall results (will 
under-estimate TTR of group) 
 • Not influenced by extent of INR out-of-
range 
• Does not take into account actual days 
within target range 
• Does not consider individual patients 
   
Time in therapeutic 
range (Rosendaal 
linear interpolation) 
• Takes into account actual days in target 
range 
• Allows one to calculate INR specific 
incidence rates of adverse events 
• Calculation more difficult 
• Makes assumptions about INR 
between actual tests 
• Does not consider individual patients 
• Extreme out-of-range INR values may 
bias overall results 
(Adapted from Schmitt, 2003 [57]) 
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1.1.11. Warfarin initiation and maintenance therapy   
Warfarin is prescribed usually empirically, in which an initial dose is given, followed 
by at least weekly INR measurement, and further dose adjustment. The initial dose 
may depend on population average, e.g. 3-5 mg/day in Asians or 5-10 mg/day in 
Caucasians [49, 58]; however, stable doses to reach the target INR range of 2.0-3.0  
range between 0.5-20 mg per day.   The process to achieve the desired dose by “trial 
and error” adjustments could take weeks to months, during which patients are at 
particular risk of over- or under- anticoagulation and hence at risk of thrombosis or 
bleeding [59].  
Warfarin is characterized by many drug and food interactions, as well as genetic 
polymorphisms leading to variability in its metabolism and pharmacological activity. 
These, together with patient age and body size and some as yet unestablished factors, 
give rise to a 40-fold inter-individual variability in warfarin maintenance dose 
requirement (0.5 to 20 mg daily) to attain the same degree of anticoagulant intensity. 
Currently, there is no other commonly prescribed drug which resembles warfarin in this 
regard [60].       
The risk of bleeding caused by excessive anticoagulation is greatest during the 
initiation phase of warfarin therapy. Figure 1-4 shows the risk of bleeding events with 
increasing INR.  Several warfarin dosing regimens have been developed and tested in 
an attempt to improve warfarin safety. There is debate as to whether a 
pharmacogenetics-based loading dose improves the safety of warfarin (please refer to 
section 1.1.18 for further detail). In addition, there is debate about the optimal  
frequency of monitoring  during maintenance therapy in order to keep patients within 
their target therapeutic INR range as frequent monitoring is expensive for health care 
systems and burdensome for patients and physicians [61]. 
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Figure 1-4: The influence of INR on bleeding risk[40] 
 
 
It has been noted that evidence-based models can be underused for warfarin 
maintenance dosing by primary care physicians and specialists [62].  The American 
College of Chest Physicians (ACCP) recommended the commencement of warfarin 
with doses between 5 mg and 10 mg for the first 1 or 2 days for most patients, with 
subsequent dosing based on INR value [38, 63].  A systematic review has shown that 
there is no advantage of using the traditional 10 mg loading dose over 5 mg, but clinical 
practice has been slow to adopt the new recommendation. There is evidence that lower 
starting doses or doses adjusted by age might be even more beneficial, leading to 
fewer supratherapeutic INR values [64].  
The maximum acceptable follow-up interval to measure INR in some services 
seems to be dependent on prescriber discretion and experience, in spite of the 
existence of evidence-based dosing guidelines.  For example, Rose, et al, 2011, 
studied 100 Veterans’ Health Administration sites of care; these sites managed 
104,451 patients taking warfarin. Each site had a specialized anticoagulation clinic. 
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The study estimated the mean follow-up interval after low (≤1.5) or high (≥4.0) INR. 
57% of the patients were assigned to the low INR analysis, and 36% of the patients 
were assigned to the high INR analysis. The average interval until the next INR reading 
was 6-18 days after a high INR, and 10-24 days after a low INR. The study suggested 
that, after getting the first or second therapeutic INR reading, the maximum interval 
should be 28 days. However, after getting the third or higher consecutive INR 
therapeutic reading, a longer interval might be acceptable [65, 66].  
On the other hand, Schulman, et al, (2011), in a non-inferiority randomized study 
recruited 250 patients and monitored their warfarin dose every 12 or 4 weeks. Every 
12 weeks monitoring of warfarin dosing was found efficient and comparable to every 4 
weeks monitoring. However, the study was done in one centre, and patients in the 12-
week group were seen and examined by clinic staff  regularly every 4 weeks [67].  
 
1.1.12. Warfarin failure and resistance 
Warfarin resistance should be differentiated from warfarin failure. Warfarin failure 
is defined as a new thrombotic episode in the presence of a therapeutic INR. Around 
5% of patients will have had a recurrent thrombotic episode by 3 months after starting 
treatment. Risk factors for recurrent thrombosis include previous history of an 
idiopathic VTE, sub-therapeutic anticoagulation, malignancy, antiphospholipid 
antibody syndrome (APLAS), and rare inherited thrombophilia such as antithrombin, 
protein C and S deficiency [46]. Warfarin resistance is defined as “the inability to 
prolong the prothrombin time or raise the INR into the therapeutic range when the drug 
is given at normally prescribed doses”. Warfarin resistant patients are defined as those 
requiring more than 15 mg daily. Warfarin resistance might be due to extrinsic factors 
such as low treatment compliance (the most common cause), drug interactions, food 
interactions, or hereditary factors. Warfarin resistance related to genetic factors is not 
well characterized. Osinbowale, has suggested an algorithm to evaluate and manage 
suspected warfarin resistance [68].     
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1.1.13. Warfarin therapy complications  
Since warfarin is a difficult-to-control medication, the main complications occur 
from supra-therapeutic (the most common) or sub-therapeutic status, which results in 
haemorrhage or thrombosis, respectively.  It has been demonstrated in the USA that 
the most common drug-related cause of hospitalisation for adverse events among 
older adults is related to warfarin use, which accounted for 33% of cases requiring 
hospitalisation. From 2007-2009, it was estimated that 21,010 hospitalisation cases 
were due to warfarin related bleeds [69].  
Major bleeding episodes related to warfarin usage have been estimated to be 
between 1.3% and 4.2% per annum [70]. In those bleeding as a result of warfarin 
toxicity, 0.4-2.0% need blood transfusion, hospitalization, or surgery [39]. A study has 
shown that around 1 in 10 major haemorrhages were fatal, and 1 in 12 patients re-bled 
after warfarin was restarted [71]. Intracranial haemorrhage is the most serious adverse 
effect caused by excessive anticoagulation, affecting  about 4 per 1000 patients on 
warfarin annually [72], with a mortality rate approaching 50% [73]. Warfarin is one of 
the ten drugs most regularly responsible for elderly patients visiting the emergency 
department because of an adverse drug reaction [74].   It has been demonstrated that 
the risk of bleeding in patients aged 80 years or above and having an INR of ≥4.0 is 
increased by more than 22 times [75]. Acute bleeding events requiring a visit to the 
emergency department associated with the use of antiplatelet drugs, clopidogrel and 
aspirin, have been calculated to be 12 per 10,000 outpatient prescription visits whereas 
twice as many number of cases were recorded, 25 per 10,000 outpatient prescription 
visits, for warfarin usage (Risk Ratio = 0.49, 95% CI, 0.15-0.83) [76]. In the UK, 
absolute risk of harm is high as between 10-24 cases of bleeding occur per 100 
patients using warfarin per annum [42]. A systematic review of the medical literature 
has advised that there is no association between covariates described in the warfarin 
prescribing information and enhanced bleeding risk, except possibly for those suffering 
from renal disease, and malignancy [77].  
For all these reasons and others, it has been estimated that warfarin is 
underutilized in AF patients by 60-70% [8]. Data predating NOAC availability 
suggested that, of AF patients with indications for anticoagulation for stroke prevention, 
only about 50% are treated with warfarin [78].  Physicians are hesitant to prescribe it 
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[79], and patients prefer to stop taking it [80].  A study found that 26% of patients aged 
80 years or over discontinued warfarin within the first year of treatment due to safety 
issues [75]. The outcome is that high-risk patients eligible for warfarin therapy who are 
not treated with it are at greater risk of stroke [81].  
Because of the difficulties with warfarin therapy, various methods have been 
implemented to enhance anticoagulation management, such as initiating specialised 
anticoagulation clinics for routine monitoring, launching of dosing algorithms and 
dosing software programmes to improve dosing efficiency, and improving treatment 
compliance among patients through education programmes [82].       
   
1.1.14. Other non-bleeding adverse reactions associated with warfarin 
treatment 
 Skin necrosis is an unusual complication occurring in the first few days of 
warfarin treatment, more commonly in women. It is associated with a high 
warfarin dose of more than 10 mg daily. Lesions are typically seen in the 
extremities [83].   
 Purple toes syndrome is another rare complication. It occurs from 3 to 10 weeks 
after starting warfarin therapy, and is characterized by dark, purplish or mottled 
colour of the toes. This syndrome is reversible.  However, in some instances, it 
progresses to necrosis, which requires debridement or amputation [83].    
 Patients with frail skin (e.g., elderly, or those using steroids long term), or with 
over anticoagulation, may develop ecchymosis and purpura [84].  
 Macular-papular, vescicular, or urticarial itchy rashes may occasionally occur 
after several weeks or months from commencement of treatment [84].    
 
1.1.15. Management of supratherapeutic INRs with and without bleeding 
Reversal of excessive anticoagulation is commonly required in patients using 
warfarin.  Variations in INR might be attributed to one or more of the following 
situations: (a) incorrectness in INR measurements; (b) changes in vitamin K intake; (c) 
changes in vitamin K or warfarin absorption; (d) changes in warfarin metabolism; (e) 
changes in vitamin K-dependent coagulation factor synthesis or metabolism; (f) some 
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effects related to  concomitant drug use or comorbidities; or (g) patient noncompliance 
[38].  
 
1.1.15.1. Warfarin antidotes 
Patients on warfarin have decreased levels of functional coagulation factors II, VII, 
IX, and X. Different modalities are available to treat supra-therapeutic INR and warfarin 
induced bleeding resulting from clotting factors II, VII, IX, and X deficiency. These 
include the administration of vitamin K, prothrombin complex concentrate (PCC), 
recombinant activated FVII (rFVIIa), and fresh frozen plasma (FFP).    
 
Vitamin K 
Where anticoagulation by warfarin does not require immediate reversal (where the 
risk of bleeding in the patient is low), vitamin K is a cheap and effective antidote; it 
works by enhancing endogenous production of functional vitamin K-dependent clotting 
factors. Vitamin K is administered intravenously for the swift reversal of excessive INR 
in patients deemed to be at significant risk of bleeding [39, 85]. Anticoagulation reversal 
is attained within 6-12 hours if vitamin K is given intravenously, compared to 18-24 
hours when it is given orally [45]. The subcutaneous route is no more effective than 
placebo, and the intramuscular route may lead to haematoma and bleeding in an over-
anticoagulated patient, in addition to having unpredictable absorption so these routes 
should not be used [85].   
 
Prothrombin complex concentrate (PCC) 
There are two kinds of PCCs, 3-factor PCC which contains factors II, IX, and X, 
and 4-factor PCC which contains factors II, VII, IX, and X. Advantages of PCC 
compared to FFP comprise its fast onset of action, quick reconstitution into a small 
volume for infusion over 20-30 minutes, no need for determination of blood group of 
the recipient, minimal risk of cross contamination, and lower risk of other adverse 
effects such as volume overload [85].  Moreover, clotting factor concentration in PCC 
is about 25 times higher than that available in plasma [45].  A systematic review, 
comparing 3-factor against 4-factor PCC, showed that the INR was normalised (≤1.5 
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within hour of administration) more effectively with 4-factor [86]. However, the 
systematic review lacked direct comparison studies between 3-factor and 4-factor 
PCC. In a prospective observational study, 4-factor PCC was compared against FFP 
for treatment of intracranial bleeding. 4-factor PCC reversed the anticoagulation 
significantly in a shorter time compared to FFP (65 minutes vs 256 minutes, P<0.05) 
[87]. 3-factor PCC is not recommended as it is poor at correcting INR compared to 4-
factor PCC which is able to totally antagonize the warfarin-induced anticoagulation 
within 10 min [38]. 5-10 mg intravenous vitamin K should be administered with the 4-
factor PCC because the infused clotting factors in the PCC have a limited half-life, the 
shortest of which is FVII at 6 hours, to stimulate clotting factor production. The only 
PCCs approved for warfarin reversal in the UK are 4-factor PCCs [38].  
 
Recombinant activated FVII (rFVIIa) 
 It has been shown that rFVIIa rapidly corrects the INR; however, its impact on 
stopping bleeding is unclear and its use is not approved for warfarin reversal in the UK 
[38].  
 
Fresh frozen plasma (FFP) 
 FFP is administered as a blood group specific product, and has to be thawed 
before use. The blood group of the recipient needs to be determined before 
administration. Theoretically, one unit of each clotting factor is present in each milliliter 
of FFP. FFP possesses exogenous clotting factors and has a quick onset of action, but 
because of its short half-life, it has a temporary effect on INR. As it offers a diluted form 
of clotting factors more than one liter of FFP may be required to normalise the levels 
of clotting factors. As it may not be feasible to infuse very large volumes of plasma 
(15–30 ml/kg) rapidly (the FFP typical dose is 10-15 ml/kg), this is a major obstacle to 
FFP efficacy. Other disadvantages of FFP are the risk of volume overload in frail and 
elderly recipients (mitigated if they are losing blood), and increased risk of infectious 
disease transmission. Moreover, as FFP produces poorer correction of INR compared 
to other agents, it cannot be recommended for life-threatening bleeding.   
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  Anticoagulation management prior to surgery  
Anticoagulation has to be reversed before most surgical interventions in order to 
avoid serious bleeding intra-operatively. In consequence, stopping warfarin 5 days 
prior to elective surgery is recommended [88].   
The optimal choice for warfarin reversal depends on the time available before 
surgery, the capability of estimating and managing blood loss, injury risk, and whether 
anticoagulation is needed after surgery. Vitamin K should be administered 
intravenously for procedures that could be delayed for 6-12 hours when urgent surgery 
is required. PCC should be used when the surgical procedure cannot be delayed, 
accompanied by intravenous vitamin K to provide sustained anticoagulation reversal 
[45]. As shown in Table 1-6, many minor surgical procedures have a low risk of 
bleeding, and warfarin reversal might not be needed although this can be controversial 
[39]. 
 
Table 1-6: Bleeding risk and type of surgery 
Low risk of bleeding 
- minor surgery 
- percutaneous needle procedures in readily 
compressible sites 
- dermatological procedures 
- routine dental procedures 
- cataract procedures 
-Ideal target is INR of 2.0  
- If INR<2.5, the patient can proceed to 
surgery 
- If INR is >2.5, decide whether the level 
of anticoagulation is safe for surgery to 
proceed. 
High risk of bleeding 
- all major surgery/surgery in which a body 
cavity is entered 
- percutaneous needle procedures in non-
compressible sites 
- organ biopsies - prostatic surgery 
- sites where bleeding can be catastrophic, e.g., 
intracranial and some opthalmological 
procedures 
-Target INR<1.5 
- Supplement with heparin if required, 
e.g., patients with prosthetic valves. 
(Adapted from Grobler, 2010) [39] 
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Anticoagulation reversal according to guidelines (4th edition), published in 
the British Journal of Haematology 2011 [89]   
Major bleeding 
If the reversal of warfarin anticoagulation is urgently needed due to major bleeding, 
25–50 u/kg of 4-factor PCC should be used with 5 mg intravenous vitamin K. rVIIa is 
not recommended. If PCC is not available, FFP should be used as it produces 
suboptimal anticoagulation reversal. 
 
Non-major bleeding 
1–3 mg intravenous vitamin K should be used for reversal of anticoagulation for 
non-major bleeding.  
 
Head injury in patients on warfarin 
INR should be measured as soon as possible, and a head CT scan should be done. 
If a strong possibility of intracerebral bleed is present, the anticoagulation should 
reversed before the results of any investigations are known.  
 
Non-bleeding with INR>5.0 and <8.0 
For patients without bleeding, if their INR is >5.0, they should stop warfarin for 1-2 
doses, and their maintenance dose should be reduced also; and if their INR is >8.0, 
they should also receive vitamin K 1-5 mg orally.  
 
It is feasible to stop warfarin and wait until the INR  returns to the required 
therapeutic range in case of asymptomatic supra-therapeutic INR without 
administration of vitamin K. Vitamin K may be used to lower a high INR in such a case; 
however, lowering INR too much in asymptomatic patients might increase the 
thrombotic propensity, or warfarin resistance may develop once warfarin is restarted 
[90].             
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Anticoagulation reversal according to guidelines published by the American 
College of Chest Physicians 2012, 9th edition [63] 
The guidelines are summarised in Table 1-7. 
 There are many similarities between the American and British guidelines; 
however, rVIIa is not recommend by the British guidelines for use in major bleeding, 
whereas it is recommended by the American ones.  
 26 
 
 
 
Table 1-7: Recommendations for managing high INRs or bleeding in patients receiving VKAs according to ACCP guidelines  
Condition Intervention 
INR more than therapeutic range 
but < 5.0; no significant bleeding 
Lower dose or omit dose; monitor more frequently and resume at lower dose when INR therapeutic; if only minimally 
above therapeutic range, no dose reduction may be required 
INR≥ 5.0, but< 9.0; no significant 
bleeding 
Omit next one or two doses, monitor more frequently, and resume at an appropriately adjusted dose when INR in 
therapeutic range. Alternatively, omit dose and give vitamin K (1–2.5 mg po), particularly if at increased risk of bleeding. 
If more rapid reversal is required because the patient requires urgent surgery, vitamin K (≤ 5 mg po) can be given with 
the expectation that a reduction of the INR will occur in 24 h. If the INR is still high, additional vitamin K (1–2 mg po) can 
be given 
INR ≥ 9.0; no significant bleeding Hold warfarin therapy and give higher dose of vitamin K (2.5–5 mg po) with the expectation that the INR will be reduced 
substantially in 24–48 h. Monitor more frequently and use additional vitamin K if necessary. Resume therapy at an 
appropriately adjusted dose when INR is therapeutic. 
Serious bleeding at any elevation 
of INR 
Hold warfarin therapy and give vitamin K (10 mg by slow IV infusion), supplemented with FFP, PCC, or rVIIa, depending 
on the urgency of the situation; vitamin K can be repeated q12h. 
Life-threatening bleeding Hold warfarin therapy and give FFP, PCC, or rVIIa supplemented with vitamin K (10 mg by slow IV infusion). Repeat, if 
necessary, depending on INR. 
Administration of vitamin K In patients with mild to moderately elevated INRs without major bleeding, give vitamin K orally rather than subcutaneously 
(Adapted from  Ansell, 2008[38])
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1.1.16. Patient factors which influence warfarin sensitivity 
1.1.16.1. Age  
Higher warfarin sensitivity and lower warfarin dose requirements are associated 
with advancing age [91], with older women requiring the lowest warfarin doses to 
achieve the same degree of anticoagulation intensity [92]. This is linked to liver mass 
shrinkage in elderly people which leads to decrease in liver capacity to eliminate 
warfarin and also a reduction in the synthesis of vitamin K-dependent clotting factors 
[93]. Plasma protein binding is decreased by 15%-25% which leads to an increase in 
the free warfarin concentration initially [94]. It has been shown that  mean warfarin daily 
dose requirement deceased by 0.5 to 0.7 mg every 10 years between the ages of 20 
to 90 years [95]. Age has been consistently identified as a significant contributor to 
warfarin dose requirements in multiple linear regression models used to develop 
warfarin dosing algorithms [95-97]. 
 
1.1.16.2. Body Mass Index (BMI) 
As the effect of body size on warfarin dosing is confounded by other variables, such 
as age, polypharmacy, comorbid diseases, and presence of genetic polymorphisms, 
the influence of BMI on warfarin has not been firmly established [91, 94, 98, 99].  An 
association between body size and warfarin dose is likely to be indirect and reflect the 
link between liver size and dose, body size being positively correlated with liver size. 
Although the association between body weight and VKA dosing was not confirmed in 
a recent review of studies due to the variability in the methods of the 32 studies 
included, evidence suggests that at the time of VKA commencement, obese or 
morbidly obese patients require a 30-50% larger dose of warfarin than do people of 
standard weight[99].  
  
1.1.16.3. Alcohol consumption  
The anticoagulation activity of warfarin is affected by consumption of even small 
amounts of alcohol. Free unbound warfarin has been estimated to be increased by 3-
34% with alcohol consumption [100]. The anticoagulation effect of warfarin might 
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increase after consumption of a few drinks in one sitting, putting the individual at a 
higher risk of bleeding. Alcohol enhances the anticoagulant effect of warfarin by 
inhibiting its metabolism by cytochrome P450 enzymes in the liver. In contrast, long-
term ingestion of alcohol by chronic drinkers induces cytochrome P450, and hence 
warfarin metabolism; thus larger warfarin doses are needed to attain the required 
anticoagulation effect. As alcohol can both inhibit and promote warfarin's metabolism, 
it is advisable to check the INR if the patient has a sudden change in the amount of 
alcohol consumed, for example, stopping or ingesting more than 3 alcoholic drinks 
daily [101-103].   
 
1.1.16.4. Nutritional Status 
Warfarin interacts with certain foods and supplements which can lead, 
unintentionally, to a reduction or increase in its anticoagulant effect.  Ingestion of 
regular meals has no effect on warfarin bioavailability; however, fluctuations in 
consumption of vitamin K containing foods such as  green leafy vegetables or 
supplements containing vitamin K, in particular, affect anticoagulation response [104-
106].    
 
1.1.16.4.1. Vitamin K  
In 1929, vitamin K was discovered accidentally by Henrik Dam (1895-1976), the 
Danish nutritional biochemist, as part of sterol metabolic experiments, and it was linked 
to blood coagulation.  He found that chickens had a bleeding diathesis when they ate 
a fat-free diet. In 1935, Dam was able to rule out cholesterol as the missing agent and 
named this fat soluble compound as vitamin K for “Koagulations vitamin”. 
Subsequently, vitamin K1 was isolated from alfalfa, and vitamin K2 from putrefied fish. 
Edward Doisy (1893–1986) was able to identify and synthesize the chemical structure 
of vitamin K1 (2-methyl-3-phytyl-1,4-naphtoquinone), and vitamin K2  (2-methyl-3-(all 
trans-farnesylfarnesyl)-1,4-naphthoquinone) to have an unsaturated polyprenyl side 
chain at the 3-position of the naphthoquinone ring [107, 108]. The Nobel Prize for 
Physiology or Medicine in 1943 was granted to Henrik Dam of the Polytechnic Institute 
of Copenhagen, Denmark, for his “discovery of vitamin K” and to Edward Adelbert 
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Doisy of the Saint Louis University at St. Louis, Missouri, for his “discovery of the 
chemical nature of vitamin K” [109].    
 
1.1.16.4.2. Chemical structures of vitamin K compounds 
Products present in nature with vitamin K activity have in common a functional 
methylated naphthoquinone (2-methyl-1,4-naphthoquinone) ring system, and an 
aliphatic side chain consisting of isoprenoid residues [110]. Vitamin K compounds differ 
in the structure of their isoprenoid side chain at position-3, and are classified into 
vitamin K1 to 3. Vitamin K exists naturally in food as phylloquinone with a phytyl side 
chain (or vitamin K1, 2-Methyl-3-phytyl-1, 4-naphthoquinone) and as bacterially 
synthesized menaquinones (MK-n, or collectively vitamin K2, 2-Methyl-3-multiprenyl-
1, 4-naphthoquinone) with unsaturated multi-prenyl side chains. Menadione (or vitamin 
K3, 2-Methyl-1, 4-naphthoquinone) is a synthetic water soluble vitamin K present in 
animal feed, and hence enters the human food chain indirectly. Menaquinone-4 (MK-
4, 2-Methyl-3-geranyl-geranyl-1,4-naphthoquinone), a short chain vitamin K2, is 
converted from phylloquinone or produced endogenously from menadione. 
Menaquinones (MK-7 to MK-11), the long chain vitamin K2, are synthesized in the 
intestine by micro-flora, for example, MK-10 and MK-11 produced by bacteroides, MK-
8 by enterobacteria, MK-7 by veillonella species [111]. Vitamin K as a supplement 
comes only from either phylloquinone, MK-4, or MK-7. Only synthetic phylloquinone 
and MK-4 are used therapeutically; phylloquinone is used in the treatment of 
haemorrhagic disease of the new-born and as an antidote to vitamin K antagonists 
(VKA), whereas MK-4 is used for osteoporosis. MK-7, a naturally fermented product, 
is used in dietary supplements for maintaining bone health [112]. 
Figure 1-5 shows the chemical structures of the vitamin K compounds. All forms of 
vitamin K serve one major function which is as a cofactor for the post-translational 
enzyme -glutamate carboxylase for activation of clotting proteins.  
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Figure 1-5: Chemical structure of vitamin K compounds  
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1.1.16.4.3. Dietary sources  
Green leafy vegetables are the main dietary source for phylloquinone which is 
present in concentrations ranging between 400 to 700 µg/100 gm, confirming the 
established association between phylloquinone and photosynthetic tissues, the 
darker green the leaf the higher the phylloquinone concentration.  The second best 
sources are certain vegetable oils (such as soybean, rapeseed and olive oils) with 
varying concentrations of 50 to 200 µg/100 gm. When these oils are regularly 
consumed as part of a daily diet, they make a significant contribution towards the 
daily intake of vitamin K. Other vegetable oils, such as peanut, corn, sunflower and 
safflower oils have lower phylloquinone concentrations (1 to 10 µg/100 gm). A 
comprehensive list of common foods containing vitamin K compiled by the United 
States Department of Agriculture (USDA) National Nutrient Database, can be 
accessed online from the following link 
(http://www.nal.usda.gov/fnic/foodcomp/Data/SR18/nutrlist/sr18w430.pdf) [94]. Table 
1-8 provides vitamin K content of some commonly eaten foods. 
 
Table 1-8: Common foods containing Vitamin K, and its amounts* 
Moderate (50-99 µg) High (100-400 µg) Very High (401-1800 µg) 
Black-eyed peas (cooked) 63 
Broccoli (raw) 89 
Cabbage (cooked) 73 
Lettuce- iceberg, green leaf, romaine 
(raw) 50-97 
Okra (cooked) 88 
Prunes 65 
Rhubarb (frozen) 71 
 
Broccoli (cooked) 220   
Brussels sprouts (cooked) 219 
Dandelion greens (cooked) 203 
Endive (raw) 115 
Lettuce- butter head, red leaf 
(raw) 130-166 
Parsley (raw), 10 sprigs, 164 
Scallions (raw) 207 
Sauerkraut (canned) 135 
Spinach (raw) 144 
Beet greens (cooked) 697 
Collard greens (cooked) 1059 
Kale (cooked) 1146 
Mustard greens (cooked) 419 
Spinach (cooked) 888 
Turnip greens (cooked) 529 
 
 
*Serving size: one cup unless otherwise specified. (Adapted from White, 2010 [94]) 
 
Long-chain menaquinones (MK-6 to MK-13) are present in various amounts in 
animal livers. According to quantitative HPLC analysis, livers from ruminant species 
(such as cow) contain values of some menaquinones (e.g., MK-7, MK-11, MK-12, and 
MK-13) in a range of 10-20 µg/100 gm. Other animal organs (such as kidney, heart, 
and muscle) are nutritionally not significant sources of menaquinones as they contain 
very low concentrations. Menaquinones are present in cheese (10-20 µg/100), other 
fermented dairy products and eggs (≤2 µg/100 gm) and fermented soya-containing 
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food [113, 114]. Table 1-9 shows menaquinone concentrations in dairy foods and 
fermented food products. Phylloquinone consumption has been reported to vary 
greatly between populations (70 to 250 µg per day), mirroring different patterns of food 
consumption in different geographical regions [115-117].     
 
Table 1-9: Menaquinones concentrations in dairy foods and fermented food 
products 
       Food Menaquinones 
MK-4 MK-5 MK-6 MK-7 MK-8 MK-9 MK-10 
Milk (µg/100ml) 
Whole 0.8 0.1 ND ND–2.0 ND ND ND 
Buttermilk 0.2 0.1 0.1 0.1 0.6 1.4 ND 
Yogurt 
Whole 0.6–1.0 0.1–0.3 ND–0.2 ND–0.4 0.2–2.0 ND–4.7 ND 
Skimmed ND ND ND ND ND–0.1 ND ND 
Cheese(µg/100ml) 
Curd 0.4 0.1 0.2 0.3 5.1 18.7 ND 
Hard 4.7–10.2 1.5 ND–3.0 ND–2.3 ND–16.9 ND–51.1 ND–6.5 
Semihard NR NR 1.0–3.5 ND–2.1 2.5–7.3 10.0–32.1 ND–13.8 
Soft 3.7 0.3 0.4–2.6 ND–1.7 2.1–14.0 6.6–94.0 ND–5.7 
Other(µg/100ml) 
Salami 9.0 ND ND ND ND ND ND 
Sauerkraut 0.4 0.8 1.5 0.2 0.8 1.1 ND 
Natto ND–2.0 7.5 13.8 939–998 84.1 ND ND 
ND=not determined (Adapted from Walther, 2013 [118]) 
 
1.1.16.4.4. Vitamin K pharmacokinetics 
Vitamin K as phylloquinone, among all fat-soluble vitamins, has the highest inter- 
and intra- individual variability ratios for fasting plasma and diet concentrations, even 
after taking into consideration the effect of the different food matrices. Most of the 
circulating vitamin K is believed to be obtained from the diet, and not from other vitamin 
K forms by metabolic conversion.  Dietary vitamin K is absorbed in the proximal 
intestine. Around 80% of an oral phylloquinone dose is absorbed as free form when 
administered to healthy adults. However, the efficiency of phylloquinone absorption 
from natural food is affected by the types of the foods eaten; for example, 
phylloquinone absorption is increased in the presence of fatty food. As no specific 
plasma carrier protein has been identified for vitamin K, it is probably transported 
completely by lipoproteins. Dietary vitamin K is integrated, chemically unchanged, into 
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chylomicrons in the intestinal mucosa, secreted into the lymph, and finally enters the 
liver via chylomicron remnant particles. Ingested vitamin K is taken to the liver and 
possibly other body parts, including bone marrow, in the form of chylomicron remnants. 
After reaching plasma, vitamin K levels show temporal fluctuations, with a mean 
maximum at 10 pm and mean minimum at 10 am, and the levels of plasma triglyceride 
reflect vitamin K levels changes. Phylloquinone absorption is reduced in subjects with 
biliary insufficiency or malabsorption syndromes.            
Although the majority of vitamin K is retained in the liver, the capacity for liver 
storage is limited, with a half-life of 10-15 hours. In humans, vitamin K is stored in the 
liver as around 90% menaquinones and 10% phylloquinone. Around 75% of the 
original stored amount will have been lost after 3 days of severe dietary deprivation. 
As phylloquinone dietary consumption is significantly correlated with fasting plasma 
levels [113, 119], vitamin K plasma concentration closely reflects hepatic reserves. The 
median hepatic concentration of phylloquinone in adults is about 5 ng/gm of liver.  
Compared to long-chain menaquinones, phylloquinone is the main circulating form 
of vitamin K, and its level is considerably lower compared to other fat-soluble vitamins. 
MK-4 has been found predominantly in certain extra-hepatic sites, such as pancreas, 
salivary gland and brain.  Independently of intestinal bacterial action, MK-3 has been 
shown to be a metabolite of vitamin K1, MK-4 and MK-7.  The common hepatic forms 
MK-9 and MK-13 are not detectable in plasma (which might be attributed to their 
different route of absorption), whereas MK-7 and possibly MK-8 are present.  
Vitamin K is mainly metabolized in the liver. Regardless of the amount of the dose, 
around 20% is excreted in the urine, and around 40-50% is excreted into bile and 
excreted via faeces.  Phylloquinone is extensively catabolized by the liver to water-
soluble metabolites which rapidly appear in the plasma, urine, and bile. Thus, around 
60-70% of the amounts of phylloquinone absorbed from each meal will eventually be 
lost to the body by excretion. The Recommended Dietary Allowance (RDA) of vitamin 
K is ≥1µg/kg/day (65-80 µg for adult males and 55-65 µg for adult females), which has 
been suggested to be adequate to maintain a normal prothrombin time; however, the 
National Academy of Science recommends a higher daily intake of vitamin K (90µg for 
women and 120µg for men) for maintaining healthy bones and vascular integrity  [100, 
112, 114, 120-123].  
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1.1.16.4.5. Safety of excessive vitamin K intake 
Cases of toxicity from phylloquinone or menaquinones have not been reported. 
Whilst it has been claimed that high amounts of vitamin K could cause over-
coagulation, increasing risk of thrombosis, in reality, more -carboxylation or extreme 
coagulation could not be achieved as vitamin K dependent clotting factors have a 
limited number of glutamate residues capable of -carboxylation per molecule. 
Therefore, the use of menaquinones as a source of vitamin K added for nutritional 
purposes presents no safety concerns when used as low doses, as concluded by the 
European Food Safety Authority [117, 124]. 
 
1.1.16.4.6. Warfarin and dietary vitamin K interaction  
Vitamin K status influences warfarin sensitivity both during the initiation and 
maintenance therapy. Sconce, et al, in 2007 [125] hypothesized that variability in the 
consumption of food containing vitamin K would lead to a larger impact on 
anticoagulation outcome in patients with low vitamin K status compared with those with 
higher vitamin K status. They found that patients with low vitamin K intakes spent a 
lower amount of time in their therapeutic range (TTR) than patients with high vitamin 
K intake. Subsequently, in a randomized controlled study, Sconce et al, demonstrated 
that unstable patients who were given daily oral vitamin K supplementation 
experienced more stable control of anticoagulation, with a significantly higher reduction 
in standard deviation of INR versus their counterparts who received placebo (-
0.240.14 vs. -0.11 0.18; P<0.001). Moreover, those given vitamin K had a 
significantly higher increase in the percentage TTR (28%20% vs. 15%20%; P<0.01) 
[125]. With regard to improving anticoagulation control, patients should be educated to 
consume consistent daily amounts of vitamin K.  There is now sufficient evidence to 
indicate that daily vitamin K supplementation improves stability of anticoagulation 
control in previously unstable patients [70, 126-128].  
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1.1.16.5. Comorbidity 
1.1.16.5.1. Liver disease 
Production of coagulation factors V, VII, X, and prothrombin formation are 
decreased in liver disease, which is reflected by increased sensitivity to warfarin [129]. 
Contributory factors are hypoalbuminaemia, decreased vitamin K dietary intake, 
vitamin K malabsorption and a dysfunction in the carboxylation process, which is the 
essential step in the synthesis of vitamin K-dependent clotting factors, and  a reduction 
in warfarin metabolism [94]. 
 
1.1.16.5.2. Renal disease 
Warfarin is metabolised by the liver and excreted renally, with a very small amount 
excreted unchanged; therefore, warfarin dose adjustment in chronic renal failure is not 
required. Renal insufficiency can influence bleeding risk in warfarin users related to 
uraemic state and simultaneous use of heparin in dialysis sessions. A study reported 
that the mortality rate increased by 27% (HR=1.27, 95% CI=1.18-1.37) in patients on 
warfarin undergoing hemodialysis [130]. Another retrospective large study, in which 
data from 132,372 patients were analysed, showed that among patients with renal 
disease, the risk of bleeding increased by 33% (HR=1.33, 95% CI= 1.16 to 1.53, 
P<0.001) compared to those with no renal disease [131]. Patients with renal 
insufficiency receiving warfarin therapy should therefore be closely monitored. 
 
1.1.16.5.3. Thyroid disease 
Warfarin clearance does not appear to be affected by thyroid dysfunction [132]. 
However, warfarin sensitivity increases in hyperthyroidism, and this might be related 
to enhanced prothrombin and factor VII catabolism, or vitamin K-dependent clotting 
factor reduction. Consequently, due to the interaction between warfarin and drugs used 
to treat hyperthyroidism which  affect thyroid hormones concentrations, a  lower 
warfarin dose is required at the time of initiation, which should be increased later once 
euthyroidism is achieved [133]. In hypothyroidism, warfarin dose requirement is 
increased, and INR should be monitored more frequently, especially at the time of 
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starting thyroid replacement treatment; upon achieving euthyroidism, warfarin dose 
should be reduced accordingly [94, 133].  
 
1.1.16.5.4. Fever 
There are several anecdotal reports suggesting that fever increases sensitivity to 
VKAs. A very recent study reviewed data published from 1943 to 2014 about the effect 
of fever on the response to VKAs. The study showed that the extent by which fever 
potentiates anticoagulation response to VKAs is variable and is possibly contributed to 
by enhancement of vitamin K-dependent clotting proteins catabolism, reduction in 
vitamin K intake, and VKA metabolism inhibition [134].     
      
1.1.17. Drug interactions  
There are many drugs which interact with warfarin, sometimes resulting in serious 
adverse events [3, 30]. Interactions which enhance or inhibit the activity of warfarin by 
pharmacokinetic or pharmacodynamic mechanisms are shown in Table 1-10.  
 
Table 1-10 High-quality evidence of interactions of warfarin with commonly 
prescribed medications 
 Potentiate warfarin  
(increase INR) 
Inhibit warfarin 
(decrease INR) 
No interaction 
 
Medications with 
high quality data 
for interaction 
 
Amiodarone, 
clofibrate, 
fluconazole, 
metronidazole, 
omeprazole, 
propafenone, 
ciprofloxacin, 
quinidine, 
tamoxifen,     
phenytoin (initial phase) 
Barbiturates, 
carbamazepine, 
cholestyramine, 
nafcillin, rifampin, 
 
Atenolol, 
fluoxetine, 
famotidine, 
metoprolol, 
ibuprofen, 
ketoconazole 
(Adapted from Moualla, 2011 [4]) 
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1.1.18. Pharmacogenetics 
The term  pharmacogenetics was first used in the late 1950s [135], and is defined 
as the study of how genetic differences between people affect drug response [94]. 
There is a large overlap between pharmacogenetics and the recent discipline of 
pharmacogenomics, which uses the whole genome-approach to elucidate the inherited 
basis of differences between persons and their response to drugs [136], and the two 
terms are often used interchangeably. The main objective of pharmacogenetics and 
personalized medicine is to introduce the right dose of the right drug to the right 
individual.  Genetic variants are used in pharmacogenetics fundamentally to classify 
subgroups of patients who may respond differently to a specific group of drugs.  
Anticoagulation response to warfarin is influenced by a number of factors including 
genetics. I will hereon describe polymorphisms in the genes that express enzymes 
which mediate both warfarin pharmacokinetics and pharmacodynamics.  
 
1.1.18.1. CYP2C9 Polymorphism 
As mentioned in section 1.1.7, warfarin is prescribed as a 50:50 mixture of R- and 
S- enantiomers. CYP2C9 is the primary metabolizing enzyme for S-warfarin. Body 
weight, age, sex, and specifically CYP2C9 genotype have a strong influence on S-
warfarin clearance; factors which significantly affect R-isomer clearance are body 
weight, age, and genotypes of CYP2C19, and CYP3A4 [137].  
Coding variation in the CYP2C9 gene, which is located on chromosome 10, leads 
to the presence of proteins with altered catalytic actions. A minimum of 34 allelic 
variants of CYP2C9 as markers related to warfarin dosing have been reported [46].  
CYP2C9*1 is the primary wild-type allele (most common).  All other CYP2C9 
genotypes are compared with CYP2C9*1, since it is considered the reference. Each 
named CYP2C9 star (*) allele is defined by a genotype at one or more specific single-
nucleotide polymorphisms (SNPs) and is linked with enzyme activity. Variation in the 
CYP2C9 gene in exon 3, with substitution of a cysteine for arginine at position 144 
produces the CYP2C9*2 allele (C430T, rs1799853), and substitution of leucine for 
isoleucine at amino acid position 359 produces the CYP2C9*3 allele (A1075C, 
rs1057910) in exon 7. CYP2C9*2 and CYP2C9*3 are considered the most common 
variants. Considering that autosomal chromosomes are paired, persons can be 
 38 
 
homozygous for each of the alleles (CYP2C9 *1*1, CYP2CP *2*2, or CYP2C9 *3*3), 
or heterozygous (CYP2C9 *1*2, CYP2C9 *1*3, or CYP2C9 *2*3). The reduction of S-
warfarin metabolism is attributed to enzymes expressed through these alleles. Patients 
with CYP2C9*1 (wild type gene / normal metabolizer) metabolize warfarin faster than 
those with CYP2C9*2 genotype (30% reduction of enzyme activity), and in turn 
patients with CYP2C9*2 metabolize warfarin faster than those with CYP2C9*3 
genotype [43, 138]. CYP2C9 enzyme activity is the lowest in patients who are 
homozygous for *3*3, in which the activity is decreased by 80%. Enzymatic activity 
reduction is subsequently associated with slower warfarin metabolism and decreased 
warfarin clearance [95, 139, 140].  Therefore, a higher maintenance dose is required 
for persons who are homozygous for the CYP2C9*1 allele, versus CYP2C9*2 and 
CYP2C9*3 homozygotes, respectively, and for *3*3 carriers the required warfarin dose 
is the lowest. A study has confirmed that the average warfarin maintenance doses vary 
across CYP2C9 variant alleles, compared to wild-type carriers enzyme activity is at 
87% in CYP2C9*1*2, 72% in CYP2C9*2*2, 59% in CYP2C9*1*3, 42% in CYP2C9*2*3, 
and 28% in CYP2C9*3*3 [140]. Warfarin dose in those with single allele of CYP2C9*2 
or CYP2C9*3 is reduced by 1 and 1.6 mg/day, respectively, as shown in a meta-
analysis study [141].  
Aithal et al, in 1999 were the first to demonstrate a strong association between 
CYP2C9 genotype and warfarin sensitivity, and found that those requiring  low warfarin 
doses (≤1.5 mg per day) were more than six times more likely to carry one or two of 
CYP2C9 variant allele (*2 or *3) than those requiring more than 1.5mg per day[142].  
In a meta-analysis study published in 2005, Sanderson et al demonstrated the 
association between CYP2C9 genotype and warfarin dosing, and suggested that no 
further studies are required to confirm this association, at least in Caucasians [143].  
In 2002, the association between CYP2C9 genotype and anticoagulation status or 
bleeding was firstly reported by Higashi et al [140]. People with one or more alleles of 
CYP2C9*2 or *3 are at higher risk of bleeding (around 3-4 times) during warfarin 
therapy, need lower doses to attain similar anticoagulation levels, and need more time 
to reach a stable INR, compared with those with CYP2C9*1 allele, [94, 141, 142, 144-
146]; however, the risk of bleeding is decreased once warfarin maintenance dose is 
achieved during long-term therapy. 
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In the European-American population,  CYP2C9*2 and CYP2C9*3 variants are 
more common than in the African-American population [147].  For the CYP2C9*2 
genotype, 22% of Caucasians are found to be heterozygous (*1*2), and 1% to be 
homozygous (*2*2). Homozygous (*3*3) and heterozygous (*1*3) genotypes are found 
in 0.4% and 15% of Caucasians, respectively. Another 1.4% of Caucasians are found 
to be (*2*3) heterozygous.    
 
1.1.18.2. Vitamin K Epoxide Reductase Complex Sub Unit 1 Polymorphism   
VKORC1 is the gene that encodes the vitamin K-epoxide reductase enzyme 
(VKOR), the target protein for warfarin. The conversion of vitamin K-epoxide to vitamin 
K is the rate limiting step in vitamin K recycling. Two groups independently discovered 
VKORC1 in 2004, and described that polymorphism of VKORC1, which is located in 
chromosome 16,  is significantly associated with warfarin sensitivity and lower dose 
requirements [50, 148]. Rieder et al sequenced the VKROC1 gene from 186 
Caucasians and determined ten common SNPs in various regions (also known as 
haplotypes) of the gene [149]. These SNPs are “in strong linkage disequilibrium” with 
each other, which means that they are very close on the chromosome, and a variant 
allele in one position usually suggests a variant allele in the other. Based on linkage 
disequilibrium values between SNPs, 9 VKORC1 haplotypes have been identified. 
Group A haplotypes (H1, H2) were associated with lower warfarin doses, and group B 
haplotypes (H7, H8, H9) were associated with higher warfarin doses independent of 
CYP2C9 *2 and *3 status.  SNPs were used to classify haplotype groups; a low-dose 
haplotype (A), and a high-dose haplotype (B). As with CYP2C9 allele variations, 
patients can be classified into B/B (homozygous for B) with normal activity which 
requires higher warfarin dose, A/A (homozygous for A) with lowest activity which 
requires lower warfarin dose, and A/B (heterozygous for A and B) with average activity 
which requires average warfarin dose [150]. Further analyses have demonstrated that 
genotyping patients for either of the two SNPs in high linkage disequilibrium ( 1173C 
> T rs9934438 switch in intron 1 and the -1639G > A  rs9923231 switch in the promoter 
region, located 1639 nucleotides upstream from the ATG start codon) explains nearly 
identical percentages in the variability of warfarin dosing and could substitute for 
haplotype A [151]. Therefore, VKORC1 allele variations could also be classified as AA 
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(or TT) (mutant homozygous with lower enzyme activity), AG (or CT) (heterozygous 
with intermediate enzyme activity), and GG (or CC) (wild homozygous with 
higher/normal enzyme activity).  Lower maintenance doses of warfarin are required for 
VKORC1 variants compared to wild-type variants [152]. D'Andrea and colleagues have 
confirmed this; they found that the mean warfarin dose was higher (6.2 mg/day) in 
patients with the VKORC1 1173CC genotype than that in patients with the CT (4.8 
mg/day; p=0.002) or TT genotype (3.5 mg/day; p<0.001), independently of the 
presence of confounding variables [153]. As it has been reported in the literature, 
VKORC1 polymorphism is associated with variability in warfarin dose requirement and 
anticoagulation response [50, 149, 153, 154]. 
VKORC1 complex prevalence varies in different populations. In Caucasians, the 
prevalence for this mutation is 14% AA, 47% AG, and 39% for GG [155], Table 1-11 
shows the frequency of VKROC1, and CYP2C9 *2 and *3 in different ethnic groups. 
 
 Table 1-11: CYP2C9 *2*3 and VKORC1 haplotypes among different ethnicities 
 European–American African–American Asian 
CYP2C9*2 0.14 0.02 0.0 
CYP2C9*3 0.06 0.01 0.04 
VKORC1 haplotype A group 0.42 0.21 0.85 
VKORC1 haplotype B group 0.57 0.58 0.14 
VKORC1 haplotype other 0.01 0.21 0.01 
Low-dose group 0.55 0.22 0.86 
Haplotype A and 2C9 variant 0.18 0.01 0.06 
(Adapted from Eby, 2011  [156]) 
 
The association between VKORC1 and CYP2C9 genotypes and warfarin 
therapeutic dose has been established in several ethnic groups [69, 157]. For example, 
patients with wild-type CYP2C9*1*1 and VKORC1-1639GG require doses in the range 
of 5 to 7 mg daily, whereas those with double variants CY92C9 *3*3 (the slowest 
metabolizers) and homozygous VKORC1 -1639AA (highly sensitive to warfarin) 
require therapeutic warfarin doses ranging between 0.5 and 2.0 mg daily [156, 158]. 
In a Japanese population, the median warfarin daily dose also varied significantly, the 
lowest at 2.0 mg per day was reported in the  CYP2C9 *3*3 and VKORC1 1173TT 
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group, and the highest at 3.5 mg per day in the CYP2C9 *1*1 and VKORC1 1173CC 
group (P=4.4 x 10-13) [159].  
Table 1-12 shows an example of warfarin dose prediction for an average or typical 
patient. Although age, weight, gender, and other clinical factors collectively were found 
to account for about 12% of warfarin dosing variability [160], CYP2C9 and VKORC1 
genotypes were found to account for 35% of variability [153]. Only around 60% of 
warfarin dosing variability is explained by pharmacogenetics-based algorithms, 
whereas the causes for the remaining 40% of the variability are still poorly understood 
[161]. 
 
Table 1-12: Warfarin dose prediction in a typical patient* 
VKORC1 Genotype 
CYP2C9 Genotype 
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 
GG 6 5 4 4 3.5 3 
GA 5 4 3 3 2.5 2 
AA 3 2.5 2 2 2 1.5 
*Typical patient= (65 years old, male, Caucasian, body surface area 2.0, nonsmoker, no other 
concomitant medications, with atrial fibrillation, target international normalized ratio of 2.5) 
(Adapted from Kim, 2009  [160]) 
 
In 2007, the US Food and Drug Administration (FDA) updated its warfarin product 
label to contain information on pharmacogenetics. This change did not contain a 
genotype-based dose modification recommendation; thereafter, from 2010, based on 
data from around 15,000 patients, the product label has precise advice with tables on 
how to use a patient’s genotype (i.e. VKORC1, CYP2C9*2 and CYP2C9*3) to 
anticipate the therapeutic dose needed in an individual patient [162]. Information about 
VKORC1 and CYP2C9 genotypes have been included in warfarin labels by other 
medical agencies such as the European Medicines Agency (EMA) [163]. However, 
none of these agencies mandated using of genotyping information before the initiation 
of warfarin therapy. In consequence, genotyping is used only in some specialist health 
centres to aid warfarin dosing [164]. 
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1.1.18.3. Polymorphisms in other genes 
Both CYP1A2 and CYP3A4, the major metabolizing enzymes for R-warfarin, have 
been screened for genetic polymorphism. For CYP1A2, a SNP in intron 1 (C163A) has 
been associated with increased enzyme activity although it has been observed only 
among tobacco smokers [165]. CYP1A2 polymorphism does not appear to influence 
warfarin dose requirements although CYP1A2 contributes to warfarin metabolic 
clearance [166]. CYP3A4 is a major contributor to the metabolism of many drugs 
including R-warfarin, and shows a great degree of variability within individuals. Several 
polymorphisms have been reported for CYP3A4 gene; however, they are very low in 
frequency in the general population, and their functional significance is uncertain [166]. 
CYP3A5 genotype, another member of CYP3A family, shows no effect on R-warfarin 
clearance and warfarin dose requirements [166].    
Mutation in CYP4F2 gene (V433M; rs2108622; C>T nucleotide substitution), which 
metabolises vitamin K, was first reported as a contributor to warfarin dose requirements 
in Europeans, with those with homozygous variant allele requiring higher warfarin 
doses [167]. The polymorphisms in CYP4F2 enzyme result in its reduced vitamin K 
metabolising activity. As a result, patients carrying the polymorphism require larger 
dose of warfarin to achieve the same level of anticoagulation intensity as those without 
the CYP4F2 polymorphism.  However, recently, CYP4F2 polymorphism has been 
identified as the least contributor (1 to 5%) towards warfarin dose compared to 
CYP2C9 and VKORC1 polymorphisms [163, 168].  
It has been identified that apolipoprotein E (APOE) genotype, which is a major 
component of plasma lipoprotein involved in the transportation of lipids, affect 
lipoprotein uptake by hepatocyte. Polymorphisms in APOE can affect sensitivity to 
VKAs because vitamin K is transported bound to lipoprotein including APOE [121], and 
therefore APOE genotype might influence the rate of hepatic vitamin K uptake. ε2, ε3, 
and ε4 are the three alleles which encode APOE variants with functional differences. 
Many studies have been conducted examining the effect of APOE genotype as 
predictor of VKAs dose requirement, with contradictory results; some studies showed 
positive contribution while the others showed negative contribution towards dose 
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requirement. In general, all the previous studies have shown that the overall 
contribution of APOE genotype to warfarin dose requirement is low [43, 168].    
In the vitamin K cycle, -glutamyl carboxylase enzyme (GGCX) is a vitamin K-
dependent enzyme which activates several coagulation proteins by modification of 
glutamic acid residues by carboxylation. GGCX gene exhibits a single polymorphism. 
This polymorphism was identified to have a small effect (2%) on warfarin dose 
requirements in a European population [169].   
Calumenin is a calcium binding protein, that when overexpressed in animal model 
it binds and inhibits VKOR, and hence protects the enzyme from warfarin inhibition. 
Calumenin was also found to target the carboxylase enzyme and thus prevent the 
effective transfer of the reduced active form of vitamin K from VKOR to the carboxylase 
enzyme, which it also inhibits, promoting warfarin resistance.  
Two polymorphisms have been reported in microsomal epoxide hydrolase encoded 
gene. Microsomal epoxide hydrolase is responsible for the hydrolysis of epoxides to 
trans-hydrodiols and works as vitamin K 2,3-epoxide binding site. Warfarin dose 
requirements is shown not to be influenced by polymorphisms in either calumenin or 
microsomal epoxide hydrolase genes [43, 168]. 
 
1.1.18.4. Pharmacogenetic-based dosing algorithms  
The main aim of warfarin genotype-guided therapy is to decrease the risk of 
bleeding by avoiding over-anticoagulation (supratherapeutic INR), and the risk of 
thrombosis by avoiding under anticoagulation (subtherapeutic INR) particularly during 
the initiation phase of warfarin therapy [170]. Therefore, it would be beneficial to predict 
an individual's initial warfarin doses accurately by implementing genetic testing, which 
has been shown to decrease the number of INR tests and number of dose adjustments 
required to reach the therapeutic INR range [160].  
Most of the pharmacogenetics-based dosing algorithms for VKAs have been based 
on studies involving Caucasian populations, although some algorithms have been 
developed from data from Asian populations. These algorithms are particularly helpful 
in identifying those patients who require low doses of warfarin and therefore who might 
be at increased risk of bleeding if dosed according to conventional dosing algorithms. 
The most well studied genetic alleles that have an influence on warfarin dosing are 
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CYP2C9*2, CYP2C9*3, and VKORC1 -1639, whereas several polymorphisms have 
been found to be associated but are less well studied[171]. Compared to Caucasians, 
the prevalence of the minor alleles CYP2C9*2, CYP2C9*3, and VKORC1 -1639 are 
much lower among African Americans. These algorithms therefore show more clinical 
advantages for Caucasians and Asians [44], for whom they predict around 50-60% of 
warfarin dose variability whereas they predict only 20% of the dosing variability in 
African Americans [97].   
Three separate genome-wide association studies (GWAS) [172-174] have 
established the association between CYP2C9, VKORC1, and CYP4F2 polymorphisms 
and warfarin dose requirement [163], with VKORC1 contributing the most and CYP4F2 
the least.  
The joint effect of polymorphisms in CYP2C9 and VKORC1 has been 
demonstrated to be responsible for about 35% of warfarin dosing variability. 
Furthermore, around 20% of the interpersonal differences in warfarin dosing has been 
attributed to the joint effects of age, comorbid diseases, nutrition, sex, smoking, and 
co-administered drugs [40, 152]. Pharmacogenetic dosing algorithms are available 
online, such as, http://warfarindosing.org/ and http://www.pharmgkb.org/ [96].  
IWPC and Gage algorithms are the two most commonly cited algorithms.  Data 
collected from 4,043 patients (55% Caucasians, 30% Asians, and 9% Blacks) were 
used to develop pharmacogenetic algorithms in The International Warfarin 
Pharmacogenetics Consortium (IWPC) study. The study was a collaborative work 
between 21 research groups from nine countries, including UK (Newcastle and 
Liverpool) across four continents. The developed algorithms, in which CYP2C9 and 
VKORC1 genetic polymorphism were incorporated, were validated in a group of 1,009 
subjects. The study demonstrated that warfarin dosing based on the pharmacogenetic 
algorithm was more accurate in maintenance dose prediction compared to the clinical 
or fixed-dose algorithm. It was also observed that patients who required a warfarin 
dose of ≤ 21 mg/week or ≥49 mg/week benefited greatly from the pharmacogenetic 
algorithm, with little difference between the predicted and actual dose in those requiring 
>21 or <49 mg/week [175].  The pharmacogenetic-based dosing algorithm developed 
in the IWPC study has been used as a basis for warfarin dosing in two recent RCTs 
[163].   
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In a US study, data of 1,015 patients on warfarin (83% Caucasians, 15% African 
Americans, and 2% Hispanics) were used to develop the Gage algorithm [97]. Both 
CYP2C9 and VKORC1 genetic polymorphisms were incorporated in the algorithm, 
which was validated prospectively in a group of 292 subjects commencing warfarin 
treatment. The study demonstrated that VKORC1 was the most important predictor of 
dose when commencing warfarin. It was found that, by incorporating CYP2C9 and 
VKORC1 genotypes in the pharmacogenetic algorithm, 53-54%, of the variability in 
warfarin dose could be explained compared to 17-21% when the clinical algorithm was 
used.   
 
1.1.18.4.1. Pharmacogenetics-based dosing algorithms in ethnic groups 
African–Americans are significantly under-represented in pharmacogenetic studies 
of warfarin, and Hispanics are even less well represented [69], as demonstrated by the 
IWPC and Gage studies [97, 175].         
Whereas CYP2C9*2 and *3 alleles account for 9-12% of the variability in warfarin 
dose requirement, the dose variability is significantly lower for African-Americans; and 
20-28% of total dose variability is explained by the VKORC1 allele in Caucasians, 
whereas for  African-Americans it is 5-7% [69]. Since warfarin pharmacogenetic 
algorithms have largely been developed using Caucasian populations, by comparison 
African-Americans, for whom accurate algorithms are lacking, might be at greater risk 
of adverse outcomes as a consequence of sub-therapeutic anticoagulation caused by 
under-dosing [69]. Hernandez et al 2014, developed a specific warfarin dosing 
algorithm for African Americans, and found that the use of the algorithm allowed more 
accurate prediction of the stable therapeutic warfarin dose, which was within 20% of 
the actual dose, compared to IWPC algorithms [44]. Limdi et al 2015 and Sheth et al 
2015 showed that the impact of predictors on warfarin dosing requirements varies by 
ethnicity, and they recommended that warfarin dosing algorithms should be stratified 
by ethnicity rather than adjusted for ethnicity [176, 177].   
It is worth mentioning that most of commercially available genotyping assays do 
not detect rare CYP2C9 and VKROC1 alleles that may affect warfarin dosing [144]. 
Specifically, variants in African Americans that are predictive of warfarin dose 
requirements are not included in most algorithms, even in the FDA-approved warfarin 
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dosing table or FDA-cleared genotyping platforms [69]. Lack of their inclusion will likely 
have resulted in lower performance of pharmacogenetics-based dosing algorithms in 
such populations.  Therefore, there is a need to develop appropriate warfarin 
pharmacogenetics-based dosing algorithms for ethnic groups of patients as genetic 
structure and genotype frequencies differ between different races.  Table 1-13 shows 
gene alleles frequency, including rare ones, contributing to warfarin response among 
different ethnicities.  
   
Table 1-13: Gene allele frequency contributing to warfarin response among 
different ethnicities  
Allele  Location  
Frequency 
European 
Caucasians 
US 
Hispanics 
African– 
Americans 
CYP2C9*2   Exon 3 10% 7% 2% 
CYP2C9*3 Exon 7 6% 5% 1% 
CYP2C9*5 Exon 7 <1% <1% 1% 
CYP2C9*6 Exon 5 <1% <1% 1% 
CYP2C9*8 Exon 3 <1% <1% 6% 
CYP2C9*11 Exon 7 <1% <1% 4% 
CYP2C9 rs7089580 Intronic 24% 11% 23% 
VKORC1 -1639A 5-UTR 40% 46% 11% 
VKORC1 rs61162043 5-UTR Unknown Unknown 47% 
CYP4F2 433M Exon 2 23% 22% 9% 
(Adapted from Cavalalri, 2012) [69] 
 
1.1.18.4.2. EU-PACT and COAG studies  
The results of two large prospective multi-centre randomized clinical trials, the US 
trial Clarification of Optimal Anticoagulation through Genetics (COAG) [178] and the 
European trial Pharmacogenomic Approach to Coumarin Therapy (EU-PACT) [179] 
investigating the extent to which pharmacogenetics-guided dosing improves the safety 
of oral anticoagulation therapy have been recently published. The COAG trial 
evaluated the merits of pharmacogenetics-based dosing for warfarin whilst EU-PACT, 
which was made up of 3 separate arms, evaluated the impact of pharmacogenetics-
based dosing on the safety of warfarin, acenocoumarol and phenprocoumon. The 
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warfarin arm of the EU-PACT study was carried out in the UK (Newcastle and 
Liverpool) and Sweden where newly diagnosed patients with thromboembolism were 
recruited and randomized to either a genotype-guided dosing regimen or a fixed 
loading dose regimen, whereas the COAG study compared genotype-guided dosing 
versus a clinical dosing algorithm. The primary outcome measure was percentage time 
within target INR (TTR) in both studies; in EU-PACT TTR was assessed over the first 
3 months of therapy, and from day 4/5 after treatment initiation to day 28 in COAG. 
The  COAG study failed to show a difference in terms of TTR between those treated 
with genotype-guided dosing and those treated with a clinical algorithm (45.2% vs 
45.4%, P=0.91, mean difference of 0.2%), while EU-PACT demonstrated that 
genotype-guided dosing significantly improved TTR compared to the fixed-dose 
regimen (67.4% vs 60.3%, P<0.001, mean difference of 7%).  
Of relevance, there was more ethnic variation in COAG (67% White, 27% Black, 
and 6% Hispanic) compared to EU-PACT (>98% White). In the COAG study, African-
American patients experienced significantly lower TTR in the genotype-guided dosing 
group compared to those in the clinically guided group (35.2% vs 43.5%, P=0.01, mean 
difference of 8.3%). It has been established that the frequencies of CYP2C9*2 and 
CYP2C9*3 alleles are much higher in European Caucasians (10% and 6%, 
respectively) than in African Americans (2% and 1%, respectively), and the frequency 
of the VKORC1-1639A allele is 40% in European Caucasians and 11% in African 
Americans [69]. Other SNPs are found only in African Americans, such as CYP2C9*8 
and CYP2C9*11, with a frequency of 6% and 4%, respectively [69]. These genotypes 
were not considered while dosing African Americans individuals, and this could to 
some extent explain why there was an 8% deterioration in TTR in African Americans 
in the genotype-guided dosing group compared to clinically guided group [163]. 
  
1.1.19. The effect of ethnicity on warfarin sensitivity  
Racial and cultural diversity has a significant impact on warfarin dose 
requirements. It has been demonstrated that Hong Kong Chinese patients need only 
50% of the warfarin maintenance dose of Caucasian patients to achieve the same 
degree of anticoagulation intensity. The mean warfarin dose for Asian patients resident 
in southern California is about 40% lower than that for Caucasian or Hispanic patients. 
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Likewise, the adjusted average weekly warfarin dose needed to sustain INR readings 
in the range of 2.0 to 3.0 was lowest in Asian Americans, and highest in African 
Americans, compared to Hispanics and Caucasians [138]. The observed racial 
differences in warfarin dose requirements were contributed to by racial differences in 
genotype frequencies between the different ethnicities [69], Table 1-14 and Table 
1-15.18% of  warfarin dose variability in Caucasians is explained by CYP2C9 and 30% 
by VKORC1 polymorphisms, whereas these variants account for less of the dose 
variability among Asian and African people [144].    
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Table 1-14: Warfarin daily dose requirements for CYP2C9 variants among different ethnicities 
 Mean ± S.D. range of warfarin sodium dose by CYP2C9 variant (mg/day) 
Ethnicity *1*1 *1*2 *1*3 *2*2 *2*3 *3*3 
Caucasian 4.08 ± 2.13–   
7.20 ± 3.7 
3.56 ± 1.82–    
4.88 ± 2.57 
2.70 ± 1.38–    
3.80 ± 1.6 
1.92 ± 1.12–    
4.30 ± 1.6 
1.58 ± 0.79–     
2.58 ± 0.81 
0.78 ± 0.2–    
1.60 ± 0.81 
Japanese 2.50–3.60 ± 1.7 NA 1.80 ± 0.5–2.00 NA NA 2.00 
Chinese/Malay/East 
Indian 
3.9 ± 1.8 for any 
*1 allele 
4.0 for any *2 
allele 
2.5 ± 1.6 for any 
*3 allele 
See *1/*2 See *1/*2 and *1/*3 See *1/*3 
(Adapted from Gulseth, 2009  [180]) 
 
 
Table 1-15: Warfarin daily dose requirements for VKORC1 variants among different ethnicities 
 Mean ± S.D. Range of Warfarin Sodium Dose by VKORC1 Haplotype (mg/day) 
Ethnicity A/A A/B B/B 
Japanese 2.50–3.30 3.50–5.40 4.00–7.00 
Chinese 2.93 ± 1.22–3.12 ± 1.20 4.38 ± 1.68–4.96 ± 1.53 6.50 and 6.75 
Malay 2.70 ± 1.02 3.90 ±1.2 5.10 ± 1.92 
East Indian 1.98 ± 0.90 4.92 ± 1.74 5.58 ± 2.22 
Caucasian 2.11–3.77 ± 0.2 3.49–5.20 ± 0.40 5.48–7.30 ± 0.60 
African/African American 2.50 4.73 5.71 
(Adapted from Gulseth, 2009  [180])
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1.2. New oral anticoagulants   
1.2.1. Introduction  
Vitamin K antagonists as a class, warfarin in particular, have been the cornerstone 
for the treatment and prophylaxis of thromboembolic disorders for decades. 
Anticoagulation response to warfarin is difficult to predict because of its wide inter-
individual variability in clinical response, as well as interaction with many drugs and 
foods. As a result significant efforts have been made to develop safer alternative drugs 
which obviate the need for frequent dose adjustment/monitoring along with minimal 
food and drug interactions. Initially these were known as “novel” oral anticoagulant 
(NOACs), but because this designation expires after one year several alternative terms 
have been suggested. These include Target-Specific Oral antiCoagulants (TSOCs), 
Direct Oral AntiCoagulants (DOACs), Oral Direct Inhibitors (ODIs), Non-monitored Oral 
AntiCoagulants (NOACs), Non-warfarin Oral AntiCoagulants (NOACs), Non-vitamin K 
antagonist Oral AntiCoagulants (NOACs). To avoid confusion, the European Society 
of Cardiology (ESC) Working Group on Thrombosis Task Force on Anticoagulants in 
Heart Disease, and others recommends keeping the  “NOAC” acronym to indicate 
“Non-vitamin K antagonist Oral AntiCoagulants” [181, 182]. For this reason I will be 
using the latter throughout my thesis.  
Compared to warfarin, NOACs have a more predictable anticoagulation response 
and a wider therapeutic index, and as such they, do not need frequent monitoring as 
is the case with warfarin. Moreover, NOACs are characterized by quick onset and 
offset of action, which avoids the necessity for bridging with heparin in many clinical 
situations.  Table 1-16 shows some of the advantages of NOACs compared to 
conventional anticoagulants.   
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Table 1-16: Advantages of newer anticoagulants over conventional 
anticoagulants 
Conventional anticoagulants Newer anticoagulants 
Effective As or more effective than current 
agents Significant adverse effects As or afer than current agents  
Oral/SC/IV Oral  
Dose variable Fixed dosing  
Significant food and drug interactions Minimal food and drug interactions 
Unpredictable anticoagulant response 
(needs monitoring) 
Predictable anticoagulant response 
(no monitoring)  
Slow onset and offset of action Rapid onset and offset of action 
Irreversible  Reversible  
(Adapted from Ranganathan, 2013 [183]) 
 
1.2.2. Historical background to NOACs 
Ximelagatran (the prodrug of the active agent, melagatran), a direct thrombin 
inhibitor (DTI), was the first novel oral anticoagulant which was developed by 
AstraZeneca. It was marketed in 2005, but was withdrawn from the market in 2006 
[184] because of hepatic toxicity, despite its initial promising results [185-187]. 
Ximelagatran was compared with  warfarin in patients with AF in the SPORTIF III study 
[188], and in stroke prophylaxis in atrial fibrillation (SPAF) [60]. It was also studied in 
other clinical trials versus LMWH for VTE prevention after major orthopaedic surgery 
[60].  Initially, similar efficacy and haemorrhage rate was observed compared to 
warfarin and LMWH.  Later, it was found that the hepatotoxicity was related to 
ximelagatran alone and was not generalisable to this class of drugs.  
Four NOACs have so far been approved for clinical use; the direct thrombin 
inhibitor, dabigatran, and FXa inhibitors rivaroxaban, apixaban, and edoxaban, Figure 
1-6 shows their chemical structures.    
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Betrixaban, the direct factor Xa inhibitor, is the latest investigational NOAC that has 
been shown to have the lowest renal clearance and hepatic metabolism and longest 
half-life among the NOACs [189], but it will not be discussed here.   
 
  
Figure 1-6: NOACs chemical structures (Adopted from http://www.chemspider.com) 
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1.2.3. Pharmacological properties of NOACs  
After oral administration, NOACs have a rapid onset of action with peak plasma 
levels reached  at 1-4 hours [2, 190]. This compares favourably to warfarin where the 
anticoagulant effect takes at least 4-5 days to reach the therapeutic range [38]. 
Consequently, initiation of anticoagulation therapy is easier with NOACs than with 
warfarin.  
Warfarin is characterised by having a longer half-life, of around 40 hours [38], 
compared to the half-lives of NOACs, which range between 5-17 hours [2, 190]. This 
property makes NOACs management easier, and might reduce the need for specific 
antidotes in critical bleeding situations, or when an urgent intervention or surgery is 
required.     
Whereas warfarin is minimally excreted renally, all four NOACs are excreted to 
varying degrees via the kidneys. Dabigatran, rivaroxaban, apixaban, and edoxaban 
are excreted renally by 77%, 36%, 21-24%, and ~50%, respectively. Therefore, the 
active drug accumulates in the presence of kidney dysfunction [2, 190], which 
increases the risk of bleeding.      
Both rivaroxaban and apixaban are metabolised by the cytochrome P (CYP) 450 
enzyme system, whereas dabigatran and edoxaban are not. All four NOACs are 
substrates for p-glycoprotein (P-gp). Therefore, drug-drug interactions with dabigatran 
and edoxaban differ from those with rivaroxaban and apixaban [2, 190]. 
Table 1-17, Table 1-18 and Table 1-19 summarise NOACs pharmacological 
properties, drug interactions, and drugs contraindicated with their use, respectively.   
 
 
 
 
 
 
 
 54 
 
  
 
Table 1-17: Pharmacological properties of NOACs 
  Dabigatran Rivaroxaban Apixaban Edoxaban 
Time to Cmax (h) 2 2–4 3–4 1–2 
Half-life (h) 12–17 5–9 ~12 10–14 
Bioavailability (%) 3–7 ≥ 80 50 62 
Renal elimination (%) 80 66 27 50 
Protein binding (%) 35 92–95 87 55 
Transporters P-gp P-gp/BCRP P-gp P-gp 
Potential drug 
interactions 
P-gp 
inhibitors and 
inducers 
Potent dual 
inhibitors of 
CYP3A4 and P-gp 
Potent dual 
inhibitors of 
CYP3A4 and P-gp 
Potent P-gp 
inhibitors and 
inducers 
(Adapted from Weitz, 2016) [190] 
 
 
 
Table 1-18: NOACs drug interactions 
Mechanism Dabigatran Rivaroxaban, 
apixaban, 
edoxaban 
P-gp inhibition Interacting drug Interacting drug 
Ketoconazole Ketoconazole 
Quinidine 
Amiodarone 
Verapamil 
P-gp induction Rifampicin Rifampicin 
St. John’s Wort St. John’s Wort 
CYP3A4 inhibition  Ketoconazole 
 Clarithromycin 
 Ritonavir 
CYP3A4 induction 
 
 Rifampicin 
  Carbamazepine  
 
  Phenobarbital 
  Phenytoin  
(Adapted from Schulman, 2013 [191])  
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Table 1-19: Contraindicated drugs with NOACs 
Dabigatran Rivaroxaban, 
Apixaban,  
Edoxaban 
Quinidine Azole antimycotics Quinidine (dose should 
be adjusted)   Ketoconazole 
Itrakonazole 
Vorikonazole 
Posakonazole 
 HIV protease inhibitors 
 Ritonavir 
(Adapted from Schulman, 2014 and Lip, 2014 [191, 192])  
 
1.2.4. Clinical indications for NOACs  
The US Food and Drug Administration (FDA) approved dabigatran, rivaroxaban, 
apixaban, and edoxaban in 2010, 2011, 2012, and 2015, respectively, for clinical use 
in adults. They are indicated to reduce the risk of stroke and systemic embolism in 
patients with non-valvular AF, and for treatment of DVT and PE. In patients undergoing 
knee or hip replacement surgery, rivaroxaban and apixaban are only indicated for 
prophylaxis of DVT which might lead to PE. With the exception of edoxaban, they are 
indicated to reduce the risk of recurrent DVT and PE [193-196]. However, recently (Feb 
2016) their use has been recommended for long-term anticoagulant therapy (in 
patients without cancer) over warfarin, according to antithrombotic therapy for venous 
thromboembolism (VTE) disease guidelines [33].   
In adults, dabigatran, rivaroxaban, apixaban, and edoxaban are recommended in 
the UK by The National Institute of Health and Clinical Excellence (NICE) for prevention 
of stroke and systemic embolism in patients with non-valvular AF [197-200], and 
treatment and prevention of recurrent DVT and PE [201-204]. However, only 
dabigatran, rivaroxaban, and apixaban are recommended as prophylactic agents 
against thromboembolism in adults after elective hip or knee replacement surgery 
[205-207].  
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1.2.5. Landmark studies 
The effectiveness of NOACs was examined in landmark studies for 
thromboprophylaxis after knee or hip arthroplasty, stroke prevention in AF patients, 
and for treatment and prophylaxis of VTE.  The aim of these studies was to show that 
NOACs are “as good as” current therapy (i.e. NOACs are non-inferior to warfarin). The 
primary efficacy result of non-inferiority in comparison with standard therapy was used 
in most NOAC studies for acute treatment of VTE, stroke prevention in non valvular 
AF patients, and thromboprophylaxis after knee or hip surgeries. It is worth mentioning 
that there are no head-to-head comparison studies among NOACs as yet. 
   
1.2.5.1. Thromboprophylaxis after knee or hip arthroplasty studies  
During the last 20 years, unfractionated heparin (UFH), or low molecular weight 
heparin (LMWH) have been used as prophylactic agents for VTE after total knee (TKA) 
or hip arthroplasty (THA) [208, 209]. Dabigatran, rivaroxaban, and apixaban safety and 
efficacy after TKA or THA were compared to enoxaparin in phase III double-blind 
randomized controlled clinical trials. Dabigatran in RE-MODEL [210], RE-MOBILIZE 
[211], RE-NOVATE [212], and RE-NOVATE II [213] trials; rivaroxaban in RECORD 1-
4 trials (REgulation of Coagulation in major Orthopaedic surgery Reducing risk of DVT 
and pulmonary embolism) [214-217]; and apixaban in ADVANCE 1-3 trials (Apixaban 
Dose Orally vs. Anticoagulation with Enoxaparin) [218-220]. Patients recruited in the 
studies were 18 years or above and scheduled for elective total unilateral or same-day 
bilateral hip or knee arthroplasty in rivaroxaban and apixaban studies, or primary 
elective unilateral arthroplasty in dabigatran studies. 
  Primary results of the studies are shown in Table 1-20 and Table 1-21. A pooled 
analysis for all of the above mentioned studies demonstrated that dabigatran, 
rivaroxaban, and apixaban compared to enoxaparin had a significantly lower primary 
efficacy outcome which was reduced by 29% (RR=0.71, 95%CI=0.56-0.90), major VTE 
was significantly reduced by 41% (RR=0.59, 95%CI=0.41-0.84), and proximal DVT 
was significantly reduced by 49% (RR=0.51, 95%CI=0.35-0.76). Individually, 
rivaroxaban showed superiority (RR=0.50, 95% CI=0.34-0.73), then apixaban 
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(RR=0.63, 95% CI=0.36-1.01), and finally dabigatran (RR=1.02, 95% CI=0.86-1.20), 
when compared to enoxaparin. The rate of major bleeding (RR=1.04, 95% CI=0.74-
1.46) and clinically relevant bleeding (RR=1.03, 95% CI=0.88-1.21) were similar in 
comparisons between enoxaparin versus dabigatran, rivaroxaban, and apixaban. 
Compared to enoxaparin, more major bleeding risk was observed with rivaroxaban 
(RR=1.88, 95% CI=0.92-3.82), whereas the lowest clinically relevant bleeding risk was 
reported with apixaban (RR=0.81, 95% CI=0.64-1.01) [208].  
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Table 1-20: Outcomes following hip and knee surgery   
Criteria  RE-MODEL [210] RE-MOBILIZE [211] RE-NOVATE [212] RE-NOVATE II [213] RECORD1 [214] 
Design RCT RCT RCT RCT RCT 
Type of 
Surgery 
TKR TKR THR THR THR 
Drug tested / 
Comparator 
Dabigatran 
etexilate 
150 mg 
QD(n=703)   
Dabigatran 
etexilate 
220 mg 
QD 
(n=679) 
Enoxaparin 
40 mg QD 
SC (n=694) 
Dabigatran 
etexilate 150 
mg 
QD(n=877)   
Dabigatran 
etexilate 220 
mg QD 
(n=862) 
Enoxaparin 
30 mg BID 
SC (n=876)  
 
Dabigatran 
etexilate 150 
mg 
QD(n=1174)   
Dabigatran 
etexilate 220 
mg 
QD(n=1157) 
Enoxaparin 
40 mg QD 
SC 
(n=1162)  
 
Dabigatran 
etexilate 
220 mg QD 
(n=1010) 
Enoxaparin 
40 mg QD 
SC 
(n=1003)  
 
Rivaroxaban 
10 mg QD 
(n=2266) 
Enoxaparin 
40 mg QD 
SC 
(n=2275) 
Primary 
efficacy 
outcome 
VTE or death related to VTE VTE or death related to VTE VTE or death related to VTE VTE or death related to 
VTE 
VTE or death related to 
VTE 
Primary safety 
outcome 
Bleeding Bleeding Bleeding Bleeding Bleeding 
Days of 
treatment  
6-10 12-15 28-35 28-35 31-39 
Primary efficacy 
outcome* %  
95%CI,  
P-value 
 
36.4  
32.2-40.6 
0.0003 
 
40.5 
36.3-44.7 
0.017 
 
 
 
33.7 
NR 
NR 
 
31.1 
NR 
NR 
 
25.3 
NR 
NR 
 
8.6 
-0.6-4.4 
<0.0001 
 
6.0 
4.5-7.6 
<0.0001 
 
6.7 
5.1-8.3 
 
7.7 
5.8-9.6 
0.43 
 
8.8 
6.8-10.8 
 
 
1.1 
0.7-1.8 
<0.001 
 
3.7 
2.8-4.8 
Major bleeding  
%  
(95% CI) 
P-value 
 
1.5  
(0.7-2.7) 
NR 
 
1.3  
(0.6-2.4) 
NR 
 
1.3  
(0.6-2.4) 
NR 
 
0.6 
NR 
NR 
 
0.6 
NR 
NR 
 
1.4 
NR 
NR 
 
1.3 
0.7-2.1 
NR 
 
2.0 
1.3-3.0 
NR 
 
1.6 
0.9-2.5 
NR 
 
1.4 
0.8-2.3 
0.40 
 
0.9 
0.4-1.7 
 
0.3 
0.1-.6 
0.18 
 
0.1 
<0.1-0.3 
Major or CRNM 
bleeding % 
(95% CI)  
P value 
 
 
5.9 
NR 
NR 
 
6.8 
NR 
NR 
 
5.3 
NR 
NR 
 
0.7 
NR 
NR 
 
0.8 
NR 
NR 
 
0.3 
NR 
NR 
 
4.7 
NR 
NR 
 
4.2 
NR 
NR 
 
3.5 
NR 
NR 
 
3.7 
NR 
0.33 
 
2.9 
 
 
2.9 
NR 
NR 
 
 
 
*Primary outcome vs enoxaparin for non-inferiority; RCT= double blind randomised controlled trial; TKR=total knee replacement; THR=total hip 
replacement; NR= not reported; P-value vs enoxaparin; CRNM=clinically relevant non-major bleeding. 
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Table 1-21: Outcomes following hip and knee surgery  
 
 
 
 
 
 
 
 
 
 
 
 
*Primary outcome vs enoxaparin for non-inferiority; RCT= double blind randomized controlled trial; TKR=total knee replacement; THR=total hip 
replacement; NR= not reported; P-value vs enoxaparin; CRNM=clinically relevant non-major bleeding. 
 
Criteria  RECORD2 [215] RECORD3 [216] RECORD4 [217] ADVANCE1 [218] ADVANCE2 [219] ADVANCE3 [220] 
Design RCT RCT RCT RCT RCT RCT 
Type of 
Surgery 
THR TKR TKR TKR TKR THR 
Drug tested / 
Comparator 
Rivaroxaban 10 
mg QD 
(n=1252) 
Enoxaparin      
40 mg QD SC 
(n=1257) 
Rivaroxaban 
10 mg QD 
(n=1254) 
Enoxaparin      
40 mg QD 
SC 
(n=1277) 
Rivaroxab
an 10 mg 
QD 
(n=1584) 
Enoxaparin      
30 mg BID 
SC 
(n=1564) 
Apixaban 
2.5 mg BID 
(n=1599) 
Enoxaparin 
30 mg BID 
SC 
(n=1596) 
Apixaban 2.5 
mg BID 
(n=1528) 
 
Enoxaparin 
40 mg QD 
SC 
(n=1529) 
 
Apixaban 
2.5 mg BID 
 
Enoxaparin 
40 mg QD 
SC 
 
Primary 
efficacy 
outcome 
VTE or death related to VTE VTE or death related to 
VTE 
VTE or death related to 
VTE 
VTE or death related to 
VTE 
VTE or death related to VTE VTE or death related to 
VTE 
Primary safety 
outcome 
Bleeding Bleeding Bleeding Bleeding Bleeding Bleeding 
Days of 
treatment  
31-39 
 
10-14 10-14 10-14 10-14 10-14 32-38 
Primary efficacy 
outcome* %  
95%CI,  
P-value 
 
2.0 
1.2-3.1 
<0.0001 
 
9.3 
7.5-11.5 
 
9.6 
7.7-11.8 
<0.001 
 
18.9 
16.4-21.7 
 
 
6.9 
5.4-8.7 
0.01 
 
10.1 
8.3-12.2 
 
9.0 
7.47-10.79 
NR 
 
8.8 
7.33-10.66 
NR 
 
15.06 
12.95-17.46 
<0.0001 
 
24.37 
21.81-27.14 
 
1.4 
NR 
 
3.9 
NR 
Major bleeding  
%  
(95% CI) 
P-value 
 
<1 
<0.1-0.5 
NR 
 
<1 
<0.1-0.5 
NR 
 
0.6 
0.2-1.2 
0.77 
 
0.5 
0.2-1.1 
 
0.7 
0.3-1.2 
0.10 
 
0.3 
0.1-0.7 
 
0.7 
0.4-1.3 
0.05 
 
1.4 
0.9-2.1 
 
0.6 
0.30-1.16 
0.30 
 
0.9 
0.54-1.57 
 
0.8 
0.5-1.3 
0.54 
 
0.7 
0.4-1.1 
Major or CRNM 
bleeding % 
(95% CI)  
P Value 
 
 
3.3  
NR 
NR 
 
2.7  
NR 
 
 
2.7 
1.9-3.8 
NR 
 
2.3 
1.5-3.3 
 
2.6 
1.8-3.5 
NR 
 
2.0 
1.4-2.8 
 
2.9 
2.2-3.8 
0.03 
 
4.3 
3.4-5.4 
 
 
2.9 
2.19-3.93 
0.16 
 
3.8 
2.98-4.95 
 
4.1 
3.4-4.9 
0.43 
 
4.5 
3.8-5.4 
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1.2.5.2. Stroke prevention in non-valvular AF patients 
Stroke prevention in AF patients studies include: dabigatran in Randomized 
Evaluation of Long-Term Anticoagulation Therapy trial (RE-LY) (Connolly et al 2009) 
[221], rivaroxaban in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism For Prevention Of Stroke and Embolism Trial 
in Atrial Fibrillation (ROCKET AF) (Patel et al, 2011) [222], apixaban in Apixaban for 
Reduction In Stroke And Other Thromboembolic Events In Atrial Fibrillation Trial 
(ARISTOTLE)  (Lopes et al, 2010) [223], and edoxaban in (Effective Anticoagulation 
with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial 
Infarction study 48) (ENGAGE AF-TIMI 48) (Giugliano et al, 2013) [224].  
For the RE-LY and ARISTOTLE trials, AF patients had a minimum CHADS2 [19] 
(congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke X2) 
score of one, however, a minimum score of two was required for ROCKET AF and 
ENGAGE AF trials. The mean CHADS2 scores were about 3.5 in ROCKET AF, and 
2.1-2.8 in the other three trials. Median duration of treatment was the longest in the 
ENGAGE AF trial at 907 days, shortest in the ROCKET AF trial at 590 days, and 730 
and 657 days for RE-LY and ARISTOTLE trials, respectively. Median duration of 
follow-up was longest in the ENGAGE trial at 34 months, and shortest in ARISTOTLE 
at 22 months, being 24 and 23 months for the RE-LY and ROCKET AF trials, 
respectively.  
Among the four trials, different dosages were assessed with different frequencies 
of administration, according to patient criteria. Dabigatran was assessed by using two 
fixed doses (110 or 150 mg twice daily) in the  RE-LY study; one dose for rivaroxaban 
(20 mg once daily, reduced to 15 mg once daily in those with a creatinine clearance of 
30-49 ml/min) in the ROCKET AF study; one dose of apixaban (5 mg twice daily, 
reduced to 2.5 mg twice daily in patients with ≥2 of the following baseline criteria: ≥80 
years, a body weight of ≤60 kg, or serum creatinine ≥ 1.5 mg/dl) in the ARISTOTLE 
study; and two doses for edoxaban (30 or 60 mg once daily, and every dose was 
reduced by 50% in patients with a creatinine clearance of 30-50 ml/min, body weight 
≤60 kg, or simultaneous use of a potent P-gp inhibitor such as verapamil) in the 
ENGAGE study. 
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Primary results  
As shown in Table 1-22, compared to warfarin for non-inferiority, NOACs 
decreased stroke or systemic embolic events by 34% with dabigatran 150 mg twice 
daily, and 21% with rivaroxaban 20 mg once daily, 5 mg apixaban twice daily, or 
edoxaban 60 mg once daily. Haemorrhagic stroke was decreased by 74% and 69% 
with dabigatran 150 mg and 110 mg twice daily, respectively; 41% and 49% with 
rivaroxaban 20 mg once daily and 5 mg apixaban twice daily, respectively; and by 46% 
and 67% with edoxaban 60 mg and 30 once daily, respectively. Only dabigatran 150 
mg twice daily decreased the ischaemic stroke risk by 24%, whereas the others were 
equal to warfarin. The risk of death by any cause was decreased by 11% and 13% with 
5 mg apixaban twice daily, and edoxaban 30 mg once daily, respectively, while the 
others were equal to warfarin. Major bleeding was decreased by 20% and 31% with 
dabigatran 110 mg and 5 mg apixaban twice daily, respectively;  and by 20% and 53% 
with edoxaban 60 and 30 mg once daily, respectively. In contrast to warfarin, the risk 
of gastrointestinal bleeding was increased by 50% and 23% with dabigatran 150 mg 
twice daily and edoxaban 60 mg once daily, respectively, and the risk decreased by 
33% with edoxaban 30 mg once daily, whereas it was the same with apixaban, and 
not reported with rivaroxaban. 
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Table 1-22: Stroke prevention in AF landmark studies  
 Stroke or SEE Haemorrhagic 
stroke 
Ischaemic stroke Death (any cause) Major bleeding Gastrointestinal 
bleeding 
n  
(event 
rate) 
HR 
(95% CI)  
p-value 
n  
(event 
rate) 
HR 
(95% CI)  
p-value 
n  
(event 
rate) 
HR 
(95% CI)  
p-value 
n  
(event 
rate) 
HR 
(95% CI)           
p-value 
n 
(event 
rate) 
HR 
(95% CI)      
p-value 
n 
(event 
rate) 
HR 
(95% CI)  
p-value 
RE-LY [221] 
150 mg BID      
(n = 6076) 
134  
(1.11) 
0.66  
(0.53–0.82) 
< 0.001 
12  
(0.10) 
0.26  
(0.14–0.49) 
< 0.001 
111  
(0.92) 
0.76  
(0.60–0.98)  
0.03 
438  
(3.64) 
0.88  
(0.77–1.00)  
0.051 
375  
(3.11) 
0.93  
(0.81–1.07)  
0.31 
182  
(1.51) 
1.50  
(1.19–1.89) 
< 0.001 
110 mg BID 
(n = 6015) 
182  
(1.53) 
0.91  
(0.74–1.11) 
< 0.001 
14  
(0.12) 
0.31  
(0.17–0.56) 
< 0.001 
159  
(1.34) 
1.11  
(0.89–1.40) 
0.35 
446  
(3.75) 
0.91  
(0.80–1.03)  
0.13 
322  
(2.71) 
0.80  
(0.69–0.93)  
0.003 
133 
(1.12) 
1.10  
(0.86–1.41) 
0.43 
Warfarin  
(n = 6022) 
199 
(1.69) 
 45  
(0.38) 
 142 
(1.20) 
 487 
(4.13) 
 397 
(3.36) 
 120 
(1.02) 
 
ROCKET AF [222]  
20 mg QD  
(n = 6958) 
188 
(1.7) 
0.79  
(0.66–0.96) 
< 0.001 
29 
(0.26) 
0.59  
(0.37–0.93) 
0.024 
149 
(1.34) 
0.94  
(0.75–1.17) 
0.581 
208 
(1.87) 
0.85  
(0.70–1.02) 
0.073 
395 
(3.6) 
1.04  
(0.90–1.20)  
0.58 
224 
(3.2) 
NR 
Warfarin  
(n = 7004) 
241 
(2.2) 
 50  
(0.44) 
 161 
(1.42) 
 250 
(2.21) 
 386 
(3.4) 
 154 
(2.2) 
 
ARISTOTLE [223] 
5 mg BID 
(n = 9120) 
212 
(1.27) 
0.79  
(0.66–0.95)  
0.01 
40  
(0.24) 
0.51  
(0.35–0.75)  
< 0.001 
162 
(0.97) 
0.92  
(0.74–1.13)  
0.42 
603 
(3.52) 
0.89  
(0.80–0.998)  
0.047 
327 
(2.13) 
0.69  
(0.60–0.80)  
< 0.001 
105 
(0.76) 
0.89  
(0.70–1.15) 
0.37 
Warfarin  
(n = 9081) 
265 
(1.60) 
 78  
(0.47) 
 175 
(1.05) 
 669 
(3.94) 
 462 
(3.09) 
 119 
(0.86) 
 
ENGAGE AF TIMI-48 [224] 
60 mg QD  
(n = 7012) 
182 
(1.18) 
0.79  
(0.63–0.99)  
< 0.001 
49  
(0.26) 
0.54  
(0.38–0.77) 
< 0.001 
236 
(1.25) 
1.00  
(0.83–1.19) 
0.97 
773 
(3.99) 
0.92  
(0.83–1.01)  
0.08 
418 
(2.75) 
0.80  
(0.71–0.91)  
< 0.001 
232 
(1.51) 
1.23  
(1.02–1.50) 
0.03 
30 mg QD  
(n = 7002) 
253 
(1.61) 
1.07  
(0.87–1.31)  
0.005 
30  
(0.16) 
0.33  
(0.22–0.50) 
< 0.001 
333 
(1.77) 
1.41  
(1.19–1.67) 
< 0.001 
737 
(3.80) 
0.87  
(0.79–0.96)  
0.006 
254 
(1.61) 
0.47  
(0.41–0.55)  
< 0.001 
129 
(0.82) 
0.67  
(0.53–0.83) 
< 0.001 
Warfarin  
(n = 7012) 
232 
(1.50) 
 90  
(0.47) 
 235 
(1.25) 
 839 
(4.35) 
 524 
(3.43) 
 190 
(1.23) 
 
BID=twice daily; CI=confidence interval; HR=hazard ratio; NR=not reported; QD=once daily; SEE=Systemic embolic events; P value is for noninferiority. 
All HR values are vs warfarin.  
(Adapted from Weitz, 2016[190] 
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1.2.5.3. Treatment and prophylaxis of VTE  
Initial and long-term VTE therapy 
Dabigatran in RE-COVER I (Efficacy and Safety of Dabigatran Compared with 
Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism) and 
RE-COVER II (Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate 
vs Warfarin for 6 months Treatment of Acute Symptomatic Venous Thromboembolism) 
trials [225, 226]; rivaroxaban in EINSTEIN-PE (Oral, direct Factor Xa inhibitor 
rivaroxaban in patients with acute symptomatic pulmonary embolism) and EINSTEIN-
DVT (Oral, direct Factor Xa inhibitor rivaroxaban in patients with acute symptomatic 
deep vein thrombosis) trials [227, 228]; apixaban in AMPLIFY (Apixaban for the Initial 
Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line 
Therapy) trial [229]; and edoxaban in Hokusai-VTE (Comparative Investigation of Low 
Molecular Weight Heparin/Edoxaban Tosylate Versus Low Molecular Weight 
Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots) trial [230] 
were examined for treatment of VTE against conventional treatment. The conventional 
treatment used was parenteral anticoagulant given alongside a VKA.  All of the trials 
were conducted in a double-blind design, whereas EINSTEIN used a prospective, 
randomised, open-label, blinded end point evaluation design (PROBE). Recurrent VTE 
was the end point of these trials. Major bleeding or the composite of major or clinically 
relevant non-major bleeding was the primary safety outcome in these trials.  
      The results of rivaroxaban and apixaban, which were obtained from phase 2 
studies to treat VTE, helped to decide the dose of these two NOACs to be used in 
phase 3 studies. Therefore, the rivaroxaban regimen in EINSTEIN was 15 mg twice 
daily for 3 weeks followed by 20 mg daily, and for apixaban in AMPLIFY, the regimen 
was 10 mg twice daily for 7 days followed by 5 mg twice daily. On the other hand, 
neither dabigatran nor edoxaban were  examined in phase 2 studies for VTE treatment, 
but the doses used in RE-COVER and Hokusai were based on the outcomes of phase 
2 studies in patients with AF. Therefore, in the absence of evidence supporting the 
instant use of dabigatran or edoxaban in patient with acute VTE, both  RE-COVER and 
Hokusai used treatment protocols which included at least  a 5-day initial course of a 
parenteral anticoagulant, with  patients being  switched to warfarin or treated with either 
dabigatran or edoxaban, respectively thereafter [28].    
 64 
 
The trials used different durations of treatment. A fixed duration of 6 months was 
used for the RE-COVER and AMPLIFY trials. For the EINSTEIN and Hokusai trials, a 
flexible duration of 3, 6, or 12 months was used. At the time of enrolment, the duration 
of treatment was determined by the investigators in the EINSTEIN trials, whereas the 
duration of treatment was selected subsequently in the Hokusai trial.  
With the exception of the EINSTEIN trials in which patients with DVT alone were 
enrolled separately in a trial from those with PE with or without concomitant DVT in 
another, all the trials were accomplished by recruiting at least 30% of patients who had 
PE with or without associated DVT. 
Rates of recurrent VTE in those treated with NOACs and conventional treatment 
were similar in patients with acute symptomatic PE and DVT, 2.1-3.2 vs 2.2-3.5, 
respectively. Across the trials, there is a consistency of the outcomes which suggest 
that NOACs as a class are non-inferior to conventional treatment of PE and/or DVT.  
Compared to conventional therapy, rates of major bleeding were significantly lower 
with rivaroxaban and apixaban (HR=0.55, CI 95%=0.38-0.81, P<0.002) and (HR=0.31, 
CI 95%=0.17-0.55, P<0.001), respectively; and it was non-significant with dabigatran 
and edoxaban (HR=0.73, CI=0.48-1.10) and (HR=0.85, CI=0.60-1.21), respectively. 
On other hand the rates of the composite of major bleeding or clinically relevant non-
major bleeding (CRNM) were significantly lower with dabigatran (HR=0.63, CI=0.51-
0.77, P<0.001), apixaban (HR=0.44, CI=0.36-0.55, P<0.001), and edoxaban 
(HR=0.82, CI=0.72-0.94, P<0.004), but was not significant with rivaroxaban (HR=0.94, 
CI=0.81-1.07). The results are shown in Table 1-23.    
    
Extended VTE treatment  
In double-blind controlled designs, rivaroxaban, apixaban, and dabigatran were 
examined against placebo in the EINSTEIN-Extension [227], AMPLIFY-Extension 
[231], and RE-SONATE [232] trials, respectively. All the trials examined NOACs 
against placebo, except the RE-MEDY trial [232] in which dabigatran was compared 
with warfarin for extended VTE treatment. 
In the EINSTEIN-Extension and AMPLIFY-Extension trials, patients recruited were 
treated with 6 to 12 months of anticoagulation for their primary VTE event, whereas 
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those enrolled in the RE-SONATE trial were treated for 6 to 18 months. Patients 
recruited in the RE-MEDY trial were treated with 3 to 12 months of anticoagulation for 
their primary VTE event.  
One dose of rivaroxaban (20 mg once daily) in the EINSTEIN-Extension trial, and 
one dose of dabigatran (150 mg twice daily) in the RE-SONATE trial were studied; 
however, in the AMPLIFY-Extension trial two doses  of apixaban (2.5 and 5 mg twice 
daily) were studied. 
When compared to warfarin, dabigatran in the RE-MEDY trial showed non-
inferiority for the primary efficacy endpoint (HR=1.44, 95% CI=0.78-2.64); and 
dabigatran showed a significant reduction in the primary endpoint by 92% in the RE-
SONATE placebo-controlled study (HR=0.08, 95% CI=0.02-0.25). With rivaroxaban, 
the primary efficacy result of recurrent symptomatic VTE was significantly decreased 
by 82% compared to placebo in the EINSTEIN-Extension placebo control study 
(HR=0.18, 95% CI=0.09-0.39). In the AMPLIFY-EXT trial, apixaban decreased 
significantly the primary efficacy result of recurrent symptomatic VTE or death from any 
cause by 67% with the 2.5 mg twice daily dose (HR=0.33, 95%CI=0.22-0.48), and by 
64% with the 5 mg twice daily dose (HR=0.36, 95%CI=0.25-0.53). 
In the dabigatran group, the rate of major bleeding was decreased by 48% 
(HR=0.52, 95%CI=0.27-1.02), but it was not significant (P=0.6), whereas major or 
CRNM bleeding was significantly reduced (HR=0.54, 95% CI=0.41-0.71) when 
compared to warfarin, in the RE-MEDY trial. However, in the RE-SONATE trial, both 
major or CRNM bleeding, or any bleeding, was observed to be increased significantly 
with the use of dabigatran versus placebo (HR=2.92, 95% CI=1.52-5.60) and 
(HR=1.82, 95% CI=1.23-2.68), respectively; whereas major bleeding only was not 
increased significantly with dabigatran.  In the EINSTEIN-Extension trial, there was a 
significant increase in major or CRNM bleeding in rivaroxaban treated patients 
compared to placebo (HR=5.19, 95% CI=2.3-11.7), however, major bleeding was not 
different between the two groups. It is worth mentioning that the increase in major or 
CRNM bleeding rate induced by rivaroxaban was mostly related to the increase in 
haematuria, epistaxis, and rectal bleeding events [233]. For the AMPLIFY-EXT trial, 
the major bleeding rate was lower, but not significantly so, for both of apixaban 2.5 mg 
and 5 mg twice daily arms, (HR=0.49, 95% CI=0.09-2.64), (HR=0.25, 95% CI=0.03-
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2.24), respectively; and for the rate of major or CRNM bleeding, it was higher and also 
not significant, in the apixaban 2.5 mg twice daily arm (HR=1.20, 95% CI=0.69-2.10), 
and in apixaban 5 mg twice daily arm (HR=1.62, 95% CI=0.96-2.73) in comparison 
with placebo arm. The results are shown in Table 1-24. 
Overall, treatment of VTE with NOACs is not inferior to conventional therapy, and 
it is associated with lower bleeding rates. 
Age was not an exclusion criterion in any study. However, for VTE studies 
(RECOVER I and II, EINSTEIN, AMPLIFY and Hokusai-VTE), the mean age of the 
patients was 56 years, only 13% being aged ≥75 years.  
In the hip and knee surgery studies (REMODEL, REMOBILIZE, RENOVATE I and 
II, RECORD 1, 2, 3 and 4, and ADVNCE 1, 2, and 3), no reporting of numbers of 
patients aged ≥75 years was made. The mean age ranged between 61-67years in the 
studies, and only 5 of 11 studies mentioned the age range, which was between 18-93 
years.  
For the AF studies (RELY, ARISTOTLE, ROCKET-AF, and ENGAGE), the median 
age was 72, with  those aged ≥75 being 40%, 31%, 44%, and 40%, respectively.    
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Table 1-23: VTE clinical trials overview  
(Adapted from Dobesh, 2014 ; and Yeh 2014  [28, 233]) 
Criteria RE-COVER I 
[234]  
RE-COVER II 
[226] 
EINSTEIN-DVT 
[227] 
EINSTEIN-PE 
[228]  
AMPLIFY [229] Hokusai-VTE [230] 
Study design Randomized, double-blind, 
noninferiority, parallel group 
Randomized, open-label, event-driven, 
non-inferiority, parallel group 
Randomized, 
double blind, 
parallel group 
Randomized, double- 
blind, non-
inferiority, parallel 
group 
Intervention Dabigatran 
etexilate 
150 mg bid 
(n = 1,274) 
Dabigatran 
etexilate 
150 mg bid 
(n = 1,279) 
Rivaroxaban 
15 mg bid for 3 
weeks, 
followed by 20 
mg od  
(n =1,731) 
Rivaroxaban 15 
mg bid for 3 
weeks, followed 
by 20 mg od  
(n = 2,419) 
Apixaban 10 mg bid 
for 7 days, followed 
by 5 mg bid  
(n = 2,676) 
Edoxaban 60 mg od 
or edoxaban 30 mg 
od in patients with a 
CrCl of 30–50 
mL/min, body 
weight B60 kg or 
receiving strong P-
gp inhibitors  
(n = 4,118) 
Comparator Warfarin dose-
adjusted to 
INR 2.0–3.0 
(n = 1,265) 
Warfarin dose-
adjusted to 
INR 2.0–3.0  
(n = 1,289) 
Enoxaparin 1 mg/ 
kg bid (≥5 
days)/VKA 
(warfarin or 
acenocoumarol) 
dose-adjusted 
to INR 2.0–3.0  
(n = 1,718) 
Enoxaparin 1 
mg/kg bid (≥5 
days)/ VKA 
(warfarin or 
acenocoumarol) 
dose-adjusted 
to INR 2.0–3.0  
(n = 2,413) 
Enoxaparin 1 mg/kg 
bid (≥5 
days)/warfarin 
dose-adjusted to 
INR 2.0–3.0 
(n = 2,689) 
Warfarin dose-
adjusted to      
INR 2.0–3.0  
(n = 4,122) 
Parenteral 
anticoagulation 
Mandatory, at least 5 days Optional, maximum 48 h Optional, maximum 
36 h 
Mandatory, at 
least 5 days 
Index event (%) 
Patients with DVT (%) 
Patients with PE (%) 
Patients with PE and 
DVT (%) 
 
68.9 
21.3 
9.6 
 
68.1 
23.2 
8.6 
 
 
98.7 
0 
0.1 
 
0 
75.2 
24.8 
 
65.5 
25.2 
8.8 
 
 
59.7 
30.4 
9.9 
 
Unprovoked VTE (%) NR NR 62.0 64.5 89.8 65.7 
Patients with active 
cancer (%) 
4.8 3.9 6.0 4.6 2.7 2.5 
Primary efficacy 
endpoint 
Recurrent symptomatic VTE or 
death related to VTE 
Recurrent 
symptomatic 
VTE 
Recurrent 
symptomatic VTE 
Recurrent 
symptomatic 
VTE or death 
related to 
VTE 
Recurrent 
symptomatic 
VTE 
Primary safety 
endpoint 
Major bleeding Major or CRMN bleeding 
 
Major bleeding Major or CRMN 
bleeding 
Treatment duration 6 months 3, 6, or 12 months (pre-specified) 6 months 3–12 months 
(flexible) 
Rate of major 
bleeding  
HR=0.73,  
CI=0.48-1.10,  
P>0.05 
HR=0.55,  
CI 95%=0.38-0.81,  
P<0.002 
HR=0.31,   
CI 95%=0.17-0.55, 
P<0.001 
HR=0.85,  
CI=0.60-1.21,  
P>0.05 
Rate of major or 
CRNM bleeding 
 
HR=0.63,  
CI=0.51-0.77,  
P<0.001 
HR=0.94,  
CI=0.81-1.07,  
P>0.05 
HR=0.44, 
CI=0.36-0.55,  
P<0.001 
HR=0.82,  
CI=0.72-0.94,  
P<0.004 
TTR [%(range)] 
% > INR of 3.0 
% < INR of 2.0 
60 (53–66) 
19 
21 
57 (51–62) 
19 
24 
58 (54–66) 
16 
24 
63 (58–73) 
16 
22 
61 (NR) 
16 
23 
64 (NR) 
18 
19 
DVT=deep venous thrombosis; PE=pulmonary embolism; CRNM=Clinical relevant non-major bleeding; HR=hazard ratio; NR=not reported 
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Table 1-24: Extended VTE clinical trials overview  
Criteria RE-MEDY [232]  RE-SONATE 
[232]  
AMPLIFY-EXT [231] EINSTEIN-
Extension [227] 
Study design Randomized, double-blind, placebo  
Intervention Dabigatran 
etexilate 
150 mg bid 
(n = 1,430) 
Dabigatran 
etexilate 
150 mg bid 
(n = 681) 
Apixaban 
2.5 mg bid  
(n =840) 
Apixaban 
5 mg bid  
(n =813) 
Rivaroxaban 20 mg 
daily 
(n = 602) 
Comparator Warfarin dose-
adjusted to 
INR 
2.0–3.0 
(n = 1,426) 
Placebo 
(n = 662) 
Placebo (n = 829) 
 
Placebo 
(n = 594) 
Index event (%) 
Patients with DVT (%) 
Patients with PE (%) 
Patients with PE and 
DVT (%) 
 
65.6 
22.7 
11.7 
 
63.3 
26.9 
6.9 
 
 
64.8 
35.2 
NR 
 
64.8 
35.2 
NR 
 
64.1 
35.9 
NR 
Unprovoked VTE (%) NR NR 93.2 90.7 73.1 
Patients with active 
cancer (%) 
4.2 0.1 1.8 1.1 4.7 
Primary efficacy 
endpoint 
Recurrent symptomatic VTE or 
death related to VTE 
Recurrent symptomatic 
VTE or death from any cause 
Recurrent 
symptomatic 
VTE  
Primary safety 
endpoint 
Major or CRMN bleeding 
 
Major or CRMN bleeding Major or CRMN 
bleeding 
Mean treatment 
duration before 
randomization 
(days) 
198 293 NR VKA pre-treatment 
6–12 months:          
429 (71.3 %) 
Rivaroxaban pre-
treatment 6–12 
months: 173 (28.7 
%) 
Mean duration of 
study drug (days) 
473 165 NR 
2 (0.2%)<6 months 
828 (98.6 %) 6–12 months 
10 (1.2%)>12 months 
NR 
Median 181 days–6 
months 
Median 264 days–
12 months 
Rate of major 
bleeding  
HR=0.52 
CI 95%=0.27 -1.02 
P=0.06 
(0.3%) dabigatran  
(0) placebo 
 
HR=0.49 
CI 95%=0.09-2.64 
P>0.05 
HR=0.25 
CI 95%=0.03-2.24 
P>0.05 
(0.7%) rivaroxaban  
(0) placebo 
HR=not estimable 
Rate of major or 
CRNM bleeding 
 
HR=0.54 
CI 95%=0.41-0.71 
P<0.001 
HR=2.92 
CI 95%=1.52-5.60 
P=0.001 
HR=1.20 
CI 95%=0.69-2.10 
P>0.05 
HR=1.62 
CI 95%=0.96-2.73 
P>0.05 
(5.4%) rivaroxaban  
(1.2%) placebo 
HR=NR 
DVT=deep venous thrombosis; PE=pulmonary embolism; CRNM=Clinical relevant non-major bleeding; HR=hazard ratio; 
NR=not reported 
(Adapted from Dobesh, 2014; and Yeh 2014 [28, 233]) 
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1.2.6. NOACs clinical effectiveness  
In a recent meta-analysis, results obtained for all NOACs from 50 randomized 
clinical trials involving 155,537 patients for all indications were pooled and analysed to 
evaluate the risk of major bleeding. The study showed that there was no significant 
difference for major bleeding risk between NOACs and comparators (OR=0.93, 95% 
CI=0.79–1.09), whereas when NOACs were compared to VKA specifically, major 
bleeding was significantly reduced by 23% (OR=0.77, 95% CI=0.64–0.91). When 
NOACs were analysed separately for major bleeding against pharmacologically active 
comparators, no difference was observed with rivaroxaban (OR=1.10, 95% CI=0.77–
1.58), apixaban (OR=0.81, 95% CI=0.56–1.11), or dabigatran (OR=0.96, 95% 
CI=0.76–1.20). Major bleeding was significantly increased with NOACs after hip 
surgery (OR=1.43, 95% CI=1.02–1.99), in medically ill patients (OR=2.79, 95% 
CI=1.69–4.60), and in patients with acute coronary syndrome (ACS) (compared with 
placebo) (OR=2.89, 95% CI=2.01–4.14). Bleeding was significantly reduced with 
NOACs when they were used for treatment of acute venous thromboembolism or 
pulmonary embolism (OR=0.63, 95% CI=0.44–0.90). For treatment of atrial fibrillation 
and for extended treatment of VTE, no difference was observed between NOACs and 
comparators (OR=0.89, 95% CI=0.74–1.06), and (OR=0.88, 95% CI=0.27–2.93), 
respectively [235].     
Another meta-analysis of 12 RCTs containing 102,607 patients showed that, 
compared to VKAs, NOACs significantly decrease the risk of total major bleeding by 
28% (RR=0.72, 95% CI=0.62-0.85, P<0.01), fatal bleeding by 47% (RR=0.53, 95% 
CI=0.43-0.64, P<0.01), intracranial bleeding by 57% (RR=0.43, 95% CI=0.37-0.50, 
P<0.01), clinically relevant non-major bleeding by 22% (RR=0.78, 95% CI=0.68-0.90, 
P<0.01), and overall bleeding by 24% (RR=0.76, 95% CI=0.71-0.82, P<0.01). When 
NOACs were  compared to VKAs with respect to major gastrointestinal bleeding, no 
difference was found (RR=0.94, 95% CI=0.75-1.91, P=0.62) [236].               
 
NOACs for thromboprophylaxis after THR and TKR surgery  
A review of six systematic reviews which examined NOACs against LMWH for 
thromboprophylaxis after THR or TKR showed, with the exception of dabigatran, that 
the risk of symptomatic DVT was decreased significantly with rivaroxaban and 
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apixaban (<4 events per 1000 patients, OR=0.46, 95% CI=0.3-0.7), whereas the risk 
of major bleeding increased (≥2 events per 1000 patients, OR=1.27, 95% CI=0.98-
1.65). Among NOACs, compared to dabigatran and apixaban, the lowest risk of VTE 
(not significant) was observed with rivaroxaban (RR=0.68, 95% CI=0.21-2.23) and 
edoxaban (RR=0.59, 95% CI=0.26-1.33), respectively; however, rivaroxaban 
increased non-significantly major bleeding risk (RR=1.59, 95% CI=0.84-3.02) [237].    
Another recent systematic review which included the results of 20 trials examined 
the efficacy and safety of FXa inhibitors versus enoxaparin for thromboprophylaxis 
after THR or TKR. It revealed that the risk of total VTE was reduced with rivaroxaban 
(RR= 0.70, 95% CI= 0.60-0.81), apixaban (RR=0.62, 95% CI= 0.47-0.81), and 
edoxaban (RR=0.62, 95% CI= 0.39 to 0.97) in comparison with enoxaparin. The risk 
of major or clinically relevant non-major bleeding was higher with rivaroxaban 
(RR=1.52, 95% CI=1.14-2.02), and similar to apixaban and edoxaban (RR=0.88, 95% 
CI=0.73-1.05) and (RR=1.30, 95% CI=0.72-2.33), respectively, when compared to 
enoxaparin. A linear relationship between the risks of major and clinically relevant non-
major bleeding was observed with rivaroxaban treatment doses. Rivaroxaban, 
apixaban, edoxaban, and finally enoxaparin was the low to high ranking of total VTE 
risk found [238].  
 
NOACs for stroke prevention in AF patients  
A meta-analysis study (2014) involved 30,000 AF patients on NOACs previously 
treated with warfarin. Compared to warfarin, NOACs significantly reduced the 
composite of stroke or systemic emboli by 20% (RR=0.80; 95%CI, 0.69-0.94), all-
cause mortality by 12% (RR=0.88; 95%CI, 0.79-0.98), and intracranial bleeding by 
60% (RR=0.40; 95%CI, 0.26-.62). However, no significant difference was observed for 
major bleeding (RR=0.85; 95%CI, 0.67-1.09) [239].   
A meta-analysis study, which used the results of more than 71,000 AF patients 
treated with either NOACs or warfarin in phase 3 studies, showed that NOACs for 
prevention of stroke and systemic embolism were at least as effective as warfarin; and 
also an associated reduction in intracranial bleeding by 50% [240]. Intracranial 
bleeding is the most critical complication of anticoagulation therapy.  
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NOACs for treatment and prevention of VTE 
The six studies mentioned in section 1.2.5.3 were included in a systematic review. 
No difference was found between NOACs and standard treatment (parenteral 
anticoagulant followed by a vitamin K antagonist) for the risk of VTE recurrence 
(RR=0.91, 95% CI=0.79-1.06). However, compared to standard treatment, NOACs 
significantly decreased the risk of major bleeding (RR=0.62, 95% CI=0.45-0.85). All-
cause mortality was not different between the treatments (RR=0.98, 95% CI=0.84-
1.14). The primary efficacy outcome was significantly reduced by 15% with NOACs 
compared to standard treatment (RR=0.85, 95% CI=0.75-0.97) [241].  
Another systematic review included only five of the six studies mentioned in section 
1.2.5.3. VTE recurrence and all-cause mortality did not differ with NOACs compared 
to standard treatment (RR=0.88, 95% CI=0.74-1.05), and (RR=0.97, 95% CI=0.83-
1.14), respectively. However, major bleeding and clinically relevant non-major bleeding 
were significantly reduced by 40% (RR=0.60, 95% CI=0.41-0.88) and 24% (RR=0.76, 
95% CI=0.58-0.99) with NOACs compared to standard treatment. Number needed to 
treat (NNT) with NOACs in place of VKA was calculated to be 149 to prevent one major 
bleed, which is relatively high, and 56 to prevent one clinically relevant non-major 
bleeding, whereas NNT calculated for fatal bleeding was 1111 (RR=0.36, 95% 
CI=0.15-0.87) [242]. 
  
1.2.7. Renal function and dosing of NOACs 
It has been demonstrated that the Cockcroft-Gault method to calculate renal 
function is optimal when prescribing the new anticoagulants to the elderly [243]. Kidney 
function declines with increasing age [244]. The risk of thromboembolism is increased 
with deteriorating kidney function by 54% independently of any other risk factors, 
including age, in those not treated with anticoagulants [245]. It has been shown that 
major bleeding rate was higher in those treated with dabigatran with reduced creatinine 
clearance compared to those treated with warfarin [246].  For those treated with 
NOACs with renal impairment, the risk of bleeding is increased as a result of 
prolongation of their half-lives, and hence prolongation of systemic drug exposure. 
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Therefore, NOACs should be used cautiously in patients with significant renal 
impairment. 
 
1.2.8. Choice of NOAC for anticoagulation therapy 
As revealed from the landmark studies, NOACs are not inferior to warfarin in terms 
of anticoagulation effectiveness, and are also associated with a lower rate of 
intracranial haemorrhage when used to prevent stroke in patients with non-valvular AF, 
and in the prophylaxis and treatment of VTE in general.   
Patients started on dabigatran or rivaroxaban have lower rates of drug stoppage 
and higher persistence of usage compared to those started on warfarin [247, 248]. 
NOACs treatment might not be the optimal choice for those who frequently forget their 
doses in view of their short half-lives. In these circumstances, more consistent 
anticoagulation could be offered by warfarin's long-half life. However, patients with 
good adherence and difficulties in achieving a stable INR with warfarin therapy are 
good candidates for NOACs. NOACs with a single daily dose, i.e. rivaroxaban or 
edoxaban, are good choices for those with a busy lifestyle. Table 1-25 summarises 
how to select from the four NOACs for AF patients, and Table 1-26 summarises 
suggestions on how to choose an anticoagulant for acute VTE therapy. Moreover, for 
patients who are sensitive to warfarin owing to their genetic polymorphism NOACs may 
be advantageous. 
However, warfarin is still considered as the drug of choice for treatment or 
prophylaxis of AF patients with mechanical heart valves as studies have shown 
NOACs to be less effective, for  liver disease patients with a coagulopathy, and for 
those with renal impairment (creatinine clearance < 30 ml/min) [17].  
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Table 1-25 Selection of NOACs for AF according to patient status 
Patient characteristic Drug choice Rationale 
Not currently anticoagulated NOAC NOACs are at least as effective and safe as 
VKAs, produce less intracranial bleeding and 
are more convenient because they do not 
require routine monitoring and have a low 
propensity for food and drug interactions. 
Already receiving warfarin, 
stable INR and satisfactory TTR 
Maintain VKA  
therapy or 
consider 
switching to 
NOAC 
Depends on patient and physician preference 
Already receiving warfarin, 
unsatisfactory TTR 
Any NOAC NOACs produce a more predictable and stable 
anticoagulant effect and do not require routine 
coagulation monitoring 
CrCl 30–50 ml/min Apixaban, 
rivaroxaban 
or edoxaban 
Less affected by renal impairment than 
dabigatran 
CrCl < 15 ml/min VKA NOACs are not recommended for use in this 
patient population 
Ischaemic stroke on warfarin, 
rivaroxaban, apixaban, or 
edoxaban 
Dabigatran Lower risk of ischaemic stroke with dabigatran 
(150 mg) 
Dyspepsia or upper GI 
complaints 
Rivaroxaban, 
apixaban, or 
edoxaban 
Dyspepsia with dabigatran in up to 10 % of 
patients 
Recent GI bleed Apixaban Dabigatran (150 mg), rivaroxaban, and 
edoxaban (but not  apixaban) produce more GI 
bleeding than warfarin 
Concomitant use of strong 
inhibitors or  inducers of both P-
gp and CYP3A4 
Dabigatran or  
edoxaban 
Not restricted for concomitant use 
Poor compliance with twice-
daily dosing 
Rivaroxaban or  
edoxaban 
Only agents given once-daily 
(Adapted from Weitz, 2016[190]) 
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Table 1-26: Choice of anticoagulant for acute VTE therapy 
Characteristic Drug choice Rationale 
Extensive DVT or massive PE Heparin Such patients often require advanced therapy and 
were excluded from trials with the NOACs 
High initial risk of bleeding Heparin Enables dose titration; rapid offset and availability 
of protamine as an antidote simplify 
management should bleeding occur 
Active cancer LMWH No trials comparing NOACs with LMWH 
 Pregnancy LMWH Warfarin and NOACs cross the placenta 
Liver dysfunction with increased  
prothrombin time/ INR at baseline 
Warfarin Such patients were excluded from the trials 
because NOACs undergo hepatic metabolism 
Unable to afford NOACs LMWH followed by warfarin NOACs cost less than LMWH but are more 
expensive than warfarin 
Limited access to anticoagulation clinic 
because of impaired mobility or geographical 
inaccessibility 
NOAC Given in fixed doses without monitoring 
All-oral therapy Rivaroxaban or apixaban Only NOACs to be evaluated in all-oral regimens 
Creatinine clearance <30 mL/min Warfarin Such patients were excluded from trials with 
NOACs 
Creatinine clearance 30-50 mL/min Rivaroxaban, apixaban, or 
edoxaban 
Less affected by renal impairment than dabigatran; 
if edoxaban is chosen, the 30-mg OD dose should 
be used 
Dyspepsia or upper gastrointestinal symptoms Rivaroxaban, apixaban, or 
edoxaban 
 
 
Dyspepsia in as much as 10% given dabigatran 
Recent gastrointestinal bleed Apixaban More gastrointestinal bleeding with dabigatran, 
rivaroxaban, and edoxaban than with warfarin 
Recent acute coronary syndrome Rivaroxaban, apixaban or 
edoxaban 
Small myocardial infarction signal with dabigatran 
Poor compliance with long-term twice-daily 
dosing 
Rivaroxaban or edoxaban OD regimens for long-term use 
(Adapted from Yeh, 2014 [28]) 
 
1.2.9. NOACs anticoagulation monitoring  
One of the advantages of NOACs is that they do not need to be monitored for their 
anticoagulation response.  However, monitoring is required in certain condition, such 
as bleeding, overdose/toxicity, or in an emergency.  It has been suggested that NOACs 
should be monitored for anticoagulation to determine the correct dose required by each 
patient [249].  Routine coagulation laboratory test such as INR and aPTT might not 
correctly mirror NOACs anticoagulation activity.  
Currently, there is no specific lab test which could be used as a guide in patients 
with bleeding induced by NOACs. The INR test is not recommended for NOAC 
monitoring. It has been reported that those receiving dabigatran and edoxaban showed 
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an elevation of aPTT, however, no clear dose-response relationship was seen [189]. 
Although other specialized assays such as thrombin time (TT), dilute thrombin time 
(dTT), and ecarin-clotting time (ECT) showed sensitivity for measuring dabigatran 
activity, they are not commercially available in most institutions [250, 251]. Prothrombin 
time (PT) was found to correlate with plasma rivaroxaban level qualitatively, but 
unfortunately the sensitivity differs widely between thromboplastin reagents [60, 252, 
253]. The anti-factor Xa chromogenic assay gives consistent results with dose-
response for rivaroxaban and apixaban, but the results might not be available in a 
timely manner [189, 254-256]. PT and aPTT showed a linear dose response with 
edoxaban in healthy volunteers [257]. The need for a precise and commercially 
available test which could be used quickly and easily in emergency situations to 
monitor anticoagulation response to NOACs remains.    
 
1.2.10. Reversal of NOACs bleeding 
 In order to manage the bleeding caused by a NOAC properly, plasma 
concentration should be determined. An adequately sensitive assay, using the method 
of liquid chromatography/tandem mass spectrometry (LC-MS/MS), is currently 
available for routine measurement of plasma drug concentrations [258, 259]. As 
determined by LC-MS/MS, trough and peak NOACs plasma levels at steady-state are 
shown in Table 1-27.   
 
Table 1-27: Plasma NOACs concentrations at stead-state 
Drug Dose 
Peak concentration 
(ng/mL) 
Trough concentration 
(ng/mL) 
Median 
5th to 95th 
percentile 
Median 
5th to 95th 
percentile 
Dabigatran 150 mg BID 184 64–443 90 31–225 
Rivaroxaban 20 mg daily 270 189–419 26 6–87 
Apixaban 5 mg BID 171 91–321 103 41–230 
Edoxaban 60 mg daily 170 120–250 22 10–40 
(Adapted from Cuker, 2016 [258]) 
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In the presence of minor or non-life threatening bleeding, it can be clinically 
appropriate to allow  NOACs' anticoagulant effect to simply reverse by discontinuation 
owing to their short half-lives, an advantage of  this class of drugs [260]. This  may not 
be appropriate in patients with intracranial bleeding as  hematoma may continue to 
expand with further  neurological deterioration [261]. For patients presenting with major 
bleeding due to NOACs or requiring emergency surgery NOACs should be stopped 
immediately, supportive measures applied or consideration given to postponing 
surgery for 12-24 hours after the last NOAC dose, and/or haemostatic agents should 
be considered.  
 
1.2.10.1. Reversal of NOACs by haemodialysis, and use of activated charcoal 
Given that dabigatran has a low protein-bound status and lipophilic profile, as 
shown in Table 1-17, haemodialysis could be used in bleeding associated with 
dabigatran [262, 263] although with major bleeding and hemodynamic fluctuation, 
haemodialysis is challenging. Neither rivaroxaban nor apixaban could be dialyzed 
effectively owing to their highly protein-bound status [264, 265]. For edoxaban, it is not 
clear whether it is  removed by haemodialysis [189].  
In an in vitro study, oral activated charcoal was shown to be effective in preventing 
dabigatran absorption shortly after drug ingestion [260], Table 1-28.      
 
1.2.10.2. Reversal of anticoagulation by plasma factors 
Various concentrated coagulation factors have been used to stem bleeding in 
those receiving NOACs, such as activated and inactivated prothrombin complex 
concentrates (PCC), and recombinant FVIIa. Although they have demonstrated 
efficacy with bleeding induced by NOACs, they have not been evaluated in large 
randomized controlled trials and most of the results were reported from animal models, 
in vitro studies or small healthy subject studies [189, 266-270], as shown in Table 1-28.     
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Table 1-28: Currently used agents for reversing anticoagulation  
Intervention Apixaban Rivaroxaban Dabigatran Edoxaban 
Oral activated charcoal Yes Yes Yes Yes 
Hemodialysis No No Yes No 
Hemoperfusion with activated charcoal Possible Possible Yes ? 
Fresh frozen plasma No No No No 
Activated recombinant FVIIa Unclear Unclear Unclear Unclear 
3 factor PCC Unclear Unclear Unclear Unclear 
4 factor PCC Possible Possible Possible Possible 
(Adapted from Ansell, 2016[271])  
 
1.2.10.3. Antidotes to NOACs 
1.2.10.3.1. Idarucizumab 
In 2015, idarucizumab (aDabi-Fab, BI 655075, Boehringer Ingelheim, Ingelheim 
am Rhein, Germany), a novel humanized mouse monoclonal antibody fragment was 
approved as antidote for dabigatran by US FDA [272]. The anticoagulation effect of 
dabigatran is reversed by idarucizumab, which binds to and inactivates free and 
thrombin-bound dabigatran. The bound complex is then mainly excreted renally. 
Idarucizumab has a high affinity for dabigatran (around 350 times stronger than the 
affinity of dabigatran toward thrombin). Idarucizumab administered as a 5 gm 
intravenous infusion was examined in a recent phase III study. The interim analysis 
showed that idarucizumab resulted in normalization of ecarin-clotting time in 89% and 
88% of the two studied patients groups, one with serious bleeding, and the other 
requiring an urgent procedure, with normalization of dilute thrombin time in 98% and 
93% respectively. The median maximum percentage anticoagulation reversal was 
100% in both groups [273].  Both dilute thrombin time and ecarin-clotting time 
parameters, which were increased by dabigatran, were reversed by idarucizumab, and 
the reversal was maintained for 72 hours. Idarucizumab is being  evaluated in a phase 
III study, which is expected to be completed in 2017 [189]. Figure 1-7 shows a 
suggested management chart for NOAC reversal activity. 
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Figure 1-7 A suggested management algorithm for NOAC reversal activity 
(Adapted from Abo-Salem, 2016 [274]) 
 
1.2.10.3.2. Ciraparantag 
Ciraparantag (PER977, Perosphere, Danbury, CT, USA) is a small synthetic water 
soluble and cationic molecule that binds directly to unfractionated (UFH) and low 
molecular weight heparin (LMWH) and also by forming non-covalent hydrogen bonds 
and charge–charge interactions. By the same mechanisms, ciraparantag binds to the 
specific targets of dabigatran, rivaroxaban, apixaban, and edoxaban (Factor IIa and 
Factor Xa), thus preventing their action. Phase 3 trials of ciraparantag are underway, 
and it is currently undergoing FDA review [271, 275].  
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1.2.10.3.3. Andexanet 
 Andexanet (PRT064445, Portola Pharmaceuticals, San Francisco, CA, USA) is a 
recombinant human protein made in Chinese hamster ovary cells, and is an inactivated 
form of FXa designed to be a universal factor Xa inhibitor antidote. Andexanet binds 
factor Xa inhibitors and removes them from their endogenous specific target factor Xa. 
It is currently undergoing FDA review [271, 275]. 
 
1.2.11. NOACs and food 
It is well established that diet can significantly affect anticoagulation response to 
VKAs. Whilst food delays the absorption of dabigatran and rivaroxaban, it has no effect 
on the absorption of either apixaban or edoxaban [106, 276-279]. An earlier study 
demonstrated that anticoagulation response to the direct thrombin inhibitor, 
ximelagatran, was significantly enhanced in rats receiving a vitamin K deficient diet 
compared to those receiving a normal diet [280]. However, no study to date has 
evaluated the potential effect of dietary vitamin K on NOACs pharmacodynamics in 
man.  
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1.3. Aims of my PhD research          
 
Attaining a stable anticoagulation response and effective management of patients 
is critical in achieving safe treatment. As described earlier in this chapter several 
factors can influence anticoagulation response to warfarin.  My PhD research is 
comprised of a number of studies which explored the factors contributing to the 
variability in clinical response to warfarin. Dietary vitamin K can have a significant 
impact on anticoagulation response to warfarin. It is possible that dietary vitamin K also 
affects response to NOACs since the activation of both factor II and factor X is 
dependent on vitamin K availability. Examination of the effect of diet on the 
pharmacological activity of NOACs in older patients is particularly relevant as these 
patients might be sensitive to these agents because of their generally poor dietary 
intake and thus be liable to increased risk of bleeding. 
The aim of this PhD was to elucidate the factors that influence anticoagulation 
response to the oral anticoagulants, warfarin and NOACs. Identification of the factors 
which influence clinical response to these agents could lead to improvements in patient 
management and treatment safety. 
Over the period of my PhD research, the following projects were planned to be 
undertaken: 
1. A cross-sectional study comparing the stability of anticoagulation control and 
service costs in patients monitored either at home, general practice or 
hospital clinics.  
2. To examine the influence of age and monitoring setting on long-term 
anticoagulant control in patients with atrial fibrillation. 
3. To examine the effect of dietary vitamin K on the pharmacological activity of 
the direct factor Xa inhibitor, rivaroxaban, in older and younger subjects ex 
vivo.  
 
4. To evaluate the possible association between VKORC1 genotype, dietary 
vitamin K and stability of anticoagulation control in patients on chronic 
warfarin therapy. 
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5. To assess the effect of CYP2C9 genotype on the rate of INR decline following 
the cessation of warfarin therapy in patients undergoing surgery. 
6. To further examine the effect of CYP2C9 and VKORC1 polymorphisms and 
patient demographics on warfarin pharmacokinetics and the rate of INR 
decline following cessation of warfarin therapy. 
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CHAPTER. 2 ANTICOAGULATION CONTROL AND COST OF 
MONITORING OF OLDER PATIENTS ON CHRONIC 
WARFARIN THERAPY IN THREE SETTINGS IN NORTH 
EAST ENGLAND       
 
2.1. Introduction  
Non-vitamin K antagonist oral anticoagulants, which act directly through inhibition 
of thrombin or factor Xa, were approved in 2012 by The National Institute of Health and 
Clinical Excellence (NICE) for use in patients with non-valvular atrial fibrillation (NVAF) 
aged 75 years or older in accordance with their license, as the incremental cost-
effectiveness ratio is plausibly less than £20,000 per QALY gained [281-283]. Doctors 
now have a choice of oral anticoagulants, but need evidence to guide prescribing 
decisions. Time spent in therapeutic range (TTR) is an important influence on 
outcomes of thromboembolic prophylaxis with warfarin, with patients with TTR of 70% 
or more having a 79% reduced risk of stroke compared with those with a TTR of <30% 
and lower mortality [284]. A meta-analysis of recent studies concerning 
thromboembolic and major haemorrhagic events in NVAF in patients receiving warfarin 
therapy concluded that overall survival is improved where TTR is >40% [285], and a 
TTR of >58% is needed to be confident that patients will benefit from the treatment 
[286]. 
 The RE-LY study of patients with NVAF suggested that dabigatran 150 mg bd 
might be cost-effective in high-risk patients unless INR control with warfarin is excellent 
(average TTR >72.6%), but warfarin is cost-effective in moderate-risk patients unless 
INR control is poor (average TTR <57.1%) [287, 288]. In a UK benefit-harm analysis, 
fewest net potential benefits of dabigatran versus warfarin were seen in centres which 
achieved a good TTR of ≥65.5% [55]. Non-vitamin K antagonist oral anticoagulants 
are at least as effective at reducing stroke and systemic embolism, and result in fewer 
bleeds, in particular intracranial bleeding, when compared with warfarin [289], including 
in patients aged 80 years and over [290]. Use might be particularly justified in patients 
exhibiting low TTR, for example, under 50% in spite of good patient adherence to 
therapy, and in those for whom monitoring is difficult or costly [291].  
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Difficulties with warfarin therapy are encountered by the very elderly using 
outpatient anticoagulation monitoring, including the missing of appointments and 
problems contacting them with dosing instructions [292], and gain from no monitoring 
requirements for novel anticoagulants has been recognised by NICE [281-283]. While 
domiciliary monitoring may address this issue, risk of warfarin-related bleeding is 
associated with dependency and domiciliary monitoring of INR [293].  
Novel anticoagulants may be particularly cost-effective compared with warfarin for 
dependent older people, those whose anticoagulant control is erratic or for whom 
monitoring is not feasible [294]. 
 
2.2. Aim of the study 
To examine TTR and service costs in patients housebound due to a high level of 
dependency using the Newcastle domiciliary service, and to compare these to patients 
monitored in general practice outreach clinics and patients choosing hospital 
monitoring for their convenience. 
 
2.3. Materials and Methods 
The inclusion criteria were to have atrial fibrillation with a target INR range of 2 – 
3, aged 75 years and over and to be on warfarin chronically since before December 
2010.  INR testing and warfarin dosing are performed throughout the service in 
accordance with a standard protocol facilitated by the DAWN computer dosing 
programme (version 6.10) [295] and trained staff.  The DAWN software was given the 
order of inclusion criteria (described below) such that 326 patients were selected from 
those accessing each of the hospital (n=100), general practice (n=122) and domiciliary 
(n=104) monitoring services.  INR values were collected retrospectively for 12 months 
(January to December 2011) for each patient, and dose changes and number of INR 
monitoring events were recorded.  Details of age, co-morbidities, chronic drug therapy 
and duration of warfarin therapy were also recorded.  The estimated time within target 
therapeutic range (TTR) was calculated using the linear extrapolation method of 
Rosendaal et al [53].   
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Costs for the monitoring service in 2011 were obtained from the finance department 
at the Newcastle upon Tyne Hospitals NHS Foundation Trust.  Methods followed those 
set out by the BMJ guidelines for economic submissions [296].  Costs of all 
consumables, reagents, depreciation of INR testing equipment and quality control 
materials were calculated per test.  Staff costs, transport, overheads and computer 
equipment were calculated per patient treated.  Costs which were considered common 
and equal to all patients (medical advice, consultant supervision, treatment of adverse 
events) were not included.  The price of portable coagulometer and portable computer 
(assuming a 5 year lifespan) has no impact and the cost of the hospital computer 
server, being common to all groups, was not included.  The price of each domiciliary 
phlebotomy visit was calculated by dividing salary, car lease and insurance, petrol, 
consumables and sample transport by the number of tests.  No patient relied upon 
ambulance or other NHS transport assistance as domiciliary visits are used instead.  
We assumed that patient private travel costs were the same, whether to general 
practice surgery or to the hospital clinic (all patients were eligible for free public 
transport) and we did not collect data on these.  
  
2.3.1. TTR Calculation 
INR data were manually transposed from DAWN into an Excel spreadsheet. Visual 
Basic Calculator software (2000) was used to estimate TTR as shown in Figure 2-1. 
TTR was calculated according to the target INR range 2.0 to 3.0 for all patients. 
  The TTR result obtained manually was found to be identical to that obtained from 
the DAWN software, confirming that DAWN software calculation of TTR was both 
reliable and accurate. 
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Figure 2-1: DAWN software calculator used to calculate TTR 
 
 
2.3.2. Statistical analysis  
Data were coded and entered using Statistical Package for Social Sciences 
(SPSS) version 19.  A one way analysis of covariance (ANCOVA) model was fitted to 
test the difference in TTR, number of INR monitoring events and number of dose 
changes among the three groups.  The influences of the other covariates were also 
examined. Some data were found to be skewed and not normally distributed (number 
of INR monitoring events, number of dose changes, and years on warfarin); therefore, 
they were transformed to their square roots to achieve approximate normality. Chi-
square was used for the comparison of categorical data.    
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2.4. Results  
The mean age ± SD of the hospital patients (54% male) was 83 ± 5, of the general 
practice cohort (46% male) was 82 ± 4 and of the domiciliary patients (26% male) was 
84 ± 5 years. The domiciliary patients were significantly older (F(2,323) = 8.61, P < 
0.0001) with a larger proportion of females [x2 (df = 2) =17.65, P < 0.001] than the other 
two groups. The demographics of the anticoagulated population are shown in Table 
2-1. 
 
Table 2-1: Demographics of the anticoagulated population studied 
 Hospital n(%) General Practice n(%) Domiciliary n(%) 
Male 54 (54%) 56 (46%) 27 (26%) 
Female 46 (46%) 66 (54 %) 77 (74%) 
Total 100 122 104 
Ages (years) 
(mean ± sd) 
83 ± 5 82 ± 4 84 ± 5 
 
 
The important covariates found, and hence allowed for, were age, co-morbidities, 
years on warfarin and total number of medications.  Quality of anticoagulation control 
is shown in Table 2-2. Mean (95% CI) TTR was 78% (74%, 81%) in hospital monitored 
patients, 71% (67%, 74%) in general practice monitored patients, and 68% (65%, 72%) 
in domiciliary monitored patients. After controlling for the covariates, mean TTR means 
was significantly different (F (2,277) = 7.60, P=0.001) between the three groups.  
Patients whose anticoagulation was managed by hospital clinics had a significantly 
higher TTR compared with both domiciliary and general practice groups (Tukey’s HSD 
test), while the TTR in the latter two groups did not differ significantly from each other.  
The back-transformed mean number for INR measurements (95% CI) were13.1 (12.2, 
14.1) v 11 (10.2, 11.8) v 14.2 (13.2, 15.1) and for warfarin dose changes were 2.4 (1.8, 
3.0) v 1.8 (1.3, 2.3) v 3 (2.8, 4.1) in the twelve months for the hospital, general practice 
and domiciliary monitored patients respectively; the number of INR measurements (F 
(2,283) =12.50, P<0.0001), and number of warfarin dose changes (F (2,283) =7.08, 
P=0.001) were significantly different among the three groups. Both hospital and 
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domiciliary monitored based groups had a significantly higher mean number of INR 
measurements than the general practice based group (Tukey’s HSD test), while the 
former two groups did not differ significantly from each other.  Domiciliary monitored 
patients had a significantly greater mean number of warfarin dose changes than 
general practice monitored patients with the hospital based patients being intermediate 
(Tukey’s HSD test), whilst the annual number of warfarin dose changes in hospital and 
general practice monitored groups did not differ significantly.  There was a significant 
difference (F (2,321) = 9.36, P<0.0001) in mean (95% CI) number of years of warfarin 
usage from the time of commencement for hospital 3.7 (2.9, 4.5), general practice 
3.1(2.5, 3.8) and for home 5.2 (4.4, 6.0).  Patients monitored at home were on average 
on warfarin therapy for longer by 1.5 year compared to those monitored at hospital and 
by 2 years compared to those in general practice settings (Tukey’s HSD).  The total 
number of drugs used chronically was significantly negatively related to TTR, (F (1,277) 
= 7.91, P=0.005), slope = -1.23, whereas age had a marginal negative relationship with 
TTR (F (1,277) = 3.59, P=0.05), slope = -0.40.  Both the number of years on warfarin 
therapy and co-morbidities were significantly related to the number of INR 
measurements, (F (1,283) = 6.59, P=0.01), slope = -0.2, (F (1,283) = 8.61, P=0.004), 
slope = 0.07, respectively; and the number of dose changes, (F (1,283) = 8.72, 
P=0.003) slope = -0.03, (F (1,283) = 4.65, P=0.03), slope = 0.07, respectively.   
 
Table 2-2: Mean % of time in therapeutic range (TTR), number of INR monitoring 
events and number of dose changes among the groups 
 Hospital 
Mean(95% CI) 
General Practice 
Mean(95% CI) 
Domiciliary 
Mean(95% CI) 
P-Value 
TTR %  78 (74, 82)a 71 (67, 74) 68 (65, 72) 0.0001 
Number of INR 
monitoring events 
13.1 (12.2, 14.1)b 11 (10.2, 11.8) 14.2 (13.2, 15.1)b <0.0001 
Number of dose 
changes  
2.4 (1.8, 3.0) 1.8 (1.3, 2.3) 3.4 (2.8, 4.1)c 0.001 
Number of years of 
warfarin usage 
3.7 (2.9, 4.5) 3.1 (2.5, 3.8) 5.2 (4.4, 6.0)d <0.0001 
a=hospital patients had higher TTR than GP and domiciliary patients; b=hospital and domiciliary patients 
had higher INR measurements than GP patients; c=domiciliary patients had higher number of dose 
changes than hospital and GP patients; d= domiciliary patients had longer years of warfarin usage than 
hospital and GP patients 
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Patients used a median of six drugs (five cardiovascular medications including 
warfarin) and had a median of three chronic diseases (two cardiovascular diseases 
including atrial fibrillation, plus one other) with no significant difference between the 
groups. As age and total number of drugs increased, TTR fell (P = 0.005). As years on 
warfarin increased, the number of INR measurements (P = 0.01) and dose changes (P 
= 0.003) fell while, as co-morbidities increased, more INR measurements (P = 0.004) 
and dose changes (P = 0.03) occurred. One (domiciliary monitored) patient on 10 
drugs for cardiovascular disease and malignancy, suffered intracranial bleeding, 
following a fall when his INR was 16. Workload and descriptive costs of monitoring are 
presented in Table 2-3; being similar in the three groups, it was not possible to 
calculate confidence intervals around these cost differences as we had no measure of 
variability of cost. 
 
 
Table 2-3: Actual workload and costs (pounds sterling) of the anticoagulant 
monitoring service (adjusted for year 2011)  
 Hospital General practice Domiciliary 
Total number of 
patients monitored  
1,430 2,150 520 
Total INR tests 
performed 
18,105 25,663 6,415 
 
 
C
o
s
t (£
) 
INR tests 5,612 7,955 20,996 
Staff 134,848 195,410 19,916 
Transport - 4,196 59,050 
Computers and  
Software 
2,615 3,933 951 
Total cost (£) 143,075 211,494 100,903 
 
Warfarin cost (£) /pt/yr 
(% of total cost) 
28.2 (21.8) 28.2 (22.2) 28.2 (12.6) 
Cost of warfarin 
monitoring per patient  
per annum including 
medication cost (£) 
128 126 222 
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2.1. Discussion  
In our population, TTR results for hospital and general practice patients were both 
in the upper quartile of patients in the RE-LY study, and even the domiciliary patients 
at 68% were in the second best quartile, consistent with the observation that the 
adequacy of anticoagulant control in routine practice can be broadly comparable to 
that reported in clinical trials [297], and our costs for the ambulatory services were 
similar to those estimated by NICE [281]. 
The limited long-term safety data, the increased bleeding risk for those of 80 years 
or older with impaired renal function or low body weight [298], drug interactions, and 
the lack of a direct antidote or laboratory measure of adherence and response and the 
need for good compliance in view of their short half-lives mean that warfarin will 
continue to have a role for thromboembolic prophylaxis in AF, including in patients with 
cardiac valve replacements for whom outcomes with novel anticoagulants can be 
significantly poorer [299]. Further exploration of effective interventions to increase the 
proportion of INR tests within target range would therefore be worthwhile. 
Patients can move from ambulatory to domiciliary monitoring as their physical or 
mental condition deteriorates, the longer time that our home-monitored patients had 
been taking warfarin reflecting this. Although which patient characteristics influence 
outcomes is not known, domiciliary monitoring and greater chronic disease burden are 
associated with risk of warfarin-related complications [288, 300-302]. The similar 
number of co-morbidities and prescribed drugs in our general practice and home-
monitored patients is perhaps surprising, but it is likely that, as the risk–benefit profile 
of warfarin changed over time, for more dependent patients their warfarin was 
discontinued. Although, as this patient cohort was studied before publication of NICE 
guidance [281-283] no transfers to novel anticoagulants were made, the additional 
availability of this treatment option makes further exploration of their clinical 
effectiveness in this patient group of great importance.  
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2.2. Conclusion  
The novel finding is that domiciliary-based patients had poorer anticoagulant 
control, compared with clinic monitored patients, in spite of having the highest number 
of INR measurements and dose changes, in a service which costs more than the clinic 
service per patient year to finance. As INR testing and warfarin dosing are performed 
throughout the service in accordance with a standard protocol facilitated by the DAWN 
computer dosing programme and trained staff, differences in stability of control are 
likely to be attributable to differences in patient characteristics. 
 
 
The findings of this small retrospective study may not be applicable to a wide 
population and a longitudinal study is required to better establish the relationship 
between patient characteristics and anticoagulation stability control.   
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CHAPTER. 3 IMPACT OF AGE ON LONG-TERM 
ANTICOAGULATION AND HOW GENDER AND MONITORING 
SETTING AFFECT IT: IMPLICATIONS FOR DECISION 
MAKING AND PATIENT MANAGEMENT  
 
3.1. Introduction  
Time in therapeutic INR range (TTR) [53] is an important quality measure of 
anticoagulation control with vitamin K antagonists (VKAs).  Optimising anticoagulation 
control is important as TTR correlates inversely with bleeding and thromboembolic 
complications [303, 304]. 
In an earlier cross-sectional study we established that housebound AF patients 
requiring domiciliary monitoring of INR have poorer anticoagulation control than those 
attending hospital- or general practice- based clinics [305].  Anticoagulation control 
was also poorest in the oldest patients, which may explain their higher risk of warfarin 
related complications than the more independent patients who attend clinic for 
monitoring [293].  Cross-sectional studies, however, are limited by the design, 
providing only a “snapshot” of the outcome and the characteristics associated with it 
at a specific time point and, as such, it is impossible to infer causality.  Only a 
longitudinal design study can identify true age-related changes in anticoagulation 
control, and their possible implications for treatment outcomes.  We therefore set out 
to investigate the impact of ageing, longitudinally, on anticoagulant control in patients 
with atrial fibrillation on warfarin therapy, and the extent to which gender and different 
patient settings of monitoring influence this. In  patients being managed in a standard 
way by staff of the unified Newcastle upon Tyne Hospitals Trust Anticoagulation 
Monitoring Service, for whom  dosing and testing is  guided by the DAWN computer 
dosing programme (version 6.10), Milnthorpe, Cumbria, UK [295]. I audited INR and 
dosage data for mobile patients who attended either the hospital- or general practice-
based clinic based on personal preference, and for patients housebound by physical 
dependency or limited mobility who were monitored through the domiciliary service 
whereby trained staff visited them at their place of residence for venous INR checks. 
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3.2. Aim of the study  
To investigate the impact of ageing, longitudinally, on anticoagulant control in 
patients with atrial fibrillation on warfarin therapy, comparing patients who require 
domiciliary monitoring of INR due to physical dependency and immobility with the more 
independent patients who travel either to hospital- or general practice- based clinics 
for monitoring. 
 
3.3. Materials and Methods  
This study involved the audit of anonymised anticoagulant control data held within 
the secondary healthcare Trust providing and managing the monitoring service and as 
such it was deemed not to require prior institutional board approval.  Inclusion criteria 
were to have AF with a target INR of 2.0-3.0 and to have been on warfarin for at least 
5 years, after excluding a six month initial stabilisation period.  Only patients 
anticoagulated for stroke and systemic embolism prevention in AF were selected to 
reduce bias related to different indications or target INR ranges 
As part of the unified service all patients prior to commencement of therapy 
received a standard 2-3 hour education session led by either a doctor or trained nurse 
at their local general practice, according to the UK National Patient Safety Agency 
(NPSA) educational material [306]. Patients were taught about atrial fibrillation and the 
clinical benefits and risks of anticoagulation. Information was given about the 
pharmacology of warfarin, and factors that affect the INR, particularly adherence, drug 
interactions and diet. Written information and a modified educational session were 
delivered to patients entering the domiciliary service. For clinic attending patients, at 
each monitoring visit, potential reasons for any deviation outside the target range is 
discussed, and education about these and the importance of good adherence stressed 
where appropriate. For domiciliary patients, this is done when the result from the 
venous INR sample is available either by phone or at the next monitoring visit.  
Data mining was facilitated by DAWN which allowed extraction of information on 
individual patients, including a DAWN coded patient ID (in order to preserve patient 
anonymity for data analysis), age, sex, indication for anticoagulation therapy, target 
INR range, date commencing warfarin treatment and warfarin starting dose, duration 
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of warfarin therapy, mean yearly warfarin dose, yearly number of INR monitoring 
events and warfarin dose changes. The raw data were extracted from DAWN as 
separate text files, and then transferred to Excel spread sheets. Excel pivot-tables tool 
was used to clean up and rearrange the data before merging them all in one Excel file 
for statistical analysis.  Information on co-morbidity and concurrent therapy was not 
available. Between 2000 and 2013, based on the study inclusion criteria, 1,490 AF 
patients starting warfarin therapy accessing hospital and general practice clinic and 
627 the domiciliary service were identified. Of these patients 23 were identified as 
having switched setting during the course of warfarin therapy with 10 switching from 
hospital to domiciliary, 7 from hospital to GP, 5 from GP to hospital and 1 from GP to 
domiciliary monitoring. The 23 patients were subsequently omitted from further 
analysis.  TTR and time spent below and above the therapeutic INR range were 
established using the linear extrapolation method of Rosendaal et al [53]. Time in 
therapeutic range is the estimated total percentage of time that the INR is within a 
predetermined therapeutic range which, for AF patients, is between 2.0 and 3.0, with 
time above and below being estimated as total percentage time above an INR of 3.0 
and below an INR of 2.0 respectively. 
The INR at both hospital and GP clinics was determined using the KC1 capillary 
technique according to the manufacturer’s instruction (Trinity Biotech, Bray, Eire). For 
home monitored patients venous INR was determined by Instrument Laboratories 
(their machine and reagents) IL (UK) Ltd, Warrington, and Cheshire. Internal quality 
check was performed daily and external quality assurance undertaken monthly through 
National External Quality Assessment Service (NEQAS), Sheffield, UK. 
 
3.3.1. Statistical analysis 
The mean of the individual variables was determined according to each year of 
age. On examination of the data it was clear that INR control was less good in the 
youngest and oldest patients. We decided to fit a quadratic model with age to the 
means to describe this effect in a fairly simple way and to examine how the covariates 
(setting and gender) affected this model. The numbers of warfarin dose changes were 
transformed into their square roots to approach normality. Quadratic (curvilinear) and 
linear regression models were used to examine the effect of age for all the variables 
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tested.  Weighted analysis was used in all statistical calculations because of the large 
variation in sample sizes across age groups. Individual observations were also 
analysed using random effects to take account of the longitudinal nature of the data.  
This form of analysis was more complex due to the non-normal nature of the data.  The 
same conclusions were obtained and so the analysis of means is presented here as 
the interpretation of the analysis is much more straightforward.  Data were analysed 
using Minitab statistical software (version 17). 
 
3.4. Results  
Data belonging to 2,094 AF patients [938 (44.8%) in general practice (GP) and 
531(25.4%) in hospital (H) based clinics and 625 (29.8%) through the domiciliary 
service (D); altogether 891(43%) females, and 1,203 (57%) males] on warfarin therapy 
for 5-14 years, extracted from DAWN software were analysed, which constituted a total 
of 16,604 patient years of INR monitoring.  Demographic data according to patients’ 
gender, age and setting are shown in Table 3-1.  As over 99% of the study population 
were white Caucasians, no separate analysis by race or ethnicity was possible.  The 
number of patients for every year of age for the whole population, patients monitored 
in clinic (hospital and GP) and those monitored at home are shown in Figure 3-1. 
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Table 3-1: Patients’ demographic data 
 
Home GP & Hospital Total 
Male N (%) 259 (22) 944 (78) 1203 
       *Age mean(SD) 74(7) 67(9) 
 
  
  
Female N (%) 366 (41) 525 (59) 891 
        *Age mean(SD) 76(8) 70(9)  
Total N (%) 625 (30) 1,469 (70) 2,094 
*Age at 6 months after starting warfarin therapy    
 
 
 
Figure 3-1 Number of patients in every age year 
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There was a significant relationship between TTR, time spent above and below 
target INR range and age for the whole population (P<0.0001 in each case; quadratic 
regression analysis) as shown in Figure 3-2.  For the whole patient population, age 
accounted for 70%, 48% and 53% of the variability in mean TTR, time spent above 
and below target INR range, respectively.  TTR showed a biphasic relationship with 
age, increasing to about 67 years of age, declining thereafter.  Unsurprisingly, time 
spent above and below the target INR range showed the opposite pattern (Figure 3-2).  
This relationship held when considering patient setting; thus a significant relationship 
was found between mean TTR, time spent above and below therapeutic range INR 
range and age for both home-monitored patients (P<0.001, R2=0.52; P=0.001, 
R2=0.24; P<0.001, R2=0.36, respectively) and clinic-monitored patients (P<0.001, 
R2=0.36; P=0.009, R2=0.16; P=0.001, R2=0.21, respectively) (Figure 3-3).  Only a 
small proportion of the domiciliary monitored patients were in 24 hour care with no 
difference noted in their TTR versus the cohort as a whole. 
Mean TTR (determined by age) was significantly lower (P<0.001) and the mean 
time spent below therapeutic INR range significantly higher (P<0.05), for patients 
monitored at home than for patients monitored at hospital or general practice clinics 
(Figure 3-3).  There was no significant difference in mean time spent above target INR 
range between patients monitored at home and those monitored in clinic. 
In females the mean TTR was marginally lower [by 1.3% (P<0.001)] and the mean 
time below range marginally higher [by 1.0% (P<0.001)] than those in males.  Sex had 
no significant effect on mean time spent above target INR range. 
For the whole patient population both the number of dose changes (as mean 
square root) (P<0.0001, R2=0.65) and the mean number of INR monitoring events 
(P=0.0001, R2=0.44; quadratic regression) were significantly related to age.  The 
number of warfarin dose changes and INR monitoring events were shown to decline 
until about age 67 years and then increase as patients got older.  Similar findings were 
also noted for both home-monitored patients (square root of number of warfarin dose 
changes: P<0.001, R2=0.40; mean number of INR monitoring events: P<0.001, 
R2=0.31) and clinic-monitored patients (square root of number of dose changes: 
P<0.001, R2=0.31; square root of the number of INR monitoring event: P=0.005, 
R2=0.17).  The homebound patients had a higher number of warfarin dose changes 
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and INR monitoring events compared to clinic-monitored patients for all ages, with the 
difference increasing with increasing age. 
There was a strong and highly significant negative relationship between mean TTR 
and both the mean number of warfarin dose changes and INR monitoring events 
(determined as the square root) (P<0.0001, R2=0.70 and P<0.0001, R2=0.61, 
respectively; linear regression).  Although the general pattern did not differ between 
the sexes, females had a higher age-adjusted frequency of dose changes and 
monitoring events [by 0.15 for the square root of the number of warfarin dose changes 
(P<0.001) and by 1.1 for the square root of the number of monitoring events 
(P<0.001)].  Age accounted for 97% of the variability in mean warfarin dose 
requirement, which fell with increasing age (P<0.0001; quadratic regression).  Females 
required significantly lower warfarin doses (P<0.001) than their male counterparts, 
reflecting a smaller body weight (Figure 3-4a).  Similarly, home monitored patients 
needed significantly lower warfarin doses compared to clinic monitored patients.  
However, the size of the difference in warfarin dose requirements between the two 
groups fell with increasing age (Figure 3-4b). 
A logistic regression analysis was deployed to evaluate the probability of having a 
TTR of ≤65% according to age. A quadratic regression model was found to best fit the 
data (P<0.001).  According to the model, home monitored patients had a higher 
probability of having a TTR ≤65% (P<0.001), compared to clinic monitored patients 
(Figure 3-5a), as did females compared to age-matched males (P<0.001) (Figure 
3-5b). 
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Figure 3-2: (a)TTR, (b) time above therapeutic range and (c) 
time below therapeutic range for the whole patient 
population. The solid lines are the fitted curves and the 
dashed lines are 95% confidence limits based on the 
observed sample sizes.  
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Figure 3-3: TTR for (a) home based and (b) clinic-based patients; time spent above target INR range for (c) home based and 
(d) clinic-based patients; time spent below target INR range for (e) home based and (f) clinic-based patients. The solid lines 
are the fitted curves and the dashed lines are 95% confidence limits based on the observed sample sizes. 
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Figure 3-4: (a) Mean warfarin dose in females (circles) and males (triangles) with lines of best fit (solid lines) and 95% 
confidence limits (dashed lines); (b) Mean warfarin dose in clinic-monitored (circles) and home-monitored patients 
(triangles) with lines of best fit (solid lines)  and 95% confidence limits (dashed lines) 
40 50 60 70 80 90 100
2
.5
3
.0
3
.5
4
.0
4
.5
5
.0
Age(years)
M
e
a
n
 W
a
rf
a
rin
 d
o
se
 (
m
g
)
40 50 60 70 80 90 100
2
3
4
5
6
7
Age(years)
M
e
a
n
 W
a
rf
a
rin
 d
o
se
 (
m
g
)
(a) (b) 
 103 
 
 
 
Figure 3-5: Probability of TTR ≤65% by (a) patient setting and (b) sex 
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3.5. Discussion  
In spite of evidence to support use of oral anticoagulants to prevent stroke and 
systemic embolism in patients with AF [307-309] and the high prevalence of AF of >5% 
in over 70 year olds and >10% in over 85 year olds, many patients do not get optimal 
prophylaxis [310, 311], partly because of concerns about the risk of bleeding. Benefit 
from VKA therapy is greatest for patients remaining within their target therapeutic 
range; bleeding risk is increased when INR exceeds target range and thromboembolic 
events increase when INR is below target range. Stable anticoagulation in patients 
receiving VKA is influenced by anticoagulant service provision, with patients in Europe 
and the UK having better INR control than those managed in North America [312] and 
patients managed by individual clinicians having poorer control than cohorts managed 
in anticoagulant clinics [312].  The anticoagulated patients in our area were well 
managed with a median TTR value of 78.6% at 69 years and 75.8% at 74 years, 
compatible with values reported in Sweden which has a similar anticoagulant 
management system to the UK [55]. 
A comprehensive examination of patient level characteristics predicting TTR in a 
veteran population reported that older age was associated with better TTR, although 
the population studied differed considerably from ours, as it had an upper age band of 
≥ 75, lower average TTR of 61%, a higher mental and physical health burden and only 
2.7% were female [313]. Through our large dataset which allowed a detailed 
examination of ageing effect, we found that the likelihood of having a TTR ≤65% 
increases over the age of 70 years and that not only is anticoagulation control better 
overall in clinic attending than in domiciliary monitored patients, but that in the latter, 
anticoagulation control declines more rapidly with age.  This is in spite of more warfarin 
dose changes and INR monitoring events, and a greater age-related increase in these 
in the home-monitored patients compared to clinic-monitored patients, in an attempt to 
improve control.  It is worth mentioning that TTR and dose changes may have a 
complex relationship such that too frequent changes my impair TTR. This indicates the 
importance of the need for ongoing evaluation of patients once a decision to 
anticoagulate with a VKA is made. 
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Similar to previous reports [314-316], we found that patients at a younger age 
(below 60 years) had poorer anticoagulation control compared to the older patients.  
Possible explanations include poor adherence, social factors such as employment and 
alcohol use, and clinical factors as, at an age below 65 years, in contrast to older 
people, they will have had to have additional clinical morbidities to justify 
anticoagulation.  
The 1.3% lower age-adjusted TTR of women, in spite of more dose changes and 
monitoring events, is consistent with other previous studies reporting on the predictors 
of anticoagulation control [313, 314].  Poor and erratic dietary vitamin K intake in 
women has been suggested as one possible explanation for their poorer 
anticoagulation [315].  The greater proportion of women than men in our domiciliary 
monitored group (59% v 41%) compared to the clinic monitored group (36% v 64%) 
may be one factor contributing to the difference in TTR between them.  
Although identifying modifiable factors contributing to anticoagulation control is 
required for improving care of patients receiving VKAs, the evidence base is very 
limited.  Whilst taking more than 16 medications, and four or more hospitalisations, are 
associated with erratic patterns of INR control, predictors like cancer and dementia are 
associated with directional poor control [317].  In our study domiciliary monitoring and 
female gender were associated with more time spent below target range, which could 
be due to patient factors, especially poor adherence.  Whilst dosing decisions were 
computer driven, and adhered to in the vast majority of monitoring events, staff could 
override these based on clinical circumstances which would also have had the 
potential to influence outcomes.   
In a French study of patients over 80 years, in rehabilitation or institutionalised care, 
poorer anticoagulation control was associated with being in hospital, antibiotic use and 
falls [318]. The conclusions from that study that frequent falls may be a marker of frailty 
and sacropenia, and antibiotic use a marker of acute illness which may result in 
deterioration in chronic co-morbidities and changes in drug use, leading to INR 
instability, may also be relevant to the steeper decline in anticoagulation control 
observed in our domiciliary group.  Whilst our ambulatory patients who attend clinics 
are a less dependent population, in our previous work in a cross-section of this 
population [305] we noted no significant difference in either the number of drugs taken 
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(5 cardiovascular medications including warfarin), or the number of chronic co-
morbidities (2 cardiovascular diseases including AF plus one other), between the 
groups, perhaps because warfarin is discontinued for more dependent patients as the 
risk/benefit balance changes.  This suggests that the poorer stability of anticoagulation 
noted in the domiciliary monitored patients in both our cross-sectional and longitudinal 
study of similar populations is the result of diverse factors which may include dietary 
intake of vitamin K, alcohol intake, weight differences, female gender, cognitive 
impairment, adherence, social support, attitudes and frailty, and not simply co-
morbidities and concurrent use of drugs.  Disease and drug therapy, dietary variations 
and barriers to adherence which include lower cognitive function, poorer physical 
function, living alone and a higher perceived illness burden, require elucidation as any 
influence might also extend to outcomes with the use of new oral anticoagulants 
(NOACs) [319].  The licensing of NOACs presents clinicians with a choice of oral 
anticoagulants, both for newly diagnosed patients and for those who are currently 
taking VKAs. The latter is particularly relevant if anticoagulation control is poor as cost-
effectiveness of NOACs compared to VKAs is highly dependent on anticoagulant 
control [320].  Our results indicate that, for some patients as they age, maintaining TTR 
becomes more difficult, particularly for people who cannot attend a monitoring clinic, 
which raises the question as to whether a NOAC would be a better option for them as 
NOACs offer  benefit in terms of risk reduction in stroke, largely because of reduced 
incidence of haemorrhagic stroke and a greater relative risk reduction in major 
bleeding, when centre-based TTR in VKA treated patients is <66% [240].   
It could be argued that the present study was limited by its retrospective nature.  
However, a retrospective design study for investigating stability of anticoagulation 
control is appropriate given the longitudinal nature of the investigation in a large cohort 
of AF patients, all of whom were anticoagulated with warfarin through a unified 
monitoring service using the same method of dosing.  Further, any selection and 
observational biases were minimised given that information on INR values and warfarin 
doses for individual patients was obtained directly from electronic clinic records 
through the DAWN programme, within the confines of the study inclusion criteria.  The 
effects of co-morbidity and concurrent therapy were not assessed, because data on 
these co-variates were not available through the DAWN programme [295], nor were 
any potential contributions from variances in patient education at initiation of warfarin 
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and at monitoring visits which were inevitable between the clinic and domiciliary 
monitored groups.  Nonetheless, the primary aim of the present study was to examine 
whether age in the context of patient setting per se influences anticoagulation control 
with warfarin rather than identifying the factors which contribute to the variance in 
anticoagulant control and we were able to achieve this in this large cohort studied for 
up to 14 years. This information is relevant as warfarin remains a cost-effective option 
for anticoagulation, with informed decision making between this and a NOAC being 
appropriately made by patient and clinician based on the patient's clinical features and 
preferences.  
 
3.6. Conclusion  
I have demonstrated that there are both inter- and intra-individual differences in 
anticoagulation control achieved with warfarin, influenced by age and gender.  In view 
of the poorer stability of anticoagulation control in older, homebound patients, the 
importance of reviewing patients' anticoagulant management at least annually is 
confirmed.  Exploration of factors affecting anticoagulation control with warfarin, and 
whether such factors might also affect response to NOACs, is warranted.  
There is ample evidence to show that dietary vitamin K affects anticoagulation 
response to vitamin K antagonists including warfarin. However, it is not clear whether 
dietary vitamin K affects the pharmacological activity of NOACs which needs to be 
investigated.  
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CHAPTER. 4 THE IMPACT OF VITAMIN K INSUFFICIENCY ON THE 
PHARMACOLOGICAL ACTIVITY OF RIVAROXABAN IN 
ELDERLY SUBJECTS   
4.1. Introduction  
In recent years several Non-vitamin K antagonist oral anticoagulants (NOACs), 
which selectively inhibit a single clotting factor [factor Xa or factor IIa (thrombin)] have 
been developed with the aim of providing  more predictable pharmacokinetics and 
pharmacodynamics and obviating the need for patient monitoring. The factor IIa 
inhibitor, dabigatran, and factor Xa inhibitors, rivaroxaban, apixaban and edoxaban, 
have been approved for the treatment of thrombosis as well as prevention of stroke in 
patients with atrial fibrillation (AF) according to their licensed indications, having 
demonstrated non-inferiority to warfarin in their clinical effectiveness for stroke 
prophylaxis in patients with atrial fibrillation in the RE-LY, ROCKET-AF, ARISTOTLE 
and ENGAGE AF-TIMI 48 studies [221, 222, 224, 321].  Prescription numbers for 
NOACs have grown rapidly since their launch for newly diagnosed patients requiring 
initiation of anticoagulant therapy and for existing patients on coumarin therapy who 
are switched to a NOAC because of concerns about treatment safety due to poor 
anticoagulation control [322-325]. 
Vitamin K, in its hydroquinone form, is an essential co-factor needed for the -
carboxylation of the glutamic acid residues of the amino-terminals of the coagulation 
proteins II, VII, IX and X, resulting in their activation. Coumarin derivatives, also known 
as vitamin K antagonists (VKAs), cause anticoagulation by inhibiting the recycling of 
vitamin K hydroquinone in the vitamin K cycle, thus inhibiting the activation of the above 
mentioned vitamin K-dependent coagulation proteins [326]. Alterations in dietary 
vitamin K intake affect anticoagulation response to coumarins [327, 328].  People with 
low dietary vitamin K intake require lower warfarin doses to achieve their 
anticoagulation target range and have more unstable control than those with vitamin K 
rich diets [327, 328]. 
It is possible that dietary vitamin K intake not only influences anticoagulation 
response to coumarins but also that to NOACs since the activation of both factor II and 
factor X  is dependent on vitamin K availability. The reported incidences of major 
bleeding in trials of NOACs are contributed to by patient age, with the incidence of 
 110 
 
bleeding being greater in patients aged 80 years and over [222, 321, 329].  The 
bleeding adverse reactions for NOACs may be contributed to by low dietary vitamin K 
intake, of which older patients could be particularly at risk because of their generally 
low dietary vitamin K intake [330, 331] compared to younger patients. The idea that 
dietary vitamin K can affect the pharmacological activity of NOACs in man emanated 
from the earlier findings of the research group that vitamin K insufficiency in rats 
significantly enhanced anticoagulation response to the direct thrombin inhibitor, 
ximelagatran [280]. 
 
4.2. The aim of the study 
To examine the pharmacological activity of the direct factor Xa inhibitor, 
rivaroxaban, in a group of older subjects, with a similar age and characteristics to those 
of older subjects with AF requiring anticoagulation therapy, who were deemed to have 
poor dietary vitamin K intake, compared to a group of younger subjects with adequate 
diets.  
 
4.3. Materials and methods  
The study was approved by the Newcastle upon Tyne Ethics Committee, and it 
was conducted in compliance with the Declaration of Helsinki.  
   
4.3.1. Sample size calculation 
It was hypothesized that poor dietary vitamin K intake enhances the 
pharmacological activity of rivaroxaban. Previously we reported significant differences 
in anticoagulation response between two groups of 15 vitamin K-replete and 15 vitamin 
K-deplete rats [280]. However, as there is no priori information available on the extent 
to which dietary vitamin K affects haematological measures to rivaroxaban ex-vivo in 
man a sample size of 60 subjects (30 with poor dietary vitamin K intake and 30 with 
adequate diets) was deemed to be sufficient to test our hypothesis. 
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4.3.2. Study subjects  
 Subjects with liver dysfunction, or a disease requiring drug therapy which affects 
haemostasis, were excluded from taking part in the study. Following written informed 
consent, 31 medically stable older inpatients (12 males), not on oral or parenteral 
anticoagulants, with suspected poor dietary intake in terms of calories and nutrients 
including vitamin K, and 28 healthy younger subjects (7 males) with adequate diets, 
took part in the study. The older subjects had been admitted to hospital for one of the 
following reasons; fall at home (n=6), infection [urinary tract (3), respiratory (4)], 
exacerbation of chronic obstructive pulmonary disease (4), bone fracture (3), dizziness 
(2), peripheral vascular disease (2), aortic valve implantation (1), haematuria (1), 
pacemaker insertion (1), tinnitus (1), and general poor health (3). Information on co-
morbidities and drug therapy was recorded. Each subject completed a dietary 
questionnaire and provided an overnight-fasted venous blood sample (20ml) collected 
in citrated tubes. Fasted plasma vitamin K concentration was chosen as it is 
representative of vitamin K store in the liver and is a good indicator of vitamin K dietary 
status, and also to decrease post-prandial lipidaemia effect as it is a lipid soluble 
vitamin [110]. Following centrifugation (at 4000 rpm for 7 minutes) the resultant plasma 
samples were aliquoted prior to storage at -80 oC for later analyses.  
 
4.3.3. Assessment of dietary vitamin K 
4.3.3.1. Dietary questionnaire  
Each subject completed a validated food frequency questionnaire (FFQ), based on 
the European Prospective Investigations into Cancer and Nutrition (EPIC) FFQ, for 
quantification of vitamin K content of foods eaten in the previous week [332, 333], but 
modified to expand the sections of high vitamin K-containing foods, Appendix (B) page 
215. In order to increase accuracy of participant recall, the timeframe was restricted 
for participants answering questions on food intake by removing the ‘once a fortnight’ 
and ‘once a month’ options and replacing them with recall only for the previous week. 
The dietary data captured in the questionnaire were analysed using a computerized 
programme which contains the vitamin K values for approximately 1000 food items 
collated from a number of published sources [334]. Vitamin K contents were not 
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available for some food items from these sources; therefore, USDA National Nutrient 
Database for Standard Reference, release 28 [335], was used in addition. 
 
4.3.3.2. Measurement of plasma vitamin K1 concentration 
Plasma vitamin K concentrations  were determined using an  established  high 
pressure liquid chromatography (HPLC) method using post-column derivatization  with 
zinc metal powder [336].  
 
4.3.3.2.1. Samples preparation  
Vitamin K1 was isolated from plasma by a two-step process involving liquid phase 
extraction followed by solid-phase extraction (SPE).  
 
4.3.3.2.1.1. Liquid-phase extraction  
All samples were analysed in duplicate as follows. To suitably marked glass tubes 
0.5 ml of plasma sample was transferred, and then 40 µl of internal standard solution 
(MK-6, 120 pg/µl) was added. 1ml HPLC water was added followed by 2ml ethanol to 
precipitate proteins in the plasma. After vortexing for about 15-20 seconds, 6 ml of 
hexane was added. The tubes were capped and vortexed for about 30 seconds, and 
then centrifuged at 2500 rpm for 5 minutes to allow separation of the aqueous and 
organic phases. The uppermost organic phase was transferred to a new glass tube, 
evaporated to dryness at 45ºC under a stream of air, and the residue reconstituted with 
1ml hexane. 
 
4.3.3.2.1.2. Solid-phase extraction 
Silica SPE cartridges (Sep-Pak® Vac 3 cc (200mg), Waters®, USA) were placed 
in an SPE manifold under vacuum and conditioned with 3ml of 3% diethyl ether in 
hexane followed by 6 ml of hexane. The samples extracted from the liquid phase 
extraction step were loaded onto SPE cartridges and washed with a further volume 
(6ml) of hexane. The retained vitamin K and MK6 (internal standard) were then eluted 
with 6ml 3% diethyl ether in hexane into a new tube. The eluted samples were 
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evaporated to dryness at 45ºC under a steam of air. The residue was reconstituted 
initially with 30 µl dichloromethane, vortexed for two seconds, and then with 100 µl 
mobile phase, and vortexed for a further 10-15 seconds. The reconstituted samples 
were transferred into 1.5 ml Eppendorf tubes, and spun on a benchtop centrifuge for 
2-3 minutes at maximum speed to precipitate any particulate matter, prior to HPLC 
analysis.  
 
4.3.3.2.2. Vitamin K free plasma  
Plasma was obtained from the hospital blood bank, and treated with direct sun light 
for 24-48 hours to obtain vitamin K free plasma. The sun-treated plasma was then 
subjected to HPLC to confirm that no vitamin K was present. It was subsequently 
aliquoted into small volumes and frozen at -20ºC for later use for the preparation of 
quality control samples.     
 
4.3.3.2.3. Preparation of standard curve and quality control 
Pure vitamin K1 was obtained from SIGMA-ALRICH, UK. Hexane (HPLC grade) 
was used to prepare primary vitamin K1 stock solution. The primary solution was then 
diluted with methanol (HPLC grade) to prepare a secondary working stock solution 
which was used for constructing a vitamin K1 standard curve (range 0-1620 pg/ml). 
Appropriate volumes of methanolic vitamin K solution together with 40 µl of internal 
standard (MK-6) were added to Eppendorf 1.5 ml tubes (in duplicate). After 
evaporating under a stream of air, the residue was reconstituted and injected as 
described in section 4.3.3.2.1.2. Quality control samples were extracted in duplicate in 
the same way as mentioned in section 4.3.3.2.1 and tested for with every assay run. 
  
4.3.3.2.4. HPLC instrumentation and conditions  
A Shimadzu VP HPLC machine was used for measuring plasma vitamin K1 
concentration. The system was fitted with a RF-10AXL fluorescence detector (emission 
wavelength 440 nm and excitation wavelength 243 nm). The analytical column was a 
3 µm C18 BDS hypersil, with dimensions of 150 X 3 mm (Thermo, Runcorn) to which 
a post-column zinc reducer was attached. The mobile phase was composed of 
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methanol and dichloromethane [90:10 (v/v)], and 5 ml per litre zinc acid solution (2M 
zinc chloride, 1M sodium acetate, and 2M acetic acid). The mobile phase was run at a 
flow rate of 0.5 ml/min. The run time for each sample was 12 minutes. Vitamin K1 and 
MK-6 were eluted on average at 5.82 and 7.11 minutes, respectively, as shown in 
Figure 4-1.       
 
 
       
 
Figure 4-1: The HPLC chromatogram for vitamin K1 and MK-6 
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4.3.3.2.5. Data analysis  
The chromatograms were analysed using Shimadzu LC Solutions 
Chromatographic software. The standard curve was created by plotting vitamin K to 
internal standard peak height ratio versus vitamin K1 concentration. 
 
4.3.3.2.6. Limits of detection and precision 
 The detection limit of the extracted samples was 10 pg/ml for vitamin K1 (signal/noise 
ratio =3). The inter-day coefficient of variation for vitamin K at 720 and 1008 pg/ml was 
9.4% and 13.6%, respectively. 
 
4.3.4. Haematological assessments 
All tests were carried out at the accredited Haematology Laboratory at the Royal 
Victoria Infirmary and Freeman Hospital, Newcastle Hospitals NHS Foundation Trust, 
Newcastle upon Tyne. Rivaroxaban pure powder was kindly provided by Bayer 
Schering Pharma, (Berlin, Germany). The powder was solubilised in dimethyl sulfoxide 
solution (DMSO) according to the manufacturer’s recommendations, at a final 
concentration of 10µg/ml. 
On the day of each experiment plasma aliquots were allowed to thaw at room 
temperature and utilized within 30 minutes. Using the method of Gerotziasfas et. al., 
[337], plasma samples were incubated with rivaroxaban (0, 100, 250, 400, and 500 
ng/ml) at concentrations similar to drug plasma concentrations observed following oral 
dosing [338-340]. Control plasma samples were incubated in parallel with the clinical 
samples to gauge the accuracy of the measurements. 
 
4.3.4.1. PT, mPT, APTT, and factors II, VII, IX, X 
Prothrombin time (PT) was measured using RecombiPlasTin2G®, and activated 
partial thromboplastin time (APTT) using HemosIL® (Instrumentation Laboratory 
Company, Bedford, MA, USA). Clotting time was also assessed using modified 
prothrombin time (mPT) which is a PT assay modified by adding calcium chloride 
(CaCl2) to the thromboplastin reagent (RecombiPlasTin 2G®) to enhance assay 
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dynamics and expand sensitivity [341]. For this the thromboplastin reagent was 
reconstituted with distilled water, and diluted 1:2.25 with CaCl2  [341]. Vitamin K-
dependent clotting factors II, VII, IX, and X activities in plasma were measured with 
standard clotting assays using respective clotting factor deficient plasma 
(Instrumentation Laboratory Company, Bedford, MA, USA). The IL TOP ACL CTS 
instrument (Instrumentation Laboratory Company, Bedford, MA, USA) was used for all 
the assays. 
 
4.3.4.1.1. Method validation for modified prothrombin time (mPT), PT and 
clotting factor activity   
 Plasma from healthy volunteers was obtained from the blood bank, Royal Victoria 
Infirmary (RVI), Newcastle upon Tyne. The plasma was aliquoted into small volumes 
and stored at -80 ͦ C for further analyses. On the day of each experiment plasma was 
defrosted at room temperature and incubated with rivaroxaban over a range of 
concentrations (0-2000 ng/ml) for a period of 30 minutes followed by analysis. mPT 
was checked across a range of CaCl2 concentrations (25, 50, 75, and 100 mmol/L) 
along with the measurements of  PT, APTT, fibrinogen and clotting factors II, VII, IX, 
and X. To achieve consistent results 1.3 ml plain freeze polyethylene tubes were used 
throughout all experiments. 
Figure 4-2 and Figure 4-3 show typical results for PT and mPT and for PT and 
APTT, respectively, following the incubation of plasma with different concentrations of 
rivaroxaban. 100 mmol/L CaCl2 produced the greatest prolongation of PT whilst 25 
mmol/L CaCl2 had the least effect. These findings were consistent with the results of 
Barret et al. [341]. Typical results for clotting factors II, VII, IX, and X activity are shown 
in Figure 4-4, respectively. Figure 4-5 shows typical results for fibrinogen 
concentration.   
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  Figure 4-2:  PT and mPT (25, 50, 75, 100 mmol/L CaCl2)  
 
 
 
 
Figure 4-3: PT and APTT for control plasma incubated with different 
concentrations of rivaroxaban  
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Figure 4-4: Activity of factors II, VII, IX, and X  
 
 
Figure 4-5: Fibrinogen concentration with different rivaroxaban concentrations  
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Based upon these results, 100 mmol/L CaCl2 was used for the final analysis for 
mPT. The same batch of control plasma was used for all analyses for assessing 
precision and accuracy of the measurements. 
 
4.3.4.1.1.1. PT, mPT 100 mmol/L CaCl2, and APTT 
PT, mPT, and APTT were prolonged following incubation of plasma with 
rivaroxaban as shown in Figure 4-6, and Figure 4-8. Rivaroxaban had no effect on 
fibrinogen concentration as shown in Figure 4-8(D).  The coefficient of variation for 
replicate analysis of samples at baseline and at 100, 250, 400 and 500 ng/ml 
rivaroxaban were as follows; for PT (2.6, 4.8, 2.8, 3.2, 1.9% respectively);  and for mPT 
(6.2, 8.6, 4.6, 10.1, 7.9% respectively).   
 
4.3.4.1.1.2. Clotting factors 
 Clotting factors II, VII, IX, and X activities were reduced across all rivaroxaban 
concentrations as shown in Figure 4-7, and Figure 4-8. The coefficients of variation for 
replicate analysis of samples at baseline and at 100, 250, 400 and 500 ng/ml 
rivaroxaban were as follows; for FIXa (4.5, 4.3, 6.5, 5.4, 6.6%, respectively) and for 
FXa (10.4, 11.1, 12.3, 9.1, 8.6%, respectively).
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Figure 4-6: PT (A), mPT 100 mmol/L CaCl2 (B), and APTT (C) 
prolongation with rivaroxaban in control plasma on 8 
separate days  
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Figure 4-7: The effect of rivaroxaban on clotting factors activity in control plasma on 8 separate days 
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 Figure 4-8: Mean PT and mPT (A), APTT (B),  clotting factors II, VII, IX, and X activity (C), and mean fibrinogen concentration 
(D) in control plasma incubated with rivaroxaban on 8 separate days 
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4.3.4.1.2. The effect of temperature on PT and mPT  
Control plasma samples from the same batch were spiked with rivaroxaban (final 
concentration of 125 and 500 ng/ml) and incubated in a water bath at 37ºC, alongside 
samples kept at room temperature. PT and mPT (CaCl2 100 mmol/L) were measured 
every 10 minutes for 30 minutes. The experiment was done several times on different 
days. Temperature was found to have no effect on either PT or mPT as shown in Figure 
4-9.
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Figure 4-9: The effect of rivaroxaban on PT and mPT at room temperature (A) and at 37ºC (B) 
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4.3.4.2. FIXa and FXa antigen ELISA analysis 
FXa and FIXa antigen levels were measured using a commercially available ELISA 
kit (Diagnostica Stago, Parsippany, NJ, USA). The manufacturer's protocol used is 
shown in appendices (D) and (E) (page 229 and 230). 
 
4.3.4.3.   Thrombin Generation Assay (ETP) 
A modified assay of Perzborn, Morishima, and Douxfils [342-344] was used. 
Thrombin generation assay was performed using the Calibrated Automated 
Thrombogram with Fluoroskan® Ascent Fluorometer (Thermo Fisher Scientific, 
Waltham, MA) and the thrombinoscope software (Thrombinoscope BV).  The assay 
was performed as follows: 20μl high platelet-poor plasma (HPPP) reagent (20pM 
tissue factor and 4 µM phospholipids) and 10μl rivaroxaban solution in DMSO (final 
concentration in plasma: 200 ng/ml), or 10μl DMSO (for baseline measurement) were 
pipetted into individual wells of a 96-well microtitre plate, together with 70μl plasma. 
After 10 minutes of pre-incubation at 37 °C, the reaction was started by the addition of 
20μl FluCa-kit. The fluorescence was measured for 120 minutes at 37 °C (excitation, 
390 nm; emission, 460 nm). The following parameters of the thrombin generation 
assay were analysed; lag time, maximum thrombin generation (peak), time to peak (tt 
peak), endogenous thrombin potential (ETP), and mean thrombin generation rate 
(mTGR). 
 
4.3.5. Statistical analyses 
Data were checked for normal distribution. Where data were not normally 
distributed logarithmic transformation was applied to approach normality. Data were 
compared using Student’s t-test; a p-value <0.05 was considered to be statistically 
significant.  Excel (Microsoft Corp., Redmond, WA, USA), and Statistical Package for 
Social Sciences (SPSS version 22) were used for data reporting and analyses. Data 
are presented as mean±SD. 
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4.4. Results  
4.4.1. Study subjects 
The mean age and mean weight of the older and younger subjects was 87±6 and 
36±10 years (p<0.0001) and 51±12 and 74±13 kg (p<0.0001), respectively. Whilst 
none of the healthy subjects was taking prescribed medication, the patients were 
taking a median of 6 drugs, 3 (47%) of which were classified as affecting the 
cardiovascular system, 1 (10%) the gastrointestinal tract (usually a proton pump 
inhibitor or laxative), and 1 (15%) the endocrine system (most commonly calcium and 
vitamin D or levothyroxine).  Their median number of co-morbidities was 4, most 
commonly cardiovascular disease and cerebrovascular disease (34%). 
 
4.4.1. Dietary assessment  
4.4.1.1. Food Frequency Questionnaire & Plasma vitamin K concentrations  
During the previous week, the younger subjects had consumed significantly more 
vitamin K than the older subjects (217±198 µg (range 38 to 760) v 67±98 µg (range 
<1-363); p<0.0001), with a mean difference of 150 µg, as shown in Figure 4-10.  The 
younger subjects had significantly higher plasma vitamin K concentrations than the 
older ones [383±327 (range 69-1527) pg/ml v 134±82 (range 27-359) pg/ml, 
P<0.0001), as shown in Figure 4-11. The FFQ estimated vitamin K intakes highly 
significantly correlated with plasma vitamin K concentrations (r=0.42; P=0.001). 
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Figure 4-10: Mean weekly amount of vitamin K consumed by the older and 
younger subjects 
 
 
 
Figure 4-11: Mean plasma vitamin K concentration in the older and younger 
subjects 
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4.4.2. Haematological measurements   
Rivaroxaban concentration-dependently prolonged PT and mPT in both younger 
and older subjects, as shown in Figure 4-12.  Rivaroxaban caused a significantly higher 
prolongation of PT and mPT (p<0.01 for both) in older subjects compared to younger 
ones across the rivaroxaban concentration range studied. The mean difference in PT 
between the two groups ranged from 1.8s to 5.0s at 100 ng/ml and 500 ng/ml plasma 
rivaroxaban concentrations respectively. The mean difference in mPT between the two 
groups ranged from 10.0s to 34.0s at 100 ng/ml and 500 ng/ml plasma rivaroxaban 
concentrations respectively.   
The baseline FXa activity was significantly lower (P=0.005) in the older subjects 
compared to the younger ones, whereas the reverse was the case for FIXa (P=0.01), 
as shown in Figure 4-13. According to the biogenic assay there was a significantly 
higher level of functional FX antigen in the younger group compared to the older group 
of subjects (96.2±8.6% v 85.3±18.1%, P=0.005). However, there was no significant 
difference in functional F IX antigen levels between the two cohorts. In both older and 
younger subjects, factor Xa and IXa activity was reduced by rivaroxaban in a 
concentration-dependent manner; the mean cumulative difference from baseline in 
factor Xa activity was not significantly different between the two groups. However, 
rivaroxaban at 500 ng/ml resulted in a significantly greater cumulative difference from 
baseline in factor IXa activity in the older subjects compared to the younger subjects 
(96.17 ±19.01 v 85.30 ±15.61; p= 0.02).  
There were no significant differences between the two groups in factor II and VII 
activity, as shown in Figure 4-14; or APTT, or fibrinogen concentration, as shown in 
Figure 4-15, both with and without rivaroxaban.  
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Figure 4-12: The effect of rivaroxaban on mean PT in the younger and older subjects (A), and on mean mPT (B)  
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Figure 4-13: The effect of rivaroxaban on mean Factor IX and X mean activity in the younger and older subjects 
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Figure 4-14: The effect of rivaroxaban on Factor II and VII activity in the younger and older subjects 
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Figure 4-15: The effect of rivaroxaban on APTT and fibrinogen in the younger and older subjects
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4.4.3. Thrombin Generation Assay (ETP) 
At baseline, younger subjects had a significantly lower lag time (P<0.0001), tt peak 
(P<0.0001), and significantly higher mTGR (P<0.001) compared to the older subjects. 
However, there were no significant differences in peak and ETP between the two 
cohorts Table 4-1.  
In both younger and older subjects rivaroxaban (200ng/ml) significantly affected 
the key parameters of the thrombin generation assay, Table 4-1. Rivaroxaban caused 
a significantly greater prolongation of the initiation phase of thrombin generation, as 
demonstrated by a greater prolongation of lag time, in the older subjects compared to 
the younger subjects (P<0.0001). Rivaroxaban also delayed and suppressed the 
propagation phase of thrombin generation to a greater extent in older subjects 
compared to younger ones, as shown by a prolongation of ttPeak (P<0.001) and 
decreases in both peak (P=0.001), ETP (P=0.001) and mTGR (P=0.001), Table 4-1. 
 
Table 4-1: Thrombin generation assay parameters in human HPPP 
((Mean±(SEM)) 
 
Group 
Lag 
time 
(min) 
Peak 
(nM) 
ttPeak 
(min) 
ETP 
(nM.min) 
mTGR 
(nM/min) 
Baseline 
Younger 
subjects  
2.83 
(0.10) 
304.12 
(11.27) 
5.17 
(0.15) 
1768.66 
(83.21) 
133.44 
(6.86) 
Older 
subjects 
4.05 
(0.18) 
274.90 
(11.43) 
6.85 
(0.21) 
1836.55 
(71.22) 
102.06 
(5.76) 
Rivaroxaban 
200 ng/ml 
Younger 
subjects  
10.83 
(0.49) 
93.16 
(8.00) 
22.47 
(1.00) 
1860.27 
(111.14) 
9.25 
(1.20) 
Older 
subjects 
16.76 
(1.07) 
63.82 
(4.25) 
29.33 
(1.19) 
1479.23 
(78.30) 
5.62 
(0.53) 
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4.5. Discussion 
Whilst the non-inferiority of NOACs to warfarin has been established in clinical trials 
without the need for routine laboratory measurement of clotting factor activity, no 
clinical comparisons between patient cohorts have been performed, and it is unlikely 
that such information will become available in the near future.  It is of concern that very 
old and malnourished people were not well represented in the clinical trials, and clinical 
experience is too short to provide models of use which optimise the benefits of therapy 
and ensure therapy can be safely prescribed.   
A meta-analysis of randomized trials has indicated that in patients with renal 
insufficiency, the recommended doses of NOACs are non-inferior and relatively safe 
compared to conventional anticoagulants [345], which indicates that the increase in 
bleeding risk suggested by adverse drug event reporting and case reports may be 
being contributed to by risk factors of older age and low body weight [298], which may 
themselves be markers of poor dietary intake in general, and of vitamin K in particular.   
As a proof of concept, previously we demonstrated in rats that a reduction in 
vitamin K intake greatly increased anticoagulation response to the direct thrombin 
inhibitor, ximelagatran. Briefly, the study results showed that the anticoagulant activity 
of ximelagatran was significantly greater in rats on a vitamin K deficient diet (by 6.1-
fold for PT, 2.6-fold for APTT and 2.9-fold for Ecarin clotting test), in comparison to 
those on a normal diet. Factor II activity was reduced by ximelagatran to 58% of the 
control values in rats on normal diet. However, factor II activity was virtually abolished 
(<0.1%) by the drug in rats on a vitamin K deficient diet [280]. Until now the effect of 
vitamin K intake in man on the anticoagulation activity of NOACs (direct FXa and FIIa 
inhibitors) has not been reported.  Because of the risk of bleeding it is difficult to 
examine experimentally the effect of dietary vitamin K on the pharmacological activity 
of NOACs in man in vivo. To circumvent this we instead examined ex-vivo the 
pharmacological activity of rivaroxaban in older subjects with poor dietary vitamin K 
intake in comparison with healthy younger subjects with adequate dietary vitamin K 
intake.   
To determine the effect of vitamin K deficiency on the anticoagulant effect of 
rivaroxaban, we performed the clotting time assay, PT and the global coagulation 
assay, thrombin generation assay. PT measures the time taken to initiate clot formation 
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after the stimulation of the extrinsic coagulation pathway. In contrast, the thrombin 
generation assay measures not only the time to initiate thrombin generation but also 
the amount of thrombin formed after stimulation with tissue factor.  
Rivaroxaban produced a greater prolongation of prothrombin time (both PT and 
mPT) in older subjects than in the younger subjects. Currently, there is no specific 
assay with which rivaroxaban activity can be assessed even though it prolongs all 
coagulation assays [253, 255].  However, RecombiPlasTin 2G® used in this study 
appeared to show a good correlation between clotting times and plasma rivaroxaban 
concentrations as previously indicated [252].  
The study results showed that the older subjects had a lower plasma baseline FXa 
activity compared to the younger subjects and that this was attributable to lower levels 
of FXa antigen. The inhibition of FXa activity by rivaroxaban was similar between the 
two groups as expected. However, the net FXa activity in the presence of rivaroxaban 
was significantly lower in the older subjects because of their lower baseline activity. 
Paradoxically, baseline FIXa activity was significantly greater in the older subjects 
compared to the younger ones, which is consistent with the previously reported effect 
of ageing on FXa activity [346].  
Rivaroxaban prolonged time-based parameters of thrombin generation (lag time 
and ttPeak) and suppressed the rate and amount of thrombin generation (mTGR, peak, 
and ETP) to a significantly greater extent in older subjects compared to younger ones. 
The current study results support our hypothesis that consuming low amounts of 
vitamin K can affect the functional levels of FX, and as such, it enhances the 
pharmacological activity of the factor Xa inhibitor, rivaroxaban. Our observation of 
enhanced anticoagulant response to rivaroxaban in plasma from older malnourished 
subjects with low vitamin K intake ex-vivo indicates the importance of identifying factors 
which influence the pharmacodynamics of these drugs through further study in frail, 
vitamin K deficient older people in vivo, to establish whether the therapeutic outcomes 
of using fixed doses without laboratory guidance supported by randomized trial results 
could be improved upon by laboratory-guided dose adjustment in this cohort.      
We purposefully examined the effect of poor dietary vitamin K status on the 
pharmacological activity of rivaroxaban in a group of older subjects, who in general 
had similar characteristics to those of the older population with AF requiring 
 136 
 
anticoagulation therapy. The two study groups differed in age, co-morbidities, drug 
therapy and dietary vitamin K intake.  However, none of the older subjects used any 
drug which affects haemostasis or interacts with rivaroxaban mode of action. The age 
difference and the presence of comorbidities are unlikely to have contributed to the 
significant potentiation of the effects of rivaroxaban in older subjects ex-vivo given that 
baseline clotting parameters (PT and mPT) in the older subjects were similar to those 
of the younger subjects.   
The amount of vitamin K consumed by the older subjects was less than a third of 
that of the younger subjects. The differences in vitamin K dietary status between the 
two cohorts of subjects were further confirmed through the measurement of plasma 
vitamin K concentrations. The observed highly significant correlation between the 
estimated vitamin K intake according to the FFQ and plasma vitamin K concentrations 
indicates that older patients with vitamin K deficiency, and therefore potentially 
increased sensitivity to rivaroxaban, could be identified in the clinic through the use of 
the FFQ alone without the need for using a complicated assay to measure plasma 
vitamin K concentrations. 
The poor nutritional status of the older subjects established through the FFQ in the 
current study is consistent with reports that older people living in Scotland and northern 
England consume significantly lower amounts of foods containing vitamin K, averaging 
under 60 µg per day compared to those living in southern England at around 80 µg per 
day [330, 347].  Moreover, older people living in private houses consume higher 
amounts of vitamin K containing foods, with those in residential and nursing homes 
having significantly lower vitamin K levels than free-living British people [331].  It is of 
concern that older patients requiring anticoagulation therapy were not well represented 
in the ROCKET-AF trial; the median age and BMI of the patients on rivaroxaban in that 
trial were 73 years and 28.3 (IQR 25.2-32.1) respectively with a median creatinine 
clearance of 67 (IQR 52-88) ml/min.  Only “less than a quarter” of the patients in 
ROCKET-AF trial were over 80 years of age or older and a quarter of patients had a 
BMI <25.0 [222].  In contrast 84% of our patients were over the age of 80, and 81% 
weighed less than 60 kg (BMI median 19.5 (IQR 16.8-22.5).  Because of the limitations 
of extrapolating trial data based on a younger heavier population into the older, frailer 
population with low body weight, in particular because of the risk of a major bleed, 
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clinicians must make a careful evaluation of the risk and benefits of treatment before 
starting rivaroxaban.   
 
4.6. Conclusion   
The study suggests possible augmentation of the rivaroxaban anticoagulation 
response in older patients with poor dietary vitamin K intake.  In-vivo studies to 
evaluate this further are required.  
Polymorphisms in the genes for the vitamin K reductase (the main target for 
warfarin) and CYP2C9 (the main metabolizing enzyme for S-warfarin) have been 
shown to influence warfarin sensitivity and dose requirement. However, it is not clear 
whether  genetic polymorphism in these genes in association with diet influence 
stability of anticoagulation control, or whether the polymorphisms influence the speed 
by which anticoagulation declines following cessation of warfarin as is required prior to 
conducting surgical procedure in warfarinised patients. I therefore undertook further 
studies (which are described in chapters 5-7 of my thesis to address these concerns.  
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CHAPTER. 5 VKORC1 (-1639) POLYMORPHISMS DO NOT AFFECT 
LONG-TERM STABILITY OF ANTICOAGULATION WITH 
WARFARIN  
5.1. Introduction 
 In man, vitamin K is obtained primarily from the diet in the form of phylloquinone 
which are found in greatest concentration in green leafy vegetables [334], intake of 
which varies from day to day.  Generally people enjoy having varied diets over different 
seasons of the year. The amount of dietary intake of vitamin K influences warfarin 
sensitivity and variability in INR [348].  Patients with poor dietary vitamin K intake are 
more susceptible to fluctuations in anticoagulation control [349], being more sensitive 
to day to day changes in vitamin K intake because of limited liver stores to stabilise the 
production of the functional clotting factors II, VII, IX and X, for which vitamin K is an 
essential co-factor [111].  Warfarin reduces the regeneration of vitamin K hydroquinone 
from vitamin K 2,3-epoxide by inhibiting vitamin K epoxide reductase (VKOR) in the 
vitamin K cycle [326].  The VKOR enzyme is expressed by the vitamin K epoxide 
reductase gene, VKORC1, in which a number of common polymorphisms have been 
identified.  These polymorphisms, which include a G>A polymorphism at VKORC1 
position -1639 of Intron 1, are associated with altered hepatic VKOR expression and 
lower warfarin dose requirements [149, 350]. 
Stability of anticoagulation control can be improved by daily vitamin K 
supplementation [348, 351], although an initial increase in warfarin dose may be 
required because of the antagonist effect of vitamin K on the pharmacological activity 
of warfarin.  This varies between different patients and is related to VKORC1-1639G>A 
genotype, with those carrying the GG genotype demonstrating a significantly larger fall 
in INR, and requiring a significantly greater increase in warfarin dose, by an average 
of 33%, compared with 11% for those carrying the GA, and <1% for those with the AA 
genotype, following vitamin K supplementation [352].  This is because patients with 
GG genotype are more efficient at converting vitamin K epoxide to vitamin K, leading 
to a greater regeneration of vitamin K hydroquinone and subsequently a larger 
increase in the activation of vitamin K dependent clotting factors compared to patients 
with the GA and AA genotype [352]. 
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5.2. Aim of the study  
Based upon the above observation, it was hypothesized that patients on warfarin 
therapy with the VKORC1(-1639)GG polymorphism could have less stable control of 
anticoagulation than those with GA or AA genotypes as a result of variable dietary 
intake of vitamin K. We set out to examine this possibility in a cohort of patients on 
chronic warfarin therapy. 
 
5.3. Materials and Methods  
The INR values and dose changes of atrial fibrillation patients taking warfarin who 
had attended the Newcastle upon Tyne Anticoagulation Monitoring Service for at least 
18 months for INR testing and dosage advice by staff guided by the DAWN dosing 
programme [295], and had VKORC1–1639G>A established in our previous studies of 
effect of VKORC1 on warfarin dose requirements, were analysed. Since patients 
commencing warfarin require an initial dose titration period following a loading dose 
regimen to reach anticoagulation stability, the first six months from the time of warfarin 
commencement were excluded and the subsequent 12 months data analysed. TTR 
was calculated by the method of Rosendaal et al [53]. The study was approved by the 
Regional Ethics Committee and was in accordance with the Helsinki Declaration of 
1975.   
The software used, and INR data entry to calculate TTR were as mentioned in 
section 2.3.1 page 85. 
 
5.3.1. Statistical Analysis 
Statistical analysis was conducted by Statistical Package for Social Sciences 
version 21 (SPSS). One way analysis of covariance (ANCOVA) was used to examine 
the difference in TTR, number of INR measurements, mean dose, and number of dose 
changes among the three VKORC1 variants (GG/GA/AA) taking into account the effect 
of age and sex covariates.   
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5.4. Results  
234 patients [106 (45%) female] were included in the study. The prevalence of 
VKORC1 AA, GA, and GG variants was 18.4%, 56.4%, and 25.2% respectively. The 
mean age ± SD between AA, GA, and GG variants groups were similar, 64±18, 63±15, 
and 63±13, respectively. No statistical differences were observed between the three 
variants (GG GA AA) in mean TTR (66%, 61%, 68%, respectively), mean number of 
INR monitoring events (12.4, 13.5, 13.0, respectively), and mean dose changes (3.9, 
4.0, 3.3, respectively). Similarly there were no significant differences in these 
measurements between AA and GG+GA genotypes. However, patients with GG 
variant required a significantly higher mean warfarin dose compared to those with GA 
variant (4.0 mg v 3.3 mg; P=0.02) with a mean dose difference of 0.7mg. However, no 
difference in dose requirement was observed between AA (mean dose=3.2 mg) and 
GA variants and between AA and GG variants. No influence of age and sex covariates 
was detected. 
 
5.5. Discussion  
  Identifying and controlling factors which contribute to intra-individual variability in 
response to vitamin K antagonists would improve the average time patients stay within 
their therapeutic INR range, lowering the risk of bleeding or thromboembolic 
complications associated with over and under-anticoagulation, helping individual 
patients, especially the very elderly, who have difficulty attending for monitoring and 
receiving dosing instructions [292]. Polymorphisms in CYP2C9 and VKORC1 are 
relevant to this in clinical practice as both contribute to the inter-individual variability in 
coumarin dose requirement and stability of anticoagulation control during the initiation 
phase of therapy [43]. Excessive anticoagulation occurs more frequently in the carriers 
of CYP2C9*3 variants (slow S-warfarin metabolisers) at the initiation of treatment and 
carriers have a lower TTR than those with the wild type CYP2C9 genotype [353, 354]. 
Compared to the VKORC1-GG genotype, the GA genotype results in less expression 
of VKOR enzyme, so that a lower dose of vitamin K antagonist is needed to achieve 
the same anticoagulant effect [353]. Our results, which show that GG genotype 
patients required a significantly higher mean warfarin dose compared to GA genotype 
patients, is consistent with this observation. Results of a study which employed a 
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questionnaire assisted estimation to identify patients with low, medium and high 
vitamin K intake indicated that the influence of vitamin K intake on warfarin 
anticoagulation might be VKORC1 genotype dependent as, in subjects with a variant 
VKORC1 – 1639G allele, the mean daily dose of warfarin was significantly attenuated 
by low vitamin K intake compared with medium and high whilst no such effects were 
observed in homozygous patients for the VKORC1-1639A allele [352, 355]. As 
retrospective data were used for this study, limitations for the study include lack of 
information on patients’ comorbidities and concurrent drug therapy, weight and a direct 
assessment of dietary vitamin K consumption; in consequence, any correlation 
between warfarin dose requirement and vitamin K consumption could not be 
evaluated. However, these appear not to have made any significant contribution within 
the context of this study as the results revealed no difference in % TTR between the 
three VKORC1 variants. It should be noted that the main objective of the current study 
was to investigate the long-term stability of anticoagulation control in association with 
VKORC1 polymorphism with the background of a variable diet. Therefore 
polymorphisms in genes which either affect warfarin (CYP2C9) or vitamin K 
metabolism (CYP4F2) would have no effect on anticoagulation control in patients who 
are on chronic maintenance warfarin therapy. 
 
5.6. Conclusion  
The study results, which failed to confirm the hypothesis that longterm 
anticoagulation control is affected more in patients with the VKORC1(-1639)GG 
variant, in association with the expected variability in dietary vitamin K, indicate that 
the effect of any such influence at the pharmacological level is too small to influence 
clinically relevant outcomes in our population. However, it remains possible that a 
larger prospective study, in which dietary intakes of vitamin K were measured, might 
yet establish a statistically significant link between diet, VKORC1 polymorphism and 
anticoagulation control. 
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CHAPTER. 6 INFLUENCE OF CYP2C9 POLYMORPHISM ON THE 
FALL IN INTERNATIONAL NORMALIZED RATIO IN 
PATIENTS INTERRUPTING WARFARIN THERAPY BEFORE 
ELECTIVE SURGERY 
6.1. Introduction  
Warfarin is prescribed as a racemic mixture of R- and S- enantiomers, with the S- 
enantiomer being approximately 3-5 times as potent as the R- enantiomer [356].  S- 
warfarin is hydroxylated by the CYP2C9 enzyme to its inactive metabolite [356].  
Mutations in the CYP2C9 gene result in the expression of two common allelic variants, 
CYP2C9*2 and CYP2C9*3.  Both CYP2C9*2 and CYP2C9*3 enzymes exhibit reduced 
catalytic activity compared to the wild-type CYP2C9*1 enzyme, to 12% [357] and 5% 
respectively [358].  30% of Europeans carry at least one of these variant alleles [357], 
with heterozygotes for CYP2C9*2 requiring on average almost 2 mg/day and 
CYP2C9*3 heterozygotes requiring almost 2.3 mg/day less warfarin to achieve 
therapeutic anticoagulation, than those without a variant allele [141]. 
S-warfarin elimination half-life ranges from ~28 h to ~118 h depending on CYP2C9 
genotype [359]. In recognition of this, genotype-guided dosing algorithms have been 
introduced to improve the accuracy and efficiency of warfarin dosing during the 
initiation of therapy [179, 360, 361]. Patients on anticoagulation therapy with warfarin 
who are due for invasive surgery are required to withdraw from the drug for a 
recommended period of 5 days to minimise risk of perioperative bleeding. It can also 
be predicted that normalisation of coagulation after interruption of warfarin could be 
more than the expected recommended 5 days before elective surgery in patients 
carrying the CYP2C9 variant alleles [88].  Several non-vitamin K antagonist oral 
anticoagulants (NOACs) have recently been approved which offer alternatives to 
warfarin and knowledge of how long to withdraw warfarin is important not only for 
patients undergoing planned surgical procedures, but also for when transitioning 
patients from warfarin to one of these drugs. 
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6.2. Aim of the study 
To establish whether there is a clinically relevant genetic influence upon INR decay 
and therefore a potential role for a genotype-based personalised algorithm to predict 
the time required for dissipation of anticoagulant effect of warfarin after its withdrawal. 
 
6.3. Materials and Methods  
6.3.1. Patients and materials 
 The study had approval from the South West Frenchay Research Ethics 
Committee. All patients provided written informed consent according to the Declaration 
of Helsinki. Patients aged ≥ 18 years, receiving warfarin therapy for venous 
thromboembolism or atrial fibrillation, with a target INR range of 2.0–3.0, who were to 
interrupt warfarin therapy prior to elective surgery according to our local hospital 
protocol, were identified through the surgical preadmission clinic in the Newcastle upon 
Tyne Hospitals NHS Foundation Trust and invited to take part. Exclusion criteria were 
having a chronic condition that might affect warfarin metabolism, especially 
hepatobiliary disease, having acute illness prior to surgery, and taking any medication 
or excess alcohol intake that could have affected the anticoagulation response. After 
informed consent had been obtained, demographic data on age, height, weight, 
gender, daily warfarin dose, indication for anticoagulation therapy, medical diagnosis, 
surgical operation planned and concomitant medication were recorded. A blood 
sample was taken for later CYP2C9 genotyping [362].  
The current local hospital protocol is to withhold warfarin for 5 days before any 
high-bleeding-risk invasive procedures can take place. For elective procedures, the 
patient’s INR is checked 1 day before the procedure, and, if the INR is ≥ 1.5, 0.5 mg of 
oral vitamin K may be given, and the INR checked again on the day of the procedure. 
The INR at the pre-assessment clinic and on the day before planned surgery were 
recorded, as was whether vitamin K was given to reverse anticoagulation. 
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6.3.2. Sample size calculation 
Approximately two-thirds of the general population have the CYP2C9*1*1 
genotype, and one-third have at least one CYP2C9*2 or CYP2C9*3 allele. If the 
proportion of patients having an INR of > 1.5 is 0.05 among the CYP2C9*1*1 patients 
and 0.25 among those with at least one CYP2C9*2 or CYP2C9*3 allele, then a study 
of 150 patients will have an approximately 80% power for detecting a difference in the 
incidence of having an INR of ≥ 1.5 between the two groups.  
 
6.3.3. Statistical analysis of data 
IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA) 
was used to carry out statistical analysis. The proportions of individuals with the 
CYP2C9*1*1 genotype and either CYP2C9*2 or CYP2C9*3 variant allele were 
compared with the proportion of individuals with two variant alleles for those with an 
INR of < 1.5 versus ≥ 1.5 on the day before planned surgery, by use of the chi-square 
test. One-way ANOVA was used for comparison of continuous variables. Mean 
warfarin daily doses were transformed by taking the logarithm of each value to obtain 
a normal distribution, thus allowing for parametric tests to be performed. The effects of 
genotype and other variables on the fall in INR were investigated with both logistic 
regression and multiple regression models. Data are presented as mean ± standard 
deviation, unless stated otherwise. A P-value of < 0.05 was considered to be 
statistically significant. 
 
6.3.4. Samples preparation and genotyping assay  
6.3.4.1. DNA extraction from whole blood 
Sodium ethylene diamine tetra acetic acid (EDTA) tubes were used to collect blood 
samples, and were stored at -80ºC until DNA extraction by using a modified method 
described by Daly et al [363]. Initially, preparation of nuclei was done by adding 1 ml 
of blood to 4 ml of cell lysis buffer (10mM Tris-HCL, 320 mM sucrose, 5mM MgCl2, 1% 
Triton X, pH8) followed by mixing gently for 2 minutes, and then centrifugation at 3000 
for 10min at 4º C. After discarding the supernatant, the remaining pellet was re-
suspended with 350 µl of nuclear lysis buffer (400mM Tris-HCl, 60 mM EDTA, 150 mM 
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NaCl, 1% Sodium Lauryl Sulphate, pH8) and finally 0.5 ml (5M) of sodium perchlorate 
was added to denature plasma proteins. The resulting suspension was rotary mixed 
for 15 minutes and then incubated for 30 minutes at 65ºC. 0.5 ml of chloroform was 
added and the mixture was rotary mixed for 10 minutes followed by centrifugation at 
1500 for 5 minutes. The aqueous uppermost DNA-containing phase was transferred 
to a new tube and 1ml of ethanol was added. The DNA was precipitated out of the 
solution by immediately inverting the tube, and then centrifuged at 14000 for 3 minutes. 
The ethanol was discarded gently and the DNA was allowed to dry at room temperature 
for 10-15 minutes. Finally, the DNA was re-suspended with 75 µl 5mM Tris buffer, pH8, 
and incubated overnight at 60ºC, and subsequently stored at 4 ºC until required.         
 
6.3.4.2. CYP2C9 Genotyping using TaqMan assay 
All samples were genotyped for CYP2C9 *2 and *3 alleles separately using 
TaqMan® SNP genotyping assay manufactured by Applied Biosystems.  Each 
TaqMan® SNP genotyping assay is composed of a specific, ready-to-use tube which 
contains (a) 2 sequence-specific primers for amplifying the polymorphism of interest, 
and (b) TaqMan MGB allele-specific probes for identifying the alleles for the specific 
SNP of interest. The assays are designed as 20X single tube mixtures (187.5 µl) of 
forward and reverse primers (900 µM) in addition to two reporter probes (200 µM). The 
5’ end of each probe is connected to different fluorescent allele-specific dyes; a 
Fluorescein amidite (FAM) is  allele 2 specific while VIC is the reporter for allele 1. The 
2X TaqMan universal PCR MasterMix® (Applied Biosystems) used encompasses 
AmpliTaq Gold® DNA polymerase, dNTP and passive internal reference based on 
proprietary ROX dye.   
20 µl of either *2 or *3 probes was added to 250 µl of universal MasterMix®, and 
mixed properly by vortexing. Using a (8X6) 48-well plate, 5µl was transferred from the 
mixture into each of the required wells, followed by 5µl (=50ng) from each diluted DNA 
sample. Control samples (positive and no template controls) were used in each plate 
also. The plate was covered with a sticker, and centrifuged at 100 rpm for one minute, 
and finally analysed using the One Step Applied Biosystems real time PCR machine. 
PCR temperature was retained on hold for 10 min at 95 °C then decreased to 92 °C 
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for 15 sec (denaturation) and further decreased in annealing  and extension stages to 
60 °C for 1 min each for 40 cycles.    
The allelic fluorescence detection system which determines and plots different 
fluorescence signals on a partitioning chart (X or Y axis) is linked to the StepOne® 
software v2.1. Upon finishing the experiment, distinct groups with different colours (red, 
green, or blue) are usually displayed with wide separation based on their defined 
genotypes in an allelic discrimination plot. Signals which located horizontally to the end 
side towards the X axis was described as homozygous of one allele (XX); signals which 
located upward vertically towards the Y axis were represented homozygosity for the 
other allele (YY) whereas those which moved in between the X and Y axis showed the 
heterozygous genotype (XY), as shown in Figure 6-1.  
As two CYP2C9 variants (*2 and *3) were examined for each subject, the result 
from each variant was combined with the other, resulting in combinations mentioned 
in Table 6-1.  
 
Table 6-1: Subjects' genotypes according to CYP2C9 *2 and *3 variants results  
Subject  *1 *2  Variant *3 Variant Genotype 
1 +ve -ve -ve *1*1 
2 +ve -ve +ve *1*3 
3 +ve +ve -ve *1*2 
4 -ve +ve +ve *2*3 
5 -ve +ve -ve *2*2 
N.B. No CYP2C9 *3*3 genotype was detected in our study population  
    
 
 
 
 
 148 
 
 
Figure 6-1: Allelic discrimination plot of TaqMan SNP genotyping assay.  Blue 
cluster is homozygous wild type (*1*1 = XX), red cluster is homozygous mutant (*2*2 
or *3*3 = YY), and the green one is heterozygous (*1*2 or *1*3 =XY). Black cluster 
shows the no template control and samples that failed to amplify. 
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6.4. Results 
One hundred and fifty-two patients (50 [33%] females, and 102 [67%] males) were 
studied. Patient characteristics, reasons for anticoagulation and type of surgery are 
shown in Table 6-2.  
 
Table 6-2: Patient characteristics, reasons for anticoagulation and type of 
surgery undergone 
  Male Female 
N (%) 102 (67) 50 (33) 
Age (years) [mean (range)] 74 (43-90) 72 (49-93) 
Weight (Kg) (mean±SD) 88±17 81± 19 
Warfarin weekly dose (mg)  
(mean±SD) 28.7±10.3 27.4± 14.0 
   
Indication for anticoagulation  N % 
Atrial fibrillation 125 82 
Venous thromboembolism 27 18 
   
Type of Surgery N % 
Musculoskeletal  58 38 
Genitourinary 55 36 
Renal 17 11 
Cardiovascular 11 7 
ENT 8 5 
Other  3 2 
 
The patients were of white British ethnic background, had a median of two chronic 
diseases (interquartile range [IQR] 1–3), one of which was a cardiovascular disease, 
and received chronically a median of four drugs (IQR 3–6); three cardiovascular drugs, 
including warfarin, and one from another pharmacologic class. None of the 
concurrently taken drugs was deemed to interfere with warfarin disposition or its 
pharmacologic activity, as per the study exclusion criteria. 
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The proportion of individuals with CYP2C9 genotypes, their INR status before 
surgery and whether they received vitamin K are shown in Table 6-3. In total, INRs 
were ≥ 1.5 by day 5 of warfarin interruption in 27 patients. Of these, 14 (52%) were 
given vitamin K on day 5, according to surgical preference. For 10 patients, the INR 
was < 1.5 on the following day, and they underwent surgery; for four patients, surgery 
was postponed. Haemoglobin levels were significantly lower in the patients after 
surgery (mean difference of 1.54 g dL–1, P < 0.0005), with no difference being seen 
between the groups who did and did not receive vitamin K, and no patient in the latter 
group had a clinically significant bleed.  
 
Table 6-3: The proportion of individuals with CYP2C9 variant alleles, their INR 
status before surgery, and whether they received vitamin K 
Genotype 
Status of INR 
Total 
N(%) 
% INR 
≥ 1.5 
Patients with INR ≥1.5 
who received vitamin K 
N(%) 
<1.5 
(N) 
≥1.5 
(N) 
*1*1 78 14 92 (61) 15 6 (43) 
*1*2 30 5 35 (23) 14 4 (80) 
*1*3 13 2 15 (10) 13 1 (50) 
*2*2 1 3 4 (3) 75 0 (0) 
*2*3 3 3 6 (4) 50 3 (100) 
Total 125 27 152 18 14 (52) 
 
A forward selection and backward elimination logistic regression analysis indicated 
evidence of a significant relationship between genotype and INR status on the day 
before surgery (logistic regression chi-square = 9.74, d.f. = 1, P = 0.002). For those 
with two CYP2C9 variant alleles (CYP2C9*2*2 or CYP2C9*2*3), the odds of having an 
INR of ≥ 1.5 on the day before planned surgery were 8.64 times greater (95% 
confidence interval [CI] 2.25–33.25) than for other patients. There was no significant 
correlation between warfarin dose and the probability of an INR of ≥ 1.5, or < 1.5, after 
withdrawal, and no influence of other variables on the fall in INR was detected with the 
logistic regression model. Multiple regression analysis revealed that the rate of the fall 
in INR was significantly influenced by CYP2C9, age, weight, index INR value (the INR 
at the preadmission clinic), and number of comorbidities (F5,132 = 242.9, P < 0.0001), 
which accounted for ~ 90% of the interindividual variability in the fall in INR, as shown 
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in Table 6-4. The results show that the rate of the fall in INR is reduced in the presence 
of two CYP2C9 variant alleles, as well as increasing age, weight, and number of 
comorbidities, and is increased with increasing index INR.  
As expected, patients with two variant alleles (CYP2C9*2*2 or CYP2C9*2*3) 
required significantly lower mean weekly warfarin doses (20 ± 6.2 mg; F2,138 = 3.7, P = 
0.03) than those with homozygous CYP2C9*1*1 alleles (29.4 ± 10.4 mg), with those 
with a single variant allele, i.e. CYP2C9*1*2 or CYP2C9*1*3 (28.0 ± 13.9 mg) being 
intermediate. The algorithm for the rate of INR decline is as follows: 
𝐼𝑁𝑅 𝑑𝑒𝑐𝑙𝑖𝑛𝑒 = −0.195 − 0.00428(𝐴𝑔𝑒(𝑦𝑒𝑎𝑟𝑠)) − 0.2374(𝐶𝑌𝑃2𝐶9 𝑑𝑜𝑢𝑏𝑙𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡)
+ 0.9143 (𝐼𝑁𝑅 𝑣𝑙𝑎𝑢𝑒 5 𝑑𝑎𝑦𝑠 𝑏𝑒𝑓𝑜𝑟𝑒 𝑠𝑢𝑟𝑔𝑒𝑟𝑦) − 0.00246 (𝑊𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔))
− 0.0306 (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑖𝑒𝑠) 
 
Table 6-4: Summary statistics and results from multiple regression analysis 
     95% CI 
Term Estimate Std. Error t P-value Lower Upper 
(Constant) -0.195 0.234 -0.84    0.4040 -0.616 0.238 
Age -0.00428 0.00211 -2.03    0.0450  -0.008 -0.001 
CYP2C9 
variants 
-0.2374 0.0680 -3.49    0.0010  -0.365 -0.103 
Weight (Kg) -0.00246 0.00102 -2.42    0.0170  -0.004 -0.001 
Number of 
comorbidities 
-0.0306 0.0130 -2.36    0.0200  -0.048 0.000 
Index INR  0.9143 0.0291 31.37    <0.0001  0.851 0.958 
CI=confidence interval; INR=International Normalized Ratio. R2 = 89.9%, adjusted R2 = 89.5% 
 
6.5. Discussion  
Coagulation returns to normal over several days after warfarin withdrawal.  In 
consequence, for patients on chronic therapy with warfarin awaiting invasive surgery, 
guidelines suggest that warfarin is stopped 5 days before the event to minimise the 
risk of perioperative bleeding [88].  Whilst evidence suggests that INR values average 
1.24 (95% CI 1.19-1.29) after a five day warfarin interruption [364], some patients have 
an INR >1.5 on the day of planned surgery. 
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In one study of 22 patients with a mean steady-state INR of 2.6, although their 
mean INR 115 hours (4.7 days) after discontinuation of warfarin therapy was 1.1, 5 of 
the 22 patients (23%) had an INR of 1.2 or greater.  In the total cohort, and consistent 
with our findings, age was a significant independent predictor of smaller decreases in 
the INR between day 1 and day 3 [365].  Warfarin dose requirements fall with 
increasing age and there is a significant positive correlation between liver volume and 
dosage [93].  The age related fall in dose requirements and the slower decline in INR 
indicating slower warfarin metabolism is explainable by the fall in liver volume with age 
with resultant fall in the absolute content of the enzymes involved in its metabolism. In 
a larger study involving 224 outpatients with high risk of arterial embolism (prosthetic 
heart valve or atrial fibrillation), 15 patients (7%) had a preoperative INR >1.5 five days 
after warfarin withdrawal and needed vitamin K administration, although the factors 
influencing this were not investigated [366].  Because some patients, despite 
withholding warfarin, remain anticoagulated for surgery, many hospitals admit 
anticoagulated patients on the day before elective surgery to check their INR and 
administer vitamin K if needed, in order to avoid surgery being postponed.  This adds 
costs to the admission and risks a potentially wasted operation slot if the INR is >1.5 
on the day of surgery in spite of vitamin K administration.   
A personalized genotype-based approach in routine care could facilitate the 
ongoing management of patients scheduled for warfarin withdrawal prior to an invasive 
procedure. This might bring benefits in terms of reducing potential harm caused either 
by discontinuing warfarin too early (thus predisposing the patient to thrombosis) or 
stopping it too late (resulting in possible perioperative bleeding).  
In recent years several direct oral anticoagulants (NOACs), which selectively inhibit 
a single clotting factor (factor Xa inhibitions or factor IIa (thrombin) inhibitors), have 
been developed and approved for the treatment of thrombosis, as well as prevention 
of stroke in patients with atrial fibrillation (AF) having demonstrated non-inferiority to 
warfarin in their clinical effectiveness [221, 222, 321].  Prescription numbers of NOACs 
have grown rapidly since their launch, mainly for newly diagnosed patients requiring 
initiation of anticoagulant therapy but also for existing patients on warfarin therapy who 
are switched to a NOAC because of concerns about the safety of warfarin therapy 
[322-325].  Tailoring the current standard warfarin withdrawal protocols according to 
each individual patient’s CYP2C9 genotype could bring potential benefit to healthcare 
 153 
 
providers in terms of improved delivery of care and patient satisfaction, and reduction 
in costs, through a reduction in cancellation or delays of planned invasive procedures 
in patients on warfarin therapy.  A genotype-guided protocol could also be beneficial 
for when transitioning patients from warfarin to one of the new oral anticoagulants. 
Polymorphisms in CYP2C9 (encoding CYP2C9, which metabolizes S-warfarin) 
and VKORC1 (encoding vitamin K epoxide reductase, to which warfarin binds, thereby 
inhibiting vitamin K recycling in the liver) significantly influence the sensitivity to 
warfarin and the daily warfarin dose requirement [43]. The study hypothesis was that 
the rate of fall in the INR following warfarin withdrawal is mainly influenced by 
polymorphisms in CYP2C9 rather than by polymorphisms in VKORC1. However, 
because we did not investigate VKORC1 polymorphisms in the study cohort, we are 
unable to refute or confirm any such influence on the fall in the INR. Although the 
assumption of 67% of the European general population having the CYP2C9*1*1 
genotype was close to the 61% achieved in the study cohort, not all patients with 
CYP2C9 variant alleles had an INR of ≥ 1.5 and our assumption regarding the 
probability of an INR of ≥ 1.5 in the different genotype groups turned out to be incorrect.  
 
6.6. Conclusion 
This is the first study to establish that rate of fall in the INR on warfarin withdrawal 
is dependent on CYP2C9 genotype, and that normalization of coagulation takes place 
more slowly in patients with CYP2C9 mutations, with those with two CYP2C9 variants 
being more than eight times more likely to have an INR of ≥ 1.5 on the fifth day of 
warfarin withdrawal. Although the influence of CYP2C9 genotype and age on warfarin 
elimination is well established, further research is needed to assess whether the 
relationships noted between the rate of fall in the INR and weight, number of 
comorbidities and the index INR can be replicated. 
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CHAPTER. 7 FURTHER EVALUATION OF THE EFFECT OF 
GENETIC AND PATIENT FACTORS ON INR DECLINE 
FOLLOWING WARFARIN WITHDRAWAL  
 
7.1. Introduction  
In my previous study (0) of the effect of CYP2C9 genotype upon INR decline, 
patients with two CYP2C9 variant alleles (CYP2C9*2*2 or CYP2C9*2*3) were found 
to be over 8 times more likely (95% [CI] = 2.25–33.25) to have an INR of ≥ 1.5 on the 
day before planned surgery compared to those with either *1*1, *1*2 or *1*3 genotypes. 
However, the possible influence of other factors, including VKORC1 polymorphism as 
well as patient and clinical factors, on the rate of INR decay after cessation of warfarin 
therapy is yet to be determined. 
 
7.2. Aim of the study 
To further characterise the contribution of genetic, patient and clinical factors 
toward warfarin elimination and its changing pharmacodynamics in patients with 
thromboembolic disease following warfarin withdrawal. 
 
7.3. Patients, materials and methods  
The study had the approval of the Newcastle upon Tyne Ethics Committee. All 
patients provided written informed consent according to the Declaration of Helsinki. 
135 Caucasian patients aged over 18 years, completing a course of warfarin for 
indications of either venous thromboembolism (VTE) or atrial fibrillation (warfarin 
therapy stopped after successful cardioversion), with a target INR of 2.0-3.0 and stable 
control of anticoagulation (defined as having a stable warfarin dose for at least the 
previous 2 clinic visits a minimum of one week apart), were identified through the 
anticoagulant clinic records at the Newcastle upon Tyne Hospitals NHS Foundation 
Trust, UK. Any patient with a condition which might affect warfarin metabolism, notably 
congestive cardiac failure, hepatobiliary or renal disease or active cancer, taking 
medication known to interact with warfarin, or drinking more than the recommended 
safe limits in the UK (14 units per week for men and women) [367] was excluded. 
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Demographic data of age, weight, sex, daily warfarin dose, indication for 
anticoagulation therapy, medical diagnoses, concomitant medication and alcohol 
intake, were recorded. Each patient attended the clinic on 3-4 separate occasions, 
spread over 9 days, beginning the day after their last dose of warfarin, with some 
variation to avoid scheduling conflicts (e.g. weekends) and missed appointments. At 
each visit venous blood (10 ml) was collected for determination of INR and plasma 
warfarin enantiomer concentrations. The blood sample obtained at the first visit was 
also used for CYP2C9 and VKORC1 genotyping.  
The rates of decline in INR and plasma warfarin enantiomer concentrations for 
individual patients were determined from the slope of the plot of INR versus time and 
plasma S- and R- warfarin concentration versus time, respectively. The rate of decline 
in plasma S- and R-warfarin concentration was subsequently used to calculate warfarin 
enantiomer half-life using the formula 0.693/slope. S- and R- warfarin clearance (CL) 
was calculated according to the formula: D/(2t X Css.av), where D is the daily dose of 
warfarin (mg), t is the dosing interval (24 hours), and Css.av is the average steady-
state plasma warfarin enantiomer concentration (mg/L), assuming that warfarin 
compliance and bioavailability are 100% [368]. 
 
7.3.1. Sample size calculation  
According to previous studies INR reached a value of <1.5 in 74±19 hours following 
warfarin withdrawal [365, 366]. To achieve 80% power and to detect a 15 hour 
difference in the time needed to reach an INR <1.5 between individuals with the 
CYP2C9 *1*1 genotype and either those with at least one variant allele (i.e. either 
CYP2C9*2 or CYP2C9*3) and allowing for the expected proportion in the three 
genotype groups, a sample size of 135 patients were needed to be studied. 
 
7.3.2. Genotyping assay and samples preparation 
All samples were prepared and genotyped for CYP2C9 *2 and *3 alleles as 
mentioned in section 6.3.4 page 145.  TaqMan® SNP genotyping assay was also used 
for VKORC1 genotyping by using VKORC1 probe with the same procedure as 
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mentioned in section 6.3.4.2 page 146. Since both of G-1639A and C1173 are in strong 
linkage disequilibrium, the samples were genotyped for only G-1639A. 
 
7.3.3. Determination of plasma warfarin enantiomer concentration  
Blood samples were collected in heparinized tubes; subsequently, plasma was 
separated by centrifugation at 2500 rpm for 10 minutes and stored at -80ºC until further 
analysis. Plasma S- and R-warfarin enantiomer concentrations were determined by 
High Performance Liquid Chromatography (HPLC) using a modified method described 
by Naidong, et al. [369] as follows.  
 
7.3.3.1. Warfarin enantiomer extraction from plasma 
   All samples were analysed in duplicate as follows. 200 µl of plasma was 
transferred into a clean tube. Then 30 µl of internal standard (S-naproxen in methanol, 
40 µg/ml), 280 µl 1N sulphuric acid and 2 ml diethylether were added. The mixture was 
then rotary mixed for 15 minutes followed by centrifugation at 2500 rpm for 10 min. 
The upper organic phase was transferred into a new tube, and evaporated to dryness 
under a stream of air at 45ºC. The residue was reconstituted with 200 µl of mobile 
phase, spun on bench top centrifuge at maximum speed, and finally 50 µl of the mixture 
was injected onto the HPLC column.  
 
7.3.3.2. Standard curve and quality control preparation 
 Warfarin racemic primary stock solution was prepared at concentration of 1 mg/ml 
in acetonitrile (0.5 mg/ml for each warfarin enantiomer). Secondary working stock 
solution was prepared with HPLC water at final concentration of 5 ng/µl (2.5 ng/ml for 
each warfarin enantiomer). The standard curve was constructed for S- and R- warfarin 
over the concentration range, 0, 125, 250, 380, 500, 750, and 1000 ng/ml. A quality 
control sample (in duplicate) was run with every assay to check for assay precision 
and accuracy.      
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7.3.3.3. HPLC instrumentations and conditions  
   Shimadzu VP HPLC machine was used with a UV detector (wavelength set at 
320). The analytic column used was Astec Cyclobond I 2000 β-cyclodextrin, 5 µm, 
25mm x 4.6mm (Supeclo Analytical, USA). The mobile phase was composed of 
acetonitrile, acetic acid, and trimethylamine (1000/3/2. v/v/v) and was pumped into the 
column at flow rate of 1.0 ml/min. The run time for each sample was 27 minutes.  Before 
using the mobile phase, it was sonicated for 10-15 minutes in order to remove any 
traces of oxygen. S- and R-warfarin, and the internal standard (naproxen) were eluted 
on average at 5.59, 6.10, and 22.95 minutes, respectively, as shown in Figure 7-1. 
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Figure 7-1: The separation and retention times of S- and R- warfarin and naproxen on the chromatogram 
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7.3.3.4. Data analysis 
  The chromatograms were analysed using Shimadzu LC solutions 
chromatographic software. For each of S- and R- warfarin, a separate standard curve 
was constructed by plotting the warfarin enantiomer to internal standard peak area 
ratio versus enantiomer concentration. Warfarin enantiomer concentration in patients’ 
plasma and that of the quality control were derived from the standard curve. 
 
7.3.3.5. Limits of detection and precision 
 The detection limit of the extracted samples was 2 ng/ml (signal/noise ratio =3). 
The inter-day coefficient of variation for S- and R- warfarin at 690 ng/ml was 4.2% and 
3.8%, respectively. 
 
7.3.4. Statistical analysis 
Statistical analysis of the data was carried out using Minitab software version 17 
(Coventry, UK). The effects of study variables on INR, and decay in plasma S- and R- 
warfarin enantiomer concentrations were assessed using multiple and logistic 
regression models. By regressing the logarithm of INR against time for each individual, 
the time for INR to reach 1.5 was estimated. This estimated time was modelled using 
CYP2C9 and VKORC1 genotypes, and other study variables. When necessary, data 
were transformed into their logarithmic values to approach normality. One way 
analysis of variance (ANOVA) was used for comparison of continuous data. A P<0.05 
was taken as being statistically significant. Data are presented as mean±SD unless 
otherwise stated. 
  
7.4. Results 
135 patients were recruited into the study. However, for statistical analysis data 
were available for 131 participants [73 (56%) males] as four later withdrew from the 
study due to inability to attend study visits. The age range for the study cohort was 21-
92 years; there was no significant difference in mean age between males and females 
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(62±15 versus 64±18 years). At the point of recruitment, patients were taking a median 
of 2 drugs (IQR 1-5), excluding warfarin, 1 of which affected the cardiovascular 
system. As well as indications for warfarin (atrial fibrillation 11%, deep venous 
thrombosis 61%, pulmonary embolism 26%, and valvular prosthesis 2%), the median 
number of comorbidities was 1 (IQR 1-2), most commonly cardiovascular disease 
(69%). The frequency of CYP2C9 and VKORC1 genotypes in the study population are 
presented in Table 7-1.  
 
Table 7-1: CYP2C9 and VKORC1 genotype frequency distribution in the study 
population  
CYP2C9 polymorphism, n (%)   
*1*1 72 (56.7) 
*1*2 33 (26.0) 
*1*3 15 (11.8) 
*2*2   6  (4.7) 
   *2*3   1  (0.8) 
VKORC1 polymorphism, n (%)   
GG 49 (38.6) 
AG 63 (49.6) 
AA 15 (11.8) 
N.B. Genotyping data missing for 4 patients
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On the screening day following the final warfarin dose (warfarin dose usually taken 
early evening the day before), mean INR was 2.4±0.6. At the first study visit (16-24 
hours after the last warfarin dose), the proportion of INR values ≥1.5 among those with 
CYP2C9 wild-type, single variant, and double variant genotype was 78%, 94%, and 
100%, respectively; CYP2C9 genotype was the only predictor of an INR <1.5 
(P=0.009) at the first visit; the odds ratio for the single variant genotype relative to the 
wild-type was 0.22 (95%CI= 0.06, 0.79). The proportion of INR values ≥1.5 at the 
second visit (mean of 102 hours) among those with CYP2C9 wild-type, single- and 
double-variant alleles was 9%, 15%, and 40%, respectively, but these differences were 
no longer statistically significant; no further genetic influences were identifiable beyond 
the second visit as most of the INR values were close to 1.0 by the third and fourth 
study visits. 
According to regression analysis, which included the variables of VKORC1 and 
CYP2C9 genotype, age, weight, sex, warfarin dose, comorbidities, concurrent drugs, 
and alcohol, CYP2C9 genotype was the only factor which influenced the rate of INR 
decline (P=0.014); the slope of the regression lines for INR for CYP2C9 (single and 
double variants) were significantly shallower than that for CYP2C9 wild-type. 
Regression analysis revealed that the time required to reach an INR value of 1.5 was 
significantly associated with both patient age (P=0.037) and CYP2C9 genotype 
(P=0.005) (R2=15.7%). Using the regression equation, it can be estimated that for 
example, a 90-year old will take 18 hours longer to reach an INR of 1.5 than a 30-year 
old, and, for example, at the age of 60, in patients with either *1*1, *1*2, *1*3, *2*2, or 
*2*3 genotype, on average it will take 61, 63, 78, 86, and 100 hours, respectively for 
INR value to reach 1.5. 
In patients possessing either a single or double CYP2C9 variant allele, S-warfarin 
half-life was longer (mean difference of 11 h for *1*2 and *1*3 and 20.5 h for *2*2 and 
*2*3; P=0.004) and its clearance slower (mean difference of 0.1 ml/hour, for both single 
and double variant alleles; P<0.0001), compared to patients with wild-type genotype. 
Warfarin clearance results were comparable to results described in literature [370]. 
Table 7-2 shows S- and R- warfarin half-life and clearance for the various CYP2C9 
genotypes. CYP2C9 genotype had no influence upon R-warfarin half-life or clearance.  
 163 
 
According to the regression analysis, neither VKORC1 genotype, concurrent 
therapy, co-morbidity, patient weight, nor alcohol consumption influenced either the 
time taken for INR to reach 1.5, or S- and R- warfarin clearance.
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Table 7-2: Influence of CYP2C9 polymorphism on mean (SD) warfarin dose, half-life and clearance 
  Warfarin 
weekly dose 
(mg)  
Warfarin half-life (hr) Warfarin clearance (L/hr) 
  S R S R Racemic  
CYP2C9 polymorphism        
*1*1 40 (16) 52.6 (19.5) 67.2 (28.0) 0.20 (0.22) 0.07 (0.07) 0.11 (0.09) 
*1*2/*1*3 29 (14) 63.3 (20.9) 70.6 (33.6) 0.09 (0.04) 0.05 (0.04) 0.07 (0.03) 
*2*2/*2*3 25 (9) 73.1 (12.1) 63.0 (32.9) 0.09 (0.05) 0.07 (0.01) 0.07 (0.02) 
N.B. Data based on 127 patients as genotyping information was missing for 4 patients.
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As expected, warfarin weekly mean dose was significantly different between 
patients according to their CYP2C9 (p=0.0003) and VKORC1 (P<0.0001) genotype. 
Patients with CYP2C9 single- or double-variant alleles had a lower weekly mean dose 
requirement compared to the wild-type carriers; mean difference of 11mg (P=0.001) 
and 15 mg (P=0.03), respectively. Patients with VKORC1 AA or AG genotypes had 
lower weekly mean dose requirement compared to those with GG genotype; mean 
difference of 21 mg (P<0.0001) and 10 mg (P=0.003), respectively. Similarly, patients 
with VKORC1 AA genotype had a lower weekly mean dose requirement compared to 
those with AG genotype; mean difference 11 mg, P=0.02. Also, as expected, warfarin 
weekly dose requirement was negatively correlated with age (r= -0.4, P<0.0001). 
   
7.5. Discussion 
Patients on warfarin are normally required to interrupt warfarin therapy for a fixed 
number of days prior to an invasive procedure. However, the anticoagulant activity of 
warfarin (as measured by INR) subsides at different rates among different patients. 
Discontinuation of warfarin too early may predispose the patient to thrombosis and 
stopping it too late may result in peri-operative bleeding. 
The results of this prospective study which investigated genetic and non-genetic 
influences upon INR decline support our hypothesis that the time required for the 
resumption of normal coagulation to take place following the cessation of warfarin 
therapy is largely dependent upon S-warfarin clearance, which in turn is influenced by 
CYP2C9 polymorphism and patient age [95]. Polymorphisms in CYP2C9 (the main 
enzyme responsible for S-warfarin metabolism) and differences in patient age (which 
influences liver size and liver blood flow [93]) thus explain the previously reported 
variation in INR decay in patients withdrawing from warfarin prior to surgery [365, 366].  
We also assessed the potential influence of VKORC1 polymorphism, based upon 
the notion that polymorphisms in VKOR, the pharmacological target for warfarin, can 
affect the fall in warfarin anticoagulant activity following warfarin cessation. However, 
VKORC1 polymorphism made no significant contribution to the variability in INR 
decline in our study population. Two previous studies, one in healthy subjects [371], 
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and the other in patients prior to surgery [372], found that neither VKORC1, nor 
CYP2C9, influenced the normalization of coagulation following warfarin withdrawal. 
However, neither study was sufficiently powered to detect the influence of either gene 
on the fall in INR; this was evident from the very small number of patients identified in 
either study as having variant alleles for VKORC1 and CYP2C9.  
In our self-reported Caucasians study population there were too few patients who 
were of CYP2C9 *2*2* genotype, whilst there was only one patient who was of *2*3 
genotype and no patient was of *3*3 genotype. As such, it was not possible to evaluate 
the effect of the individual genotypes on S-warfarin clearance and the fall in INR 
following warfarin withdrawal. Nevertheless, the frequency distribution for CYP2C9 
genotype fits in with that of the Caucasian general population in whom only about 2% 
are homozygous and ~20% are heterozygous carriers of the CYP2C9*2 allele, with a 
significantly smaller proportion being either homozygous or heterozygous carriers of 
the CYP2C9*3 allele [373]. In common with the literature we found that warfarin dose 
requirement was significantly influenced by CYP2C9 and VKROC1 genotype [95, 374, 
375]. 
  
7.6. Conclusion  
The study results show that the inter-individual variability in the time needed for 
normal coagulation to resume following warfarin withdrawal is influenced, in the main, 
by variance in S-warfarin clearance which in turn is affected by CYP2C9 polymorphism 
and age. A pharmacogenetics-based algorithm incorporating CYP2C9 genotype and 
patient age (which could be easily adopted for routine use) could be clinically useful 
for estimating the correct length of time needed for individual patients to stop taking 
warfarin prior to surgery. Such an approach could benefit patients, in terms of reducing 
potential harm caused either by discontinuing warfarin too early (thus predisposing the 
patient to thrombosis) or stopping it too late (resulting in possible peri-operative 
bleeding). A pharmacogenetic-guided intervention could also benefit the health service 
providers in terms of improved delivery of care. However, whether such approach is 
cost-effective (in terms of the balance between savings made through reductions in 
the number of cancelled surgical procedures and the cost of genotyping) needs further 
investigation. 
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CHAPTER. 8 GENERAL DISCUSSION  
 
Although warfarin has been used effectively for more than 60 years as an 
anticoagulant agent for the prophylaxis and treatment of thromboembolic diseases, 
difficulties with its management remain, owing to its narrow therapeutic index and inter- 
and intra- individual variability in anticoagulation response, which can be 
unpredictable. Variability in dietary intake of food, vitamin K in particular, as well as 
many drugs taken concomitantly with warfarin, affect resultant anticoagulation. In 
consequence, patients anticoagulated with warfarin require regular monitoring of 
prothrombin time, expressed as the INR, to ensure adequate anticoagulation and 
reduce the risk of adverse events, especially the risk of bleeding [376]. With the recent 
introduction and approval of NOACs for the treatment and prophylaxis of 
thromboembolic disease, the aim of having safe alternative oral anticoagulant drugs 
with at least the same efficiency as warfarin is being realised as they are characterised 
by a wider therapeutic range with lower drug-drug interaction profiles. Improving both 
warfarin and NOACs' safety by studying factors which affect their pharmacological 
activity is highly important. Therefore, the overall theme of this thesis was to study 
factors contributing to both inter- and intra- individual variability in clinical response to 
warfarin and the impact of diet on the NOACs' pharmacological activity.               
I found in my cross-sectional study that warfarin anticoagulation control was more 
unstable in domiciliary monitored patients, in spite of such patients having the highest 
number of INR measurements and dose changes, compared to the more mobile 
patients attending general practice or hospital based clinics for monitoring. Further 
investigations to identify the clinical and demographic characteristics of housebound 
patients which contribute to the poorer anticoagulation stability, and exploration of 
effective interventions which improve anticoagulation control in such patients is 
indicated.  Furthermore, the case for establishing the relative risks and benefits of 
NOACs as alternatives to warfarin in patients with poor anticoagulation control is 
strengthened by the results of my study.  
Age is an important factor affecting anticoagulation response [91, 93], with some 
evidence showing that physical dependency can affect anticoagulation control.  As only 
a longitudinal study can accurately identify true age-related changes, I went on to study 
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the effect of age on warfarin anticoagulation using longitudinal data belonging to more 
than 2000 patients. I showed that age, gender, and physical dependency all had an 
effect on anticoagulation stability.  
I failed to prove the hypothesis that VKORC1 (-1639) genotype has a role in 
stability of long-term anticoagulation control [377]. Warfarin anticoagulation control as 
measured by time in therapeutic range was not different between VKORC1 genotype 
groups. Owing to the type of data used (retrospective) in this study, and lack of 
information about patients’ comorbidities and concurrent drug therapy, weight and a 
direct assessment of dietary vitamin K consumption, a prospective study to investigate 
whether VKORC1 (-1639) genotype has an effect on anticoagulation control would 
allow more scientifically robust conclusions. 
Patients on warfarin therapy scheduled for invasive procedures should stop taking 
the drug (usually 5 days prior to the intervention according to guidelines) in order to 
minimise the risk of peri-operative bleeding. However, the rate of decline in INR differs 
between patients. To date the factors which influence the rate of fall in INR had not 
been identified. In the first study of its kind, I examined the effect of CYP2C9 genotype 
on the rate of INR decline after warfarin interruption. I found that normalisation of 
coagulation occurred more slowly in patients with CYP2C9 mutations. Patients with 
two CYP2C9 variant alleles were more than eight times more likely to have an INR of 
≥ 1.5 on the fifth day of warfarin interruption. In a separate study I was able to 
demonstrate that, in addition to age, the rate of fall in INR was influenced by S-warfarin 
clearance which in turn was influenced by CYP2C9 genotype. An algorithm for the rate 
of INR decline incorporating CYP2C9 genotype was developed and has the potential 
to benefit all patients requiring warfarin interruption, as the ideal period off warfarin 
could be determined for individual patients. Further study is required to validate this 
algorithm and its clinical utility examined.   
With the development of pharmacogenetics-based algorithms guiding initiation of 
anticoagulation with warfarin, a number of handheld medical devices for CYP2C9 *2/*3 
and VKORC1 − 1639G>A or 1173C>T genotyping, such as Nanosphere (Verigene®), 
Autogenomics (INFINITI®), GenMark Dx (eSENSOR®), Paragon Dx reagents with 
Cepheid Smart Cycler®, and TrimGen reagents with Roche Light Cycler® [156], have 
been developed and approved by the FDA. Genotyping results for CYP2C9 are usually 
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obtained within 2-3 days if performed in a reference molecular diagnostic laboratory or 
the next working day if testing is done locally; however, with these devices, genotype 
results are available in less than 8 hours. If the results of my study are validated within 
a wider population, such handheld devices could be used to promote the clinical utility 
of the algorithm on a wide scale.  
The clinical effectiveness of NOACs has been established in a number of landmark 
studies. These studies have shown that, within trial populations, NOACs were at least 
as effective as warfarin, and were associated with a significantly lower major bleeding 
risk. Trial populations tend to exclude frail patients, the very elderly and those with 
multiple comorbidities, many of whom have a diet low in vitamin K, an important factor 
in blood coagulation. Besides poor dietary vitamin K intake, age might play a role in 
increasing sensitivity to  anticoagulation response to NOACs, as shown by Reilly et al 
[378] in a recent pharmacokinetic analysis  of the RE-LY trial data in which they 
examined the association between efficacy and safety results and dabigatran plasma 
concentrations. Dabigatran plasma concentrations increased with age in association 
with declining renal function, trough plasma drug concentrations increasing by 68% in 
patients aged 75 years and above compared to those aged less than 65. Moreover, 
dabigatran plasma concentration was higher by 21% and 53% in those weighing below 
50 kg compared to those weighing 50 to 100 kg and ≥ 100 kg, respectively. Lower 
dabigatran plasma concentrations were positively correlated with thrombotic stroke, 
and higher trough and post-dose dabigatran concentrations were associated with more 
major bleeding events. I studied the effect of vitamin K in diet on rivaroxaban 
pharmacological response in humans ex-vivo, which has not been previously studied. 
I compared results in older subjects who were frail and underweight and with poor oral 
intake of vitamin K with those of young healthy controls with vitamin K replete diets. I 
showed that anticoagulation response to rivaroxaban ex-vivo was increased in the 
group with poor vitamin K intake, suggesting that the latter are at increased risk of 
bleeding associated with rivaroxaban treatment. Therefore, as for patients on warfarin 
therapy who are advised to have a regular dietary intake of vitamin K to maintain 
adequate anticoagulation stability [125, 349, 379], anticoagulation might be more 
within the boundaries predicted for NOACs in patients ingesting adequate amounts of 
vitamin K in their diet. These results could be applicable to all NOACs; therefore, the 
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malnourished elderly with multiple comorbidities and/or renal dysfunction might be 
candidates for NOAC dose adjustment; further studies to investigate this are required.        
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APPENDICES 
Appendix (A) TTR calculations  
Here is an example of calculating TTR manually.   
1. As shown in Table A-1, calculate number of days between each two dates, e.g. 
21 days between 07/02/2006 and 17/01/2006.  
2. Calculate the amount of total shift between every two consecutives INR 
readings, and also that within the specified therapeutic range (i.e. INR of 2-3 in 
this example), for example: 
a. between 07/02/2006 and 17/01/2006, 2.3-2.7= -(0.4). Since the two INR 
readings are still within the required range (i.e. 2-3), the TTR =0.4/0.4=1; 
therefore, the TTR in those 21 days is 100% 
b. 12/04/2006 and 04/04/2006, 8 days are the difference between these two 
dates. 1.9-2.2=-(0.3) which is the total difference between the two INR 
readings, and 2.2-2.0= 0.2 is the shift in the required range (INR of 2-3) 
i. 
𝑇ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒𝑟𝑎𝑝𝑒𝑢𝑡𝑖𝑐 𝑟𝑎𝑛𝑔𝑒 (𝑒.𝑔.2.2−2)
𝑇ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑟𝑒𝑎𝑑𝑖𝑛𝑔𝑠
=
0.2
0.3
= 0.67, or 67%.       
0.67 X 8 days= 5 days. This means that 5 out of 8 days were within 
the therapeutic range.  
ii. 25/04/2006 and 12/05/2006, 13 days are the difference. INR 
difference =1.2-1.9=0.7. Both of the two readings are out of the 
range (i.e. 2-3), and the amount within the therapeutic range is 
zero.  
Therefore, the TTR =
0
0.7
= 0 % for the 13 days. The same is 
applied if the two INR readings are above 3, e.g. 3.5 (30/05/2005) 
and 3.7 (22/05/2006).  
3. Complete the above calculation for all INR readings 
4. Take the sum of all days within the period required, 133 days in this example 
Table A-1; and the days within the therapeutic range, 89 days.  
5. Divide the days within the therapeutic range by the total days 
6. 
89
133
 =0.7, which means that the time in therapeutic range within the given period 
(from 17/01/2006 to 30/05/2006) was 70%. 
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Table A-1: Example of how to calculate TTR 
Visit Date 
INR 
Reading (a) 
Days 
since (b) 
INR 
Difference (c ) 
% in range 
(d) 
Days in 
therapeutic 
range (c X d) 
17/01/2006 2.7        
07/02/2006 2.3 21 -0.4 100=1 21 
07/03/2006 2.4 28 0.1 100=1 28 
04/04/2006 2.2 28 -0.2 100=1 28 
12/04/2006 1.9 8 -0.3 67=0.67 5 
25/04/2006 1.2 13 -0.7 0 0 
02/05/2006 1.8 7 0.6 0 0 
15/05/2006 3.9 13 2.1 48=0.48 6 
22/05/2006 3.7 7 -0.2 0 0 
30/05/2006 3.5 8 -0.2 0 0 
Total days number 133     89 
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Appendix (B) Validated dietary questionnaire 
 
How to answer the questions 
 
There are several types of question in this booklet.  Most of them can be 
answered by ticking one box (ONLY) beside each food types. 
 
For example: 
 
FOODS & AMOUNTS AVERAGE USE IN THE LAST WEEK 
 
FISH (medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Fried fish in batter, as in fish and 
chips 
 
 
 
      
 
 
Please put ONE tick in the appropriate box () on each line to indicate how often, 
on average, you have eaten each food during the past week. 
 
 Answer every question by putting ONE tick () on every line 
 
 Do not leave ANY lines blank. 
 
Another example of questions requiring boxes to be ticked: 
 
Q. Do you usually add salt to food while cooking?   
 Yes……         
 No….… 
 
Some of these questions have several boxes and you may be asked to tick ONE only.  
 
For example:  
 
What kind of fat did you most often use for frying, roasting, grilling etc? 
           Select one only 
    
Butter…… Olive oil…… 
Lard/dripping…… Walnut Oil…… 
Solid vegetable fat…… Soya Oil…… 
Margarine…… None…… 
Vegetable Oil…… Other…… 
Some of these questions have several boxes and you may be asked 
to tick all the boxes you think apply to you. 
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 For example: 
 
14. What kind of fat did you use for cooking? 
 
               Please tick all that apply 
 Butter…… 
Lard/dripping…… 
Solid vegetable fat…… 
Margarine…… 
 Vegetable oil…… 
Olive oil…… 
Walnut Oil…… 
Soya Oil…… 
None……  
         Other…… 
 
 
If “other” selected in question 14, please state ………….......... 
 
 
 
What do I do if I make a mistake? 
 
Cross out the incorrect answer, and put a tick where you think the right answer 
should be.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 217 
 
 
For Questions 1-12, please put ONE tick in the appropriate box () on 
each line to indicate how often, on average, you have eaten each food 
during the past week. Please DO NOT leave any lines blank. 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
1. MEAT 
(medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Beef: e.g. roast, steak, mince, stew, 
casserole, curry, Bolognese 
 
 
 
       
Beefburgers (single burger)  
 
       
Corned beef, Spam, luncheon meats (2 
slices – a sandwich’s-worth) 
 
 
       
Lamb: e.g. roast, chops, stew, curry   
 
       
Chicken, turkey or other poultry: e.g. 
casserole, sliced, curry  
        
Breaded or fried poultry products: e.g. 
chicken nuggets, deep fried chicken 
pieces (1 breaded chicken portion or 
c.6 nuggets) 
        
Pork: e.g. roast, chops, stew, curry   
 
       
Bacon and ham (2 rashers/slices – a 
sandwich’s-worth) 
 
        
Sausages (one) 
 
        
Savoury pies, e.g. meat pie, pork pie, 
pasties, steak & kidney pie, sausage 
rolls, scotch egg (single pie/savoury) 
        
Game and Wild-fowl: e.g. duck, rabbit, 
grouse  
        
Kidneys or liver; including liver pate, 
liver sausage 
        
 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
2. FISH and SEAFOOD 
(medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
White  fish- not coated e.g. cod, halibut, 
haddock, whiting, plaice, sole, etc (per 
portion) 
        
White fish- in batter or crumbs e.g. cod, 
haddock, plaice, etc (per portion) 
        
Oily fish e.g. herring, mackerel, (tinned) 
salmon- not tinned, trout, kippers etc 
(per portion) 
        
Tinned fish e.g. Sardines, Pichards, 
Tuna, Salmon etc (per can, or portion) 
 
 
       
Prawns, shellfish and other fish (within 
dish or one sandwich’s-worth) 
 
 
       
Fish cakes, Fish fingers (one)         
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
3. BREAD & SAVOURY 
BISCUITS  
(one slice or biscuit) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
White bread and rolls, white pitta bread 
(per slice/roll) 
        
Scones, teacakes, crumpets, muffins or 
croissants (each) 
        
Brown bread and rolls (per slice/roll) 
 
        
Wholemeal pitta bread (each) 
 
        
Wholemeal bread/rolls (per slice/roll) 
 
        
Granary bread (per slice/roll) 
 
        
Rye bread (per slice/roll) 
 
        
Naan bread, chapatti (each) 
 
        
Garlic bread (per serving) 
 
        
Cream crackers, cheese biscuits (each)         
Wholemeal crackers (per cracker) 
 
        
Crispbreads e.g. Ryvita, Ryvita currant 
crunch (one) 
 
 
       
Oatcakes (one) 
 
        
Other speciality breads (each) 
(please state and tick for frequency) 
1. 
2. 
        
 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
4. CEREALS 
(one bowl) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Porridge, Readybrek  
 
       
Sugar coated cereals e.g. Sugar Puffs, 
Cocoa Pops, Frosties 
        
Non-sugar coated cereals e.g. 
Cornflakes, Rice Crispies 
        
Muesli  
 
       
Bran containing cereals e.g. All Bran         
Cheerios         
Branflakes         
Weetabix         
Shredded Wheat, Shreddies 
 
        
Wholegrain cereals with fruit e.g. 
Sultana Bran, Fruit n Fibre 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
5. POTATOES, RICE & 
PASTA (medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ per 
day 
Boiled, mashed, instant or jacket 
potatoes (about 1/3 of a plate)  
        
Chips, potato waffles (side order with 
meal – chip-shop portions count as 2) 
 
 
       
Roast potatoes (3 – 5 potatoes)  
 
       
Yorkshire pudding, pancakes, dumpling 
(each medium) 
 
 
       
Potato salad (per small tub, c. 2 
tablespoons) 
 
 
       
White rice (1/2 plateful, or in a dish e.g. 
rice salad, risotto etc) 
 
 
       
Brown rice (1/2 plateful, or in a dish e.g. 
rice salad, risotto etc) 
 
 
       
White or green pasta, e.g. spaghetti, 
macaroni, noodles, (1/2 plate) 
 
 
       
Tinned pasta, e.g. spaghetti, ravioli, 
macaroni (1/2 standard tin) 
        
Super noodles, pot noodles, pot 
savouries (per pot) 
        
Wholemeal pasta/spaghetti (1/2 plate)  
 
       
Pasta dishes e.g. Lasagne, moussaka, 
cannelloni (as individual ready-meal) 
        
Pizza (10’’ = 1, 12’’ = 2, 12’’+ = 3-4)  
 
       
Wholegrain dishes not mentioned 
(Please state and tick for frequency) 
1. 
2. 
3. 
        
 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
6. (a) DAIRY & EGG 
PRODUCTS 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Single or sour cream (tablespoon)  
 
       
Double or clotted cream (tablespoon)  
 
       
Low fat yoghurt, fromage frais (125g 
carton) 
        
Full fat or Greek yoghurt (125g carton)  
 
       
Dairy desserts (125g carton), e.g. 
mousse 
        
Cheese, e.g. Cheddar, Brie, Edam 
(medium serving) 
        
Cottage cheese, low fat soft cheese 
(medium serving) 
        
Eggs as boiled, fried, scrambled, 
omelette etc. (one) 
        
Quiche (medium serving = 1/6 of pie) 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
6.(b) DAIRY PRODUCTS & 
FATS used on bread 
(teaspoon/curl) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Butter 
 
        
Margarines/spreads (state type and tick 
for frequency) 
1. 
2. 
3. 
        
Reduced/Low fat spreads (state type 
and tick for frequency) 
1. 
2. 
3. 
 
 
       
 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
6.(c) DAIRY PRODUCTS & 
FATS used on vegetables 
(teaspoon/curl) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Butter  
 
       
Margarines/spreads (state type and tick 
for frequency) 
1. 
2. 
3. 
        
Reduced/Low fat spreads (state type 
and tick for frequency) 
1. 
2. 
3. 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
7. SWEETS & SNACKS 
(medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Chocolate coated sweet biscuits, e.g. 
Penguin, kit-kat, chocolate digestive 
(one) 
        
Sweet biscuits, plain, e.g. Nice, ginger 
(one) 
        
Cakes e.g. fruit, sponge, sponge 
pudding (medium slice) 
        
Sweet buns & pastries e.g. doughnuts, 
Danish pastries, cream cakes (each) 
        
Flapjacks (each) 
 
        
Fruit pies, tarts, crumbles (per individual 
pie/medium serving) 
 
        
Milk puddings, e.g. rice, custard, trifle 
(medium serving) 
        
Ice cream, choc ices (one)         
Chocolates,, toffee, sweets and other 
confectionary (medium bar of chocolate, 
one snack bar, one packet) 
        
Sugar added to tea, coffee, cereal 
(teaspoon) 
        
Crisps or other packet snacks e.g. 
Wotsits (one packet) 
        
Peanuts 
(one packet) 
        
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
8. SOUPS, SAUCES AND 
SPREADS  
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Vegetable soups (medium bowl)  
 
       
Meat soups (medium bowl)  
 
       
Sauces, e.g. white sauce, cheese 
sauce, gravy (1/3 of plate or in dish) 
        
Tomato based sauces e.g. pasta 
sauces (1/3 of plate or in dish) 
        
Tomato ketchup, brown sauce (per 
tablespoon) 
        
Relishes e.g. pickles, chutney, mustard 
(per tablespoon) 
        
Salad cream, mayonnaise, other salad 
dressings (per tablespoon) (state type 
and tick for frequency) 
1. 
2. 
3. 
        
Marmite, Bovril (per teaspoon/slices of 
bread) 
        
Jam, marmalade, honey, syrup (per 
teaspoon/slices of bread) 
        
Peanut butter (per teaspoon/slices of 
bread) 
        
Chocolate spread, chocolate nut spread 
(per teaspoon/slices of bread) 
        
Dips e.g. houmous, cheese and chive 
(per tablespoon/slices of bread) 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
9. DRINKS None Once 
A 
Week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Tea (cup)  
 
       
Coffee, instant or ground (cup)  
 
       
Coffee whitener, e.g. Coffee-mate 
(teaspoon) 
        
Cocoa, hot chocolate (cup)  
 
       
Horlicks, Ovaltine 
 (cup) 
 
 
       
Wine (glass)  
 
       
Beer, lager or cider (half pint)  
 
       
Port, sherry, vermouth, liqueurs (glass)  
 
       
Spirits, e.g. gin, brandy, whisky, vodka 
(single) 
        
Low calorie or diet fizzy soft drinks 
(glass) 
        
Fizzy soft drinks, e.g. Coca cola, 
lemonade (glass) 
        
Pure fruit juice (100%) e.g. orange, 
apple juice (glass) 
 
 
       
Fruit squash or cordial 
 (glass) 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
10. FRUIT (1 fruit or medium 
serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Apples (each) 
 
        
Pears (each) 
 
        
Oranges (1x), satsumas, mandarins, 
tangerines, clementines (all 2x) 
        
Grapefruit (1/2 a fruit) 
 
        
Bananas (each) 
 
        
Grapes (per small handful) 
 
        
Melon (1 medium slice) 
 
        
Peaches (1x), plums, apricots, 
nectarines (2 – 3x) 
        
Strawberries, raspberries (per small 
handful), kiwi fruit (each) 
 
        
Tinned fruit (1/2 tin) 
 
        
Dried fruit, e.g. raisins, prunes, figs (per 
small handful) 
        
Other fruit or fruit dishes / products not 
mentioned 
(please state and tick for frequency) 
1. 
2. 
3. 
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
11. VEGETABLES Fresh, 
frozen or tinned 
(medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Carrots (2-3 table spoonfuls) 
 
        
Cooked Spinach (major ingredient in 
dish (e.g. curry) or per 2 – 3 
tablespoonfuls) 
 
 
       
Broccoli (per 4 – 5 florets)  
 
       
Brussels sprouts (2-3 tablespoonfuls)  
 
       
Cabbage (2-3 tablespoonfuls)  
 
       
Peas (2-3 tablespoonfuls)  
 
       
Green beans, broad beans, runner 
beans (2-3 tablespoonfuls) 
        
Marrow, courgettes (major ingredient in 
dish or 2-3 tablespoonfuls) 
 
 
       
Cauliflower (major ingredient in dish 
(e.g. curry) or 2-3 tablespoonfuls) 
 
 
       
Parsnips, turnips, Swedes (2-3 
tablespoonfuls) 
 
 
       
Leeks (2-3 tablespoonfuls)  
 
       
Onions (per onion)  
 
       
Garlic (2 cloves)  
 
       
Mushrooms (handful of uncooked 
mushrooms, or 2-3 tablespoonfuls) 
 
 
       
Sweet peppers (per ½ pepper)  
 
       
Beansprouts (major ingredient in dish or 
(2-3 tablespoonfuls) 
 
 
       
Mixed salad leaves, lettuce, rocket 
(side-salad or per 1/3 plate) 
 
 
       
Cucumber (per ¼ cucumber)  
 
       
Mixed vegetables (frozen or tinned) (2-3 
tablespoonfuls) 
 
 
       
Watercress (per bunch, or as a major 
ingredient in salad) 
 
 
       
Tomatoes (2 medium tomatoes, ½ can 
of tomatoes) 
 
 
       
Sweetcorn (2-3 tablespoonfuls)  
 
       
Beetroot (1 medium)  
 
       
Radishes (3-4 pieces)  
 
       
Coleslaw (2-3 tablespoonfuls)  
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FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
11. VEGETABLES Fresh, 
frozen or tinned 
(medium serving) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Avocado (per ½ fruit)  
 
       
Baked Beans (per ½ tin)  
 
       
Dried lentils, beans, peas (2-3 
tablespoonfuls, or major ingredient)  
 
 
       
Tofu, soya meat, TVP, (in dish e.g. 
curry),  Vegeburger (each) 
 
 
       
 
FOODS & AMOUNTS Average Use In LAST WEEK (Tick ONE per line) 
11. VEGETABLES Fresh, 
frozen or tinned (continued) 
None Once 
a 
week 
2-4 
per 
week 
5-6 
per  
week 
Once  
a 
day 
2-3 
per 
day 
4-5 
per  
day 
6+ 
per 
day 
Other vegetables or vegetable dishes / 
products not mentioned (please state 
and tick for frequency) 
1. 
2. 
3. 
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YOUR DIET IN THE LAST WEEK, continued  
 
12. What type of milk did you most often use? 
 
                Select one only 
 
 Full cream…… 
Channel Islands…… 
 Dried milk…… 
Semi-skimmed…… 
Skimmed…… 
 Soya…… 
 Other…… 
None…… 
 
 
 
13. Approximately, how much milk did you drink each day, including 
milk with tea, coffee, cereals etc? 
 
 None ......  
 Quarter of a pint (roughly 125mls) ......  
 Half a pint (roughly 250mls) ......  
 Three quarters of a pint (roughly 375mls) ......  
 One pint (roughly 500mls) ......  
 More than one pint (more than 500mls) ......  
 
 
 
14. What kind of fat did you use for cooking? 
 
               Please tick all that apply 
 Butter…… 
Lard/dripping…… 
Solid vegetable fat…… 
Margarine…… 
 Vegetable oil…… 
Olive oil…… 
Walnut Oil…… 
Soya Oil…… 
None……  
Other…… 
 
If “other” selected in question 14, please state……………........ 
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15. Do you usually add salt to food while cooking? 
Yes…… 
No…… 
 
 
16. Do you usually add salt to any food at the table?  
Yes…… 
No….… 
 
17. Do you usually eat the fat on cooked meats? 
Yes…… 
No….… 
 
18. Do you usually eat the skin on cooked meats? 
 
 Yes…… 
No…… 
 
19.   Do you usually add sugar to drinks i.e. tea/coffee? 
   Yes…… 
No…… 
 
20. On average, in the past week, how many portions of fruit and 
vegetables did you eat per DAY? 
 
Please 
estimate:….…………..……… 
 
21. On average, in the past week, how many servings of wholegrain 
foods did you eat per DAY? 
       Please 
estimate:………………………… 
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  22.     Have you taken any of the following during the past week? 
 
  
 None Once 
a 
week 
2-4 
per 
week 
5-6 
per 
week 
Once 
a 
day 
2-3 
per 
day 
Vitamins (e.g. multivitamins, vitamin 
B, vitamin C, folic acid) 
      
Minerals (e.g. iron, calcium, zinc, 
magnesium) 
      
Fish oils (e.g. cod liver oil, omega-3)       
Other food supplements (e.g. oil of 
evening primrose, starflower oil, royal 
jelly, ginseng) 
      
 
 Did you use any other food supplements? Please state below: 
 
1 
2 
3 
 
Thank you for taking the time to complete this 
questionnaire!!  
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Appendix (C) FIXa antigen ELISA analysis procedure  
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Appendix (D) FXa antigen ELISA analysis procedure  
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